東北大学研究者紹介

研究者詳細

ホーム

日本語 English

顔写真

ウメザワ　レイ

梅澤　玲

Rei Umezawa

所属

大学院医学系研究科　医科学専攻　内科病態学講座（放射線腫瘍学分野）

職名

准教授

学位

医学博士

researchmap

https://researchmap.jp/reirei

J-GLOBAL ID

201801011416522928

経歴 4

2020年10月～継続中

東北大学病院　放射線治療科　准教授
2017年1月～ 2020年9月

東北大学病院　放射線治療科　講師
2015年1月～ 2016年12月

国立がん研究センター中央病院　放射線治療科　医師
2012年4月～ 2014年12月

東北大学病院　放射線治療科　助教

学歴 2

東北大学大学院　医学系研究科　放射線腫瘍学分野博士課程修了

～ 2012年3月
東北大学　医学部　医学科

～ 2006年3月

委員歴 2

日本放射線腫瘍学会　用語委員会
日本放射線腫瘍学会　ガイドライン委員会

所属学協会 7

日本婦人科腫瘍学会
米国放射線腫瘍学会
日本膵臓学会
日本食道学会
日本癌治療学会
日本医学放射線学会
日本放射線腫瘍学会

︎全件表示 ︎最初の5件までを表示

研究キーワード 9

膵癌
子宮頸癌
前立腺癌
小線源治療
強度変調放射線治療
心臓MRI
放射線心筋障害
食道癌
定位放射線治療

研究分野 1

ライフサイエンス / 放射線科学 /

受賞 2

2015年5月：ICRR, 2015 young investigators travel award

2015年5月
第26回日本放射線腫瘍学会学術大会優秀演題賞（銅賞）

2013年10月　心臓MRI検査を用いた放射線治療後の心筋変化の検出

論文 238

Utilization of radiotherapy and hypofractionated radiotherapy in Japan: long-term trends and the influence of COVID-19 pandemic. 国際誌

Kazuya Takeda, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Shinsaku Okuda, Katsumasa Nakamura, Keiichi Jingu

Journal of radiation research　2026年1月30日

DOI： 10.1093/jrr/rraf088 　

詳細を見る詳細を閉じる

During the coronavirus disease 2019 (COVID-19) pandemic, a short-term decline in radiotherapy use was reported. In this study, we investigated long-term changes in the use of radiotherapy and hypofractionated radiotherapy before and after the COVID-19 pandemic period in Japan and assessed whether the pandemic influenced the adoption of hypofractionation. We obtained data for analysis from the National Database Open Data for fiscal years (FYs) 2014 to 2023. For the 5 years from FY2019 to FY2023, with detailed monthly data available, we used interrupted time series (ITS) analysis to examine changes in the level and slope of claims at the boundaries of the baseline, pandemic and post-pandemic periods. During the 10-year study period, the number of radiotherapy claims increased by an average of 1.6% per year. In FY2020, the peak of the COVID-19 pandemic, the number of radiotherapy claims decreased by 2.0% compared to the previous year. The number of claims for extra fees for hypofractionated radiotherapy for breast and prostate cancer showed a steady increase, except for a temporary decline around the April 2022 policy change in payment requirements for prostate cancer. In the ITS analysis, there were no significant changes in the level and slope of claims for radiotherapy and extra fees for hypofractionated radiotherapy at the onset of the pandemic. In conclusion, the impact of the COVID-19 pandemic on the utilization of radiotherapy in Japan was minimal, and the use of hypofractionated radiotherapy showed a steady increase throughout this period.
Long-term intelligence after high-dose radiotherapy to the primary site versus chemotherapy and whole-ventricle radiotherapy in patients with germinoma.

Masayuki Kanamori, Yumi Sugawara, Yoshiteru Shimoda, Osamu Iizuka, Yoshinari Osada, Shota Yamashita, Ichiyo Shibahara, Rei Umezawa, Naoko Mori, Ryuta Saito, Yukihiko Sonoda, Toshihiro Kumabe, Keiichi Jingu, Shunji Mugikura, Kyoko Suzuki, Hidenori Endo

International journal of clinical oncology　2026年1月30日

DOI： 10.1007/s10147-026-02976-6 　

詳細を見る詳細を閉じる

BACKGROUND: Until 1995, patients with newly diagnosed germinoma received 40-60 Gy of radiation to the primary site with or without chemotherapy (regimen A). After 2000, treatment shifted to chemotherapy followed by 24 Gy of whole-ventricle radiation therapy (WVRT) (regimen B). This study compares long-term intelligence outcomes between the two treatment regimens. METHODS: This retrospective analysis included 151 patients diagnosed with germinoma between 1983 and 2021. Intelligence was assessed using the Wechsler Adult Intelligence Scale (revised or 3rd edition) and the Wechsler Intelligence Scale for Children (3rd edition). Patient backgrounds were also collected. RESULTS: A total of 55 and 69 patients were treated with regimens A and B, respectively. The number of patients who underwent at least one longitudinal neurocognitive assessment was 35 and 29 for regimen A and 53 and 22 for regimen B, respectively. The median interval from initial treatment to the last neurocognitive assessment was 120 months. In the longitudinal intelligence assessments, the median intervals were 58 months from treatment to the first evaluation and 83 months from the first to the final assessment. Full-Scale Intelligence Quotient (FSIQ) scores declined in regimen A but were maintained in regimen B according to analysis of covariates and generalized linear mixed model analysis. CONCLUSION: Chemotherapy followed by 24 Gy of WVRT appears to be associated with a smaller decline in FSIQ over a long-term follow-up.
Evaluating the capability of large language models in radiotherapy through professional certification examinations in Japan

Noriyuki Kadoya, Yoshiyuki Takahashi, Seiya Koga, Hikaru Tanno, Kazuhiro Arai, Shohei Tanaka, Yoshiyuki Katsuta, Hinako Harada, So Omata, Takaya Yamamoto, Rei Umezawa, Ken Takeda, Keiichi Jingu

Journal of Radiation Research　2026年1月10日
出版者・発行元： Oxford University Press (OUP)
DOI： 10.1093/jrr/rraf083 　

ISSN：0449-3060

eISSN：1349-9157

詳細を見る詳細を閉じる

Abstract Large language models (LLMs), such as ChatGPT and Grok, have rapidly advanced in natural language understanding and are increasingly being applied to specialized fields, including medicine. In this study, we evaluated the domain-specific knowledge of LLMs in radiotherapy by assessing their performance on three certification examinations in Japan: the Japanese Medical Physicist Examination, the Japanese Board Examination for Radiologists and the Japanese Board Examination for Radiation Oncologists. We assessed five LLMs—ChatGPT-5, ChatGPT-5 Pro, Grok 4, Grok 4 heavy and Gemini 2.5 Pro—by inputting all multiple-choice questions from these exams into each model and recording their responses. The AI-generated answers were compared with reference answers determined by experienced medical physicists and radiation oncologists. The results demonstrated average accuracies of 84.7 ± 2.0% (ChatGPT-5), 94.7 ± 2.1% (ChatGPT-5 Pro), 78.4 ± 1.2% (Grok 4), 81.6 ± 2.2% (Grok 4 heavy) and 88.9 ± 1.2% (Gemini 2.5 Pro). All models achieved over 75% accuracy, with ChatGPT-5 Pro consistently outperforming others, attaining an average accuracy exceeding 90% across all examinations. These findings highlight the strong potential of advanced LLMs, particularly ChatGPT-5 Pro, for future integration into radiotherapy-related applications such as automated contouring and treatment planning support.
3D Organ Motion Estimation for Radiotherapy through Material Point Method-Driven Extrapolation of Multiple Orthogonal Slices. 国際誌

Ryo Eguchi, Noriyuki Kadoya, Kazuhiro Arai, Taichi Hoshino, Rei Umezawa, Keiichi Jingu, Naoto Ienaga, Yoshihiro Kuroda

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference　2025　1-7　2025年7月

DOI： 10.1109/EMBC58623.2025.11252665 　

詳細を見る詳細を閉じる

This study proposes a novel method for estimating three-dimensional organ motion during radiotherapy using real-time MRI data. The approach combines observations from axial, coronal, and sagittal cross-sectional images with vertical extrapolation and a material point method simulation to generate comprehensive three-dimensional displacement fields. Unlike existing methods that rely primarily on geometric deformation within observed slices, our method assists estimation of motion in all directions, including regions far from the observed planes. The effectiveness of the proposed approach was validated through both phantom experiments and human participant trials. The results suggest improvements in accuracy compared to conventional methods, achieving Dice scores of up to 0.748 in human trials and a minimum estimated error of 5.18 mm, a 22.6% reduction, approaching clinically acceptable thresholds for radiotherapy. The method is particularly promising for organs with complex non-periodic motion patterns, such as the pancreas, where accurate motion tracking is critical for effective treatment delivery.
強度変調放射線治療と画像誘導小線源治療を用いた局所進行子宮頸癌に対する放射線治療成績

梅澤玲, 重田昌吾, 山本貴也, 石橋ますみ, 渋谷祐介, 高橋紀善, 鈴木友, 岸田桂太, 尾股聡, 原田日南子, 島田宗昭, 神宮啓一

日本婦人科腫瘍学会学術講演会プログラム・抄録集　67回　230-230　2025年7月
出版者・発行元： (公社)日本婦人科腫瘍学会
強度変調放射線治療と画像誘導小線源治療を用いた局所進行子宮頸癌に対する放射線治療成績

梅澤玲, 重田昌吾, 山本貴也, 石橋ますみ, 渋谷祐介, 高橋紀善, 鈴木友, 岸田桂太, 尾股聡, 原田日南子, 島田宗昭, 神宮啓一

日本婦人科腫瘍学会学術講演会プログラム・抄録集　67回　230-230　2025年7月
出版者・発行元： (公社)日本婦人科腫瘍学会
Evaluation of deliverable artificial intelligence-based automated volumetric arc radiation therapy planning for whole pelvic radiation in gynecologic cancer. 国際誌

Yushan Xiao, Shohei Tanaka, Noriyuki Kadoya, Kiyokazu Sato, Yuto Kimura, Rei Umezawa, Yoshiyuki Katsuta, Kazuhiro Arai, Haruna Takahashi, Taichi Hoshino, Keiichi Jingu

Scientific reports　15　(1)　15219-15219　2025年4月30日

DOI： 10.1038/s41598-025-99717-y 　

詳細を見る詳細を閉じる

This study aimed to develop a deep learning (DL)-based deliverable whole pelvic volumetric arc radiation therapy (VMAT) for patients with gynecologic cancer using a prototype DL-based automated planning support system, named RatoGuide, to evaluate its clinical validity. In our hospital, 110 patients with gynecologic cancer were registered. The prescribed dose was 50.4 Gy/28 fr. A DL-based three-dimensional dose prediction model was first trained by the dose distribution and structure data of whole pelvic VMAT (n = 100) created on the Monaco treatment planning system (TPS). The structure data of the test data (n = 10) were then input to RatoGuide, and RatoGuide predicted the dose distribution of the whole pelvic VMAT plan (PreDose). We established deliverable plans with Monaco and Eclipse TPS (DeliDose) based on PreDose and vendor-supplied optimization objectives. Medical physicists then manually developed plans (CliDose) for the test data. Finally, we evaluated and compared the dose distribution and dose constraints of PreDose, DeliDose, and CliDose. DeliDose, in both Eclipse and Monaco, was comparable to PreDose in most Dose constraints, planning target volume (PTV) coverage, and Dmax of the bladder, rectum, and bowel bag were better for DeliDose than for PreDose. Additionally, DeliDose demonstrated no significant difference from CliDose in most dose constraints. The blinded average scores of radiation oncologists for DeliDose and CliDose were 4.2 ± 0.4 and 4.3 ± 0.5, respectively, in Eclipse, and 4.0 ± 0.6 and 3.9 ± 0.5, respectively, in Monaco (5 is the max score and 3 is clinically acceptable). We indicated that RatoGuide can eliminate variations in plan quality between hospitals in whole pelvic VMAT irradiation and help develop VMAT plans in a short time.
MR linacにおいて金属があるときの歪み影響の検討

木村智圭, 高橋紀善, 梅澤玲, 山本貴也, 鈴木友, 佐藤清和, 神宮啓一

日本放射線技術学会総会学術大会予稿集　81回　171-171　2025年3月
出版者・発行元： (公社)日本放射線技術学会
ISSN：1884-7846

eISSN：2759-9779
Efficacy and safety of diffusing alpha-emitter radiation therapy (DaRT) for head and neck cancer recurrence after radiotherapy.

Ryo-Ichi Yoshimura, Kazuma Toda, Hiroshi Watanabe, Masahiko Miura, Ryoichi Notake, Naoya Murakami, Hiroshi Igaki, Satoshi Nakamura, Rei Umezawa, Noriyuki Kadoya, Keiichi Jingu, Jun Itami

International journal of clinical oncology　2025年2月19日

DOI： 10.1007/s10147-025-02720-6 　

詳細を見る詳細を閉じる

BACKGROUND: To evaluate the efficacy and safety of diffusing alpha-emitter radiation therapy (DaRT) for recurrent head and neck cancer (rHNC) after radiotherapy. METHODS: This study was a multicenter prospective clinical trial. Eligibility criteria included all patients with biopsy-proven rHNC and history of radiotherapy. The efficacy of DaRT was evaluated in terms of tumor shrinkage after 10 weeks of DaRT seed implantation. To assess safety of DaRT, radioactivity levels in blood and urine were measured, and incidence and grade of adverse events (AEs) were evaluated. RESULTS: Between 2019 and 2021, DaRT was performed in 11 patients and completed in 10 patients with 11 tumors. The tumor sites included the tongue (n = 3), buccal mucosa (2), lips (2), floor of the mouth (1), soft palate (1), nose (1), and subcutaneous layer (1). Nine tumors were confirmed to be squamous cell carcinoma, and the remaining two tumors were basal cell carcinoma and neuroblastoma. Complete response (CR) and partial response (PR) were observed in three and six patients, respectively. The response rate was 81.8%. The maximum average radioactivity levels in blood and urine were 42.5 Bq/cm3 and 8.4 Bq/cm3, respectively, on the second day after implantation. Forty AEs were observed in all 11 patients, including 22 Grade 1 AEs, 16 Grade 2, and 2 Grade 3 (hypertension and seed remnants). CONCLUSION: The initial response of rHNC after radiotherapy to DaRT was favorable, and the incidence and grade of AEs were acceptable, as compared to existing therapies.
Utilization and regional disparities of radiotherapy in cancer treatment in Japan: a longitudinal study using NDB open data. 国際誌

Kazuya Takeda, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Hiroshi Onishi, Keiichi Jingu

Journal of radiation research　66　(1)　82-88　2025年1月22日

DOI： 10.1093/jrr/rrae100 　

詳細を見る詳細を閉じる

The National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) is a database that stores anonymized information on medical receipts and health checkups in Japan. The NDB Open Data is a publicly accessible summary table of the NDB database. To reveal annual trends and regional disparities in radiotherapy utilization in Japan, we analyzed the NDB Open Data tables for a 9-year period from 2014 to 2022. We extracted medical cost codes for radiotherapy management fees and specific types of radiotherapy, such as stereotactic irradiation (STI) and intensity-modulated radiotherapy (IMRT), to analyze nationwide changes over time. To investigate regional disparities, we counted the three subitems representing 3-dimensional conformal radiotherapy (3D-CRT), IMRT, and STI for each prefecture per year. The utilization of advanced radiotherapy techniques, such as IMRT (199% increase), increased, while the use of simpler forms of irradiation, such as 1 or 2-opposite fields irradiation (40% decrease), decreased in the period from 2014 to 2022. Regarding regional disparities, the coefficients of variation in 47 prefectures for 3D-CRT remained relatively stable at 0.17 in 2014 and 0.18 in 2022, while the coefficients of variation for IMRT and STI decreased from 0.64 and 0.39 in 2014 to 0.31 and 0.36 in 2022, respectively. The popularization of IMRT was correlated with the number of certified radiation oncologists in the prefecture. In conclusion, although the utilization of high-precision radiotherapy in Japan has been increasing and regional differences have been diminishing, there are still persistent disparities.
Residual Pattern of the Hyperintense Area on T2-Weighted Magnetic Resonance Imaging After Initial Treatment Predicts the Pattern and Location of Recurrence in Patients with Newly Diagnosed Glioblastoma

Yoshiteru Shimoda, Masayuki Kanamori, Shota Yamashita, Ichiyo Shibahara, Rei Umezawa, Shunji Mugikura, Keiichi Jingu, Ryuta Saito, Yukihiko Sonoda, Toshihiro Kumabe, Hidenori Endo

World Neurosurgery　193　517-532　2025年1月
出版者・発行元： Elsevier BV
DOI： 10.1016/j.wneu.2024.10.012 　

ISSN：1878-8750
本邦における放射線治療利用とその地域間格差 NDB Open Dataを用いた縦断的研究

武田一也, 梅澤玲, 山本貴也, 高橋紀善, 大西洋, 神宮啓一

日本癌治療学会学術集会抄録集　62回　O55-6　2024年10月
出版者・発行元： (一社)日本癌治療学会
Adaptive RT(2)

角谷倫之, 田中祥平, 新井一弘, 高橋紀善, 梅澤玲, 神宮啓一

日本医学放射線学会秋季臨床大会抄録集　60回　S379-S379　2024年9月
出版者・発行元： (公社)日本医学放射線学会
ISSN：0048-0428

eISSN：1347-7951
Craniospinal irradiation for leptomeningeal metastasis of solid tumors: survival analysis and prognostic factors. 国際誌

Kazuya Takeda, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Keiichi Jingu

Journal of radiation research　2024年8月17日

DOI： 10.1093/jrr/rrae059 　

詳細を見る詳細を閉じる

We conducted a study to examine the treatment outcomes and prognostic factors for patients who underwent craniospinal irradiation (CSI) for leptomeningeal metastasis of solid tumors. This retrospective study included patients who received CSI for leptomeningeal metastasis at a single institute between 2010 and 2021. Data from clinical records and the radiation information system were obtained and analyzed. A total of 25 patients were included in the study. Eighteen patients (72%) completed the scheduled CSI. The median overall survival (OS) period was 4.8 months (95% confidence interval (CI): 3.2-10.0 months). Symptom relief was achieved in four out of 23 symptomatic patients (17%). Non-hematological adverse events occurred in 12 patients (48%), with 1 patient (4%) developing Grade 3 bacterial meningitis and the other patients having Grade 1-2 events. Twenty patients (80%) had hematological adverse events of Grade 3 or higher. Grade 4 hematologic toxicities occurred in 3 patients (12%) due to neutropenia and in 11 patients (44%) due to lymphopenia. In multivariate Cox regression analysis, the systemic immune-inflammation index (SII) was identified as the only significant parameter for predicting OS. The median OS periods for patients with SII < 607 and SII ≥ 607 were 6.1 and 2.1 months, respectively (P = 0.003). In conclusion, this study showed the treatment outcomes of CSI for leptomeningeal metastasis of solid tumors. It was shown that a high baseline SII was associated with shorter OS after CSI. The findings will contribute to the evaluation of prognosis after CSI.
Development of deep learning-based novel auto-segmentation for the prostatic urethra on planning CT images for prostate cancer radiotherapy.

Hisamichi Takagi, Ken Takeda, Noriyuki Kadoya, Koki Inoue, Shiki Endo, Noriyoshi Takahashi, Takaya Yamamoto, Rei Umezawa, Keiichi Jingu

Radiological physics and technology　2024年8月14日

DOI： 10.1007/s12194-024-00832-8 　

詳細を見る詳細を閉じる

Urinary toxicities are one of the serious complications of radiotherapy for prostate cancer, and dose-volume histogram of prostatic urethra has been associated with such toxicities in previous reports. Previous research has focused on estimating the prostatic urethra, which is difficult to delineate in CT images; however, these studies, which are limited in number, mainly focused on cases undergoing brachytherapy uses low-dose-rate sources and do not involve external beam radiation therapy (EBRT). In this study, we aimed to develop a deep learning-based method of determining the position of the prostatic urethra in patients eligible for EBRT. We used contour data from 430 patients with localized prostate cancer. In all cases, a urethral catheter was placed when planning CT to identify the prostatic urethra. We used 2D and 3D U-Net segmentation models. The input images included the bladder and prostate, while the output images focused on the prostatic urethra. The 2D model determined the prostate's position based on results from both coronal and sagittal directions. Evaluation metrics included the average distance between centerlines. The average centerline distances for the 2D and 3D models were 2.07 ± 0.87 mm and 2.05 ± 0.92 mm, respectively. Increasing the number of cases while maintaining equivalent accuracy as we did in this study suggests the potential for high generalization performance and the feasibility of using deep learning technology for estimating the position of the prostatic urethra.
Lymphopenia after palliative radiotherapy for vertebral metastases. 国際誌

Kazuya Takeda, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Yu Suzuki, Keita Kishida, So Omata, Keiichi Jingu

Journal of radiation research　65　(4)　523-531　2024年7月22日

DOI： 10.1093/jrr/rrae038 　

詳細を見る詳細を閉じる

Lymphopenia is a well-known side effect of radiotherapy and has been shown to have a negative impact on patient outcomes. However, the extent of lymphopenia caused by palliative radiotherapy and its effect on patient prognosis has not been clarified. The aim of this study was to determine the incidence and severity of lymphopenia after palliative radiotherapy for vertebral metastases and to determine their effects on patients' survival outcomes. We conducted a retrospective analysis for patients who underwent palliative radiotherapy for vertebral metastases and could be followed up for 12 weeks. Lymphocyte counts were documented at baseline and throughout the 12-week period following the start of radiotherapy and their medians and interquartile ranges (IQRs) were recorded. Exploratory analyses were performed to identify predictive factors for lymphopenia and its impact on overall survival (OS). A total of 282 cases that met the inclusion criteria were analyzed. The median baseline lymphocyte count was 1.26 × 103/μl (IQR: 0.89-1.72 × 103/μl). Peak lymphopenia occurred at a median of 26 days (IQR: 15-45 days) with a median nadir of 0.52 × 103/μl (IQR: 0.31-0.81 × 103/μl). Long-term analysis of patients surviving for 1 year showed that lymphopenia persisted at 1 year after radiotherapy. The main irradiation site, radiation field length and pretreatment lymphocyte count were significantly related to grade 3 or higher lymphopenia. Lymphopenia was identified as a significant predictor of OS by multivariate Cox regression analysis. This study demonstrated the incidence of lymphopenia after palliative radiotherapy for vertebral metastases and its effect on patients' OS.
Impact of dose distribution by a 3D planning system for brachytherapy with 198Au grains for head and neck cancer. 国際誌

Keita Kishida, Keiichi Jingu, Kengo Ito, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Yu Suzuki, So Omata, Hinako Harada, Yasuhiro Seki, Nanae Chiba, Shinsaku Okuda

Head & neck　2024年7月16日

DOI： 10.1002/hed.27874 　

詳細を見る詳細を閉じる

BACKGROUND: There has been no study in which the correlation between clinical results and dosimetry based on a 3D treatment planning system in patients with 198Au grains for head and neck cancer was evaluated. METHODS: Thirty-two patients who were treated with 198Au grains for head and neck cancer were reviewed. Twenty-five patients were treated with brachytherapy alone and seven patients were treated with a combination of brachytherapy and neoadjuvant external beam radiation therapy. RESULTS: With a median observation period of 60 months, the 5-year local control rate was 82.9%. V85Gy of CTV in patients with local recurrence tended to be lower than that in patients without local recurrence (p = 0.07). The maximum dose of the keratinized gingiva in patients in whom bone exposure occurred was significantly higher than that in patients in whom bone exposure did not occur (p = 0.001). CONCLUSIONS: Dose distribution with 198Au grains can predict local control and late adverse events.
膵癌における予防域を含めた定位放射線治療の安全性をみる第I相臨床試験

梅澤玲, 水間正道, 中川圭, 勝田義之, 田中祥平, 高橋紀善, 海野倫明, 神宮啓一

膵臓　39　(3)　A454-A454　2024年7月
出版者・発行元： (一社)日本膵臓学会
ISSN：0913-0071

eISSN：1881-2805
患者報告アウトカムを用いた上咽頭癌照射後の長期QOL評価について

原田日南子, 田坂俊, 梅澤玲, 山本貴也, 高橋紀善, 鈴木友, 岸田桂太, 尾股聡, 神宮啓一

頭頸部癌　50　(2)　171-171　2024年5月
出版者・発行元： (一社)日本頭頸部癌学会
ISSN：1349-5747

eISSN：1881-8382
頭頸部癌に対するAu198グレインによる放射線治療成績

神宮啓一, 岸田桂太, 原田日南子, 鈴木友, 梅澤玲, 山本貴也, 高橋紀善, 尾股聡, 関康宏, 千葉菜々絵, 奥田晋作

頭頸部癌　50　(2)　189-189　2024年5月
出版者・発行元： (一社)日本頭頸部癌学会
ISSN：1349-5747

eISSN：1881-8382
【腫瘍循環器学-新しい学際領域の最新知見-】CTR-CVTの病態と機序放射線治療に伴う心血管障害の病態と機序

梅澤玲, 神宮啓一

日本臨床　82　(増刊2 腫瘍循環器学)　157-162　2024年4月
出版者・発行元： (株)日本臨床社
ISSN：0047-1852
Lymphocytopenia following adjuvant radiotherapy for breast cancer

Kazuya Takeda, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Yu Suzuki, Keita Kishida, So Omata, Keiichi Jingu

Precision Radiation Oncology　8　(1)　22-29　2024年3月

DOI： 10.1002/pro6.1221 　

eISSN：2398-7324
Beginning of clinical treatment using the 1.5 Tesla MR-Linac system in Japan: a narrative review. 国際誌

Noriyoshi Takahashi, Shohei Tanaka, Rei Umezawa, Takaya Yamamoto, Yu Suzuki, Keita Kishida, So Omata, Kazuhiro Arai, Yoshiyuki Katsuta, Noriyuki Kadoya, Keiichi Jingu

Translational cancer research　13　(2)　1131-1138　2024年2月29日

DOI： 10.21037/tcr-23-1649 　

詳細を見る詳細を閉じる

BACKGROUND AND OBJECTIVE: In the field of radiation therapy, image-guided radiotherapy (IGRT) technology has been gradually improving and highly accurate radiation treatment has been possible. Research on IGRT using 1.5 Tesla magnetic resonance imaging (MRI) began in 1999, and a radiation therapy device called 1.5 Tesla magnetic resonance linear accelerator (MR-Linac), which combines a linear accelerator with 1.5 Tesla MRI, was developed in Europe. The aim of this review is to present an overview of 1.5 Tesla MR-Linac with a review of the literature and our experience. METHODS: Reports related to 1.5 Tesla MR-Linac were searched for in PubMed and are discussed in relation to our experience. KEY CONTENT AND FINDINGS: The 1.5 Tesla MR-Linac enables IGRT using 1.5 Tesla MRI, further enhancing the precision of radiation therapy. Position verification by cone-beam computed tomography (CBCT) is performed in many institutions, but soft tissue contrast is often unclear in CBCT images of the abdomen and mediastinal organs. Since the 1.5 Tesla MR-Linac allows position verification using MRI, position verification can be performed using clear MRI even in regions where CBCT is unclear. With the 1.5 Tesla MR-Linac, it is possible to perform online adaptive radiotherapy (ART) using 1.5 Tesla MRI. Online ART is a method in which images are acquired while the patient is on the treatment table. The method is based on the current condition of the organs in the body on that day and an optimal treatment field is recreated. Additionally, it allows monitoring of tumor motion using cine images obtained by 1.5 Tesla MRI during the delivery of X-ray radiation. A previous report showed that patients with prostate cancer who received radiotherapy by MR-Linac had fewer side effects than those in patients who received conventional CBCT radiation therapy. CONCLUSIONS: The 1.5 Tesla MR-Linac obtained CE-mark certification in Europe in August 2018 and it has been used for clinical treatment. In Japan, clinical treatment using this device started in 2021. By using 1.5 Tesla MR-Linac, patients can be provided with higher precision radiotherapy. In this review, we provide an overview of 1.5 Tesla MR-Linac.
新型コロナウイルスワクチン接種後に放射線リコール現象が疑われた2症例

石川陽二郎, 梅澤玲, 山本貴也, 高橋紀善, 鈴木友, 神宮啓一, 伊藤謙吾, 古積麻衣子, 山田隆之

Japanese Journal of Radiology　42　(Suppl.)　3-3　2024年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
腎がん定位照射後にChronic expanding hematomaをきたした1例

石川陽二郎, 梅澤玲, 山本貴也, 高橋紀善, 鈴木友, 神宮啓一, 伊藤謙吾, 寺村聡司, 山田隆之

Japanese Journal of Radiology　42　(Suppl.)　7-7　2024年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
食道類基底細胞癌に根治的化学放射線療法を行った1例

奥田晋作, 石川陽二郎, 梅澤玲, 山本貴也, 高橋紀善, 鈴木友, 神宮啓一, 奥田晋作, 伊藤謙吾, 寺村聡司, 山田隆之

Japanese Journal of Radiology　42　(Suppl.)　10-10　2024年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
Current status of remote radiotherapy treatment planning in Japan: findings from a national survey†. 国際誌

Masahide Saito, Tetsuro Tamamoto, Shohei Kawashiro, Rei Umezawa, Masaki Matsuda, Naoki Tohyama, Yoshiyuki Katsuta, Takayuki Kanai, Hikaru Nemoto, Hiroshi Onishi

Journal of radiation research　65　(1)　127-135　2024年1月19日

DOI： 10.1093/jrr/rrad085 　

詳細を見る詳細を閉じる

The purpose of this study was to investigate the status of remote-radiotherapy treatment planning (RRTP) in Japan through a nationwide questionnaire survey. The survey was conducted between 29 June and 4 August 2022, at 834 facilities in Japan that were equipped with linear accelerators. The survey utilized a Google form that comprised 96 questions on facility information, information about the respondent, utilization of RRTP between facilities, usage for telework and the inclination to implement RRTPs in the respondent's facility. The survey analyzed the utilization of the RRTP system in four distinct implementation types: (i) utilization as a supportive facility, (ii) utilization as a treatment facility, (iii) utilization as a teleworker outside of the facility and (iv) utilization as a teleworker within the facility. The survey response rate was 58.4% (487 facilities responded). Among the facilities that responded, 10% (51 facilities) were implementing RRTP. 13 served as supportive facilities, 23 as treatment facilities, 17 as teleworkers outside of the facility and 5 as teleworkers within the facility. In terms of system usage between supportive and treatment facilities, 70-80% of the participants utilized the system for emergencies or as overtime work for external workers. A substantial number of facilities (38.8%) reported that they were unfamiliar with RRTP implementation. The survey showed that RRTP utilization in Japan is still limited, with a significant number of facilities unfamiliar with the technology. The study highlights the need for greater understanding and education about RRTP and financial funds of economical compensation.
Investigation of intrafractional spinal cord and spinal canal movement during stereotactic MR-guided online adaptive radiotherapy for kidney cancer. 国際誌

Takaya Yamamoto, Shohei Tanaka, Noriyoshi Takahashi, Rei Umezawa, Yu Suzuki, Keita Kishida, So Omata, Kazuya Takeda, Hinako Harada, Kiyokazu Sato, Yoshiyuki Katsuta, Noriyuki Kadoya, Keiichi Jingu

PloS one　19　(10)　e0312032　2024年

DOI： 10.1371/journal.pone.0312032 　

詳細を見る詳細を閉じる

BACKGROUND AND PURPOSE: This study aimed to investigate the intrafractional movement of the spinal cord and spinal canal during MR-guided online adaptive radiotherapy (MRgART) for kidney cancer. MATERIALS AND METHODS: All patients who received stereotactic MRgART for kidney cancer between February 2022 and February 2024 were included in this study. Patients received 30-42 Gy in 3-fraction MRgART for kidney cancer using the Elekta Unity, which is equipped with a linear accelerator and a 1.5 Tesla MRI. MRI scans were performed at three points during each fraction: for online planning, position verification, and posttreatment assessment. The spinal cord was contoured from the upper edge of Th12 to the medullary cone, and the spinal canal was contoured from Th12 to L3, using the first MRI. These contours were adjusted to the second and third MR images via deformable image registration, and movements were measured. Margins were determined via the formula "1.3×Σ+0.5×σ" and 95% prediction intervals. RESULTS: A total of 22 patients (66 fractions) were analyzed. The median interval between the first and third MRI scans were 38 minutes. The mean ± standard deviation of the spinal cord movements after this interval were -0.01 ± 0.06 for the x-axis (right-left), 0.01 ± 0.14 for the y-axis (caudal-cranial), 0.07 ± 0.05 for the z-axis (posterior-anterior), and 0.15 ± 0.08 for the 3D distance, respectively. The correlation coefficients of the 3D distance between the spinal cord and the spinal canal was high (0.92). The calculated planning organ at risk volume margin for all directions was 0.11 cm for spinal cord. The 95% prediction intervals for the x-axis, y-axis, and z-axis were -0.11-0.09 cm, -0.23-0.25 cm and -0.14-0.03 cm, respectively. CONCLUSIONS: Margins are necessary in MRgART to compensate for intrafractional movement and ensure safe treatment delivery.
VMAT with DIBH in hypofractionated radiotherapy for left-sided breast cancer after breast-conserving surgery: results of a non-inferiority clinical study. 国際誌

Keiichi Jingu, Kengo Ito, Kiyokazu Sato, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Yu Suzuki, Keita Kishida, So Omata, Hinako Harada, Yasuhiro Seki, Nanae Chiba, Noriyuki Kadoya

Journal of radiation research　2023年12月12日

DOI： 10.1093/jrr/rrad096 　

詳細を見る詳細を閉じる

The purpose of this study was to show the safety of volumetric modulated arc therapy (VMAT) with deep inspiration breath-hold (DIBH) in hypofractionated radiotherapy for left-sided breast cancer after breast-conserving surgery in a clinical setting. Twenty-five Japanese women, aged 20-59 years, who were enrolled in this prospective non-inferiority study received VMAT under the condition of DIBH with 42.4 Gy/16 fractions for whole-breast irradiation (WBI) ± boost irradiation for the tumor bed to show the non-inferiority of VMAT with DIBH to conventional fractionated WBI with free breathing. The primary endpoint was the rate of occurrence of radiation dermatitis of Grade 3 or higher or pneumonitis of Grade 2 or higher within 6 months after the start of radiotherapy. This study was registered with UMIN00004321. All of the enrolled patients completed the planned radiotherapy without interruption. The evaluation of adverse events showed that three patients (12.0%) had Grade 2 radiation dermatitis. There was no other Grade 2 adverse event and there was no patient with an adverse event of Grade 3 or higher. Those results confirmed our hypothesis that the experimental treatment method is non-inferior compared with our historical results. There was no patient with locoregional recurrence or metastases. In conclusion, VMAT under the condition of DIBH in hypofractionated radiotherapy for left-sided breast cancer after breast-conserving surgery can be performed safely in a clinical setting.
Pre-treatment Evaluation of Patients Eligible for Whole Brain Radiation Therapy: The Risk of Hippocampal Metastases in a Retrospective Study of 248 Cases at a Single Institution. 国際誌

Yojiro Ishikawa, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Keita Kishida, Satoshi Teramura, Kengo Ito, Keiichi Jingu

Cureus　15　(11)　e49170　2023年11月

DOI： 10.7759/cureus.49170 　

詳細を見る詳細を閉じる

Whole brain radiation therapy (WBRT) is effective for multiple brain metastases (BMs) but may impair neurocognitive function (NCF). The incidence of hippocampal metastasis (HM) is low, and the factors associated with the occurrence of HM remain unclear. This study aimed to assess the occurrence of limbic system metastasis (LSM), including HM, and to analyze the risk of HM. We retrospectively analyzed 248 patients who underwent three-dimensional conformal radiation therapy for BMs between May 2008 and October 2015. Gadolinium-enhanced brain MRI or CT scans were used for diagnosis. Statistical analysis involved assessing clinical factors, including age, gender, primary tumor, number of BMs, and maximum metastasis diameter, in relation to the presence of HMs using logistic regression and receiver operating characteristic (ROC) curve analysis. The median age at treatment was 62 years (range: 11-83 years). Primary lesion sites included the lung (n = 150; 60.5%), breast (n = 45; 18.1%), gastrointestinal tract (n = 18; 7.3%), and bone and soft tissue (n = 2; 0.8%). Histological cancer types included adenocarcinoma (n = 113; 45.6%), squamous cell carcinoma (n = 26; 10.5%), small cell carcinoma (n = 28; 11.3%), invasive ductal carcinoma (n = 35; 14.1%), sarcoma (n = 3; 1.2%), and others (n = 43; 17.3%). MRI or CT scans of the 248 patients were analyzed, indicating a total count of 2,163 brain metastases (median: five metastases per patient). HMs were identified in 18 (7.3%) patients. The most common location for LSMs was the cingulum/cingulate gyrus in 26 (10.5%) patients. In univariate and multivariate analyses, patients with 15 or fewer BMs had a significantly lower incidence of HMs (odds ratio (OR), 0.018 (95% confidence interval (CI), 0.030-0.24)) (p < 0.0001). A maximal tumor size of less than 2 cm significantly increased the incidence of HMs (OR, 13.8 (95%CI, 1.80-105.3)) (p = 0.0003). The presence of cingulum/cingulate gyrus metastases also demonstrated a significant increase in the incidence of HMs (OR, 9.42 (95%CI, 3.30-26.84)) (p < 0.0001). The present study has uncovered a novel association between a high number of metastases in the cingulate gyrus and the development of HMs. Patients with BMs eligible for WBRT with metastases in the cingulate gyrus may be at risk of developing HM.
【IGRT今後の展開】エレクタUnityの装置導入と1年半の臨床経験

角谷倫之, 田中祥平, 佐藤清和, 新井一弘, 高橋紀善, 梅澤玲, 神宮啓一

Rad Fan　21　(13)　48-52　2023年11月
出版者・発行元： (株)メディカルアイ
ISSN：1348-3498
The Impact of Pathological Grade Group 3 on Relapse-free Survival After Salvage Radiotherapy for Postoperative Prostate Cancer. 国際誌

Takaya Yamamoto, Rei Umezawa, Shuichi Shimada, Noriyoshi Takahashi, Kazuya Takeda, Y U Suzuki, Keita Kishida, S O Omata, Yuta Sato, Hinako Harada, Akihiro Ito, Keiichi Jingu

Anticancer research　43　(11)　5115-5125　2023年11月

DOI： 10.21873/anticanres.16712 　

詳細を見る詳細を閉じる

BACKGROUND/AIM: This retrospective study aimed to investigate the outcomes of relapse-free survival (RFS) after salvage radiation therapy (SRT) to the prostate bed for postoperative biochemical recurrence of prostate cancer. PATIENTS AND METHODS: A total of 87 patients were analyzed. There were 27, 32, and 24 patients with pathological grade groups of 1-2, 3, and 4-5, respectively. SRT doses of 64, 66 or 70 Gy were administered to 24, 3 and 60 patients, respectively. The Kaplan-Meier method was used to estimate time-to-event outcomes. The multiple imputations method was used to impute missing values, and Cox proportional-hazards models were applied for multivariate analyses. RESULTS: The median follow-up period for patients overall was 58.6 months. The 5-year RFS rates of the whole cohort was 59.4% and those for pathological grade groups 1-2, 3 and 4-5 were 88.9%, 37.7% and 39.5%, respectively. In multivariate analyses, higher pathological grade group [4-5 vs. 3 vs. 1-2: hazard radio (HR)=8.65, p<0.01], negative surgical resection margin (positive vs. negative: HR=0.41, p=0.02) and higher pre-salvage treatment serum prostate-specific antigen (cutoff value 0.31 ng/ml: HR=3.50, p<0.01) were significantly associated with poorer RFS. The cumulative incidences of grade 2 or more late rectal bleeding and late hematuria were 4.9% and 8.7%, respectively, at 5 years and 4.9% and 15.7%, respectively, at 8 years. These toxicities occurred only in the 70 Gy-treated arm. CONCLUSION: Our study revealed that pathological grade group 3 prostate cancer patients experienced moderately unfavorable RFS after SRT. Higher radiation doses might increase late toxicities without improving RFS.
放射線治療を受けた椎体転移患者における予後予測因子の検討

武田一也, 梅澤玲, 山本貴也, 高橋紀善, 鈴木友, 岸田桂太, 尾股聡, 神宮啓一

日本癌治療学会学術集会抄録集　61回　P32-4　2023年10月
出版者・発行元： (一社)日本癌治療学会
Glasgow prognostic score for assessing the efficacy of whole-brain radiation therapy in cases of recursive partitioning analysis class 2 and class 3 multiple brain metastases: a retrospective study. 国際誌

Yojiro Ishikawa, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Keita Kishida, So Omata, Satoshi Teramura, Kengo Ito, Takayuki Yamada, Keiichi Jingu

Acta neurologica Belgica　2023年9月25日

DOI： 10.1007/s13760-023-02384-x 　

詳細を見る詳細を閉じる

PURPOSE: Whole-brain radiotherapy (WBRT) may not be beneficial for patients with brain metastases (BMs). The Glasgow Prognostic Score (GPS) is a suggested prognostic factor for malignancies. However, GPS has never been assessed in patients with BMs who have undergone WBRT. The purpose of this study was to determine whether GPS can be used to identify subgroups of patients with BMs who have a poor prognosis, such as recursive partitioning analysis (RPA) Class 2 and Class 3, and who will not receive clinical prognostic benefits from WBRT. MATERIALS AND METHODS: A total of 180 Japanese patients with BMs were treated with WBRT between May 2008 and October 2015. We examined GPS, age, Karnofsky Performance Status (KPS), RPA, graded prognostic assessment (GPA), number of lesions, tumor size, history of brain surgery, presence of clinical symptoms, and radiation doses. RESULTS: The overall median survival time (MST) was 6.1 months. seventeen patients (9.4%) were alive more than 2 years after WBRT. In univariate analysis, KPS ≤ 70 (p = 0.0066), GPA class 0-2 (p = 0.0008), > 3 BMs (p = 0.012), > 4 BMs (p = 0.02), patients who received ≥ 3 Gy per fraction (p = 0.0068), GPS ≥ 1 (p = 0.0003), and GPS ≥ 2 (p = 0.0009) were found to significantly decrease the MST. Patients who had brain surgery before WBRT (p = 0.036) had a longer survival. On multivariate analysis, GPS ≥ 1 (p = 0.008) was found to significantly decrease MST. CONCLUSION: Our results suggest that GPS ≥ 1 indicates a poor prognosis in patients undergoing WBRT for intermediate and poor prognosis BMs.
Acute hematologic toxicity of radiation therapy - a comprehensive analysis and predictive nomogram. 国際誌

Kazuya Takeda, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Yu Suzuki, Keita Kishida, So Omata, Keiichi Jingu

Journal of radiation research　2023年9月22日

DOI： 10.1093/jrr/rrad069 　

詳細を見る詳細を閉じる

To investigate radiation-induced cytopenia and establish predictive nomograms for hematological toxicity, we reviewed 3786 patients aged 18 or older who received radiation monotherapy between 2010 and 2021 for non-hematologic malignancies. We collected data on patient background, treatment content and hematologic toxicities for 12 weeks after the start of radiotherapy. The patients were randomly divided into training and test groups in 7:3 ratio. In the training group, we conducted ordered logistic regression analysis to identify predictive factors for neutropenia, lymphocytopenia, anemia and thrombocytopenia. Nomograms to predict Grade 2-4 cytopenia were generated and validated in the test group. Grade 3 or higher hematologic toxicities were observed in 9.7, 44.6, 8.3 and 3.1% of patients with neutropenia, lymphocytopenia, anemia and thrombocytopenia, respectively. We identified six factors for neutropenia grade, nine for lymphocytopenia grade and six for anemia grade with statistical significance. In the analysis of thrombocytopenia, the statistical model did not converge because of a small number of events. Nomograms were generated using factors with high predictive power. In evaluating the nomograms, we found high area under the receiver operating characteristic curve values (neutropenia; 0.75-0.85, lymphopenia; 0.89-0.91 and anemia; 0.85-0.86) in predicting Grade 2-4 cytopenia in the test group. We established predictive nomograms for neutropenia, leukocytopenia and anemia and demonstrated high reproducibility when validated in an independent cohort of patients.
Evaluation of deep learning-based deliverable VMAT plan generated by prototype software for automated planning for prostate cancer patients. 国際誌

Noriyuki Kadoya, Yuto Kimura, Ryota Tozuka, Shohei Tanaka, Kazuhiro Arai, Yoshiyuki Katsuta, Hidetoshi Shimizu, Yuto Sugai, Takaya Yamamoto, Rei Umezawa, Keiichi Jingu

Journal of radiation research　64　(5)　842-849　2023年8月22日

DOI： 10.1093/jrr/rrad058 　

詳細を見る詳細を閉じる

This study aims to evaluate the dosimetric accuracy of a deep learning (DL)-based deliverable volumetric arc radiation therapy (VMAT) plan generated using DL-based automated planning assistant system (AIVOT, prototype version) for patients with prostate cancer. The VMAT data (cliDose) of 68 patients with prostate cancer treated with VMAT treatment (70-74 Gy/28-37 fr) at our hospital were used (n = 55 for training and n = 13 for testing). First, a HD-U-net-based 3D dose prediction model implemented in AIVOT was customized using the VMAT data. Thus, a predictive VMAT plan (preDose) comprising AIVOT that predicted the 3D doses was generated. Second, deliverable VMAT plans (deliDose) were created using AIVOT, the radiation treatment planning system Eclipse (version 15.6) and its vender-supplied objective functions. Finally, we compared these two estimated DL-based VMAT treatment plans-i.e. preDose and deliDose-with cliDose. The average absolute dose difference of all DVH parameters for the target tissue between cliDose and deliDose across all patients was 1.32 ± 1.35% (range: 0.04-6.21%), while that for all the organs at risks was 2.08 ± 2.79% (range: 0.00-15.4%). The deliDose was superior to the cliDose in all DVH parameters for bladder and rectum. The blinded plan scoring of deliDose and cliDose was 4.54 ± 0.50 and 5.0 ± 0.0, respectively (All plans scored ≥4 points, P = 0.03.) This study demonstrated that DL-based deliverable plan for prostate cancer achieved the clinically acceptable level. Thus, the AIVOT software exhibited a potential for automated planning with no intervention for patients with prostate cancer.
Recent Postoperative Radiotherapy for Left-sided Breast Cancer Does Not Increase Mortality of Heart Disease in Asians or Pacific Islanders: SEER Database Analysis. 国際誌

Keiichi Jingu, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Y U Suzuki, Keita Kishida, S O Omata, Hiroaki Ogawa, Yuta Sato, Hinako Harada, Yasuhiro Seki

Anticancer research　43　(8)　3571-3577　2023年8月

DOI： 10.21873/anticanres.16535 　

詳細を見る詳細を閉じる

BACKGROUND/AIM: The purpose of this study was to evaluate the impact of recent radiotherapy on mortality from heart disease in Asians or Pacific islanders with breast cancer using the Surveillance, Epidemiology, and End Results (SEER) database. PATIENTS AND METHODS: Asians or Pacific islanders with stage 0 or I (AJCC 6th) breast cancer between 2000 and 2015 were analyzed. The impact of radiotherapy for mortality from heart disease after treatment was evaluated by comparing patients who received radiotherapy for left-sided breast cancer, patients who received radiotherapy for right-sided breast cancer and patients who did not receive radiotherapy. RESULTS: In 25,684 Asians or Pacific islanders, the incidence of cardiac death was higher in patients who did not receive radiotherapy than in patients who received radiotherapy. Among patients who received external beam irradiation, the incidence of cardiac death was 2.00% for patients with left-sided breast cancer and 1.69% for patients with right-sided breast cancer, with no significant difference (chi-square test, p=0.427). In the period from 2000 to 2008, there was no significant difference between the cumulative heart-related death rates in patients who received radiotherapy and in patients who did not receive radiotherapy (Tarone-Ware test, p=0.406); however, in 2009-2015, the cumulative heart-related death rate in patients who did not receive radiotherapy was significantly higher than that in patients who received radiotherapy (log-rank test, p<0.001). CONCLUSION: Heart-related death after treatment for breast cancer is relatively rare in Asians or Pacific islanders. Since at least 2000, the cardiac impact of postoperative radiotherapy has not been significant.
Development of a prediction model for head and neck volume reduction by clinical factors, dose-volume histogram parameters and radiomics in head and neck cancer 査読有り

Ishizawa M, Tanaka S, Takagi H, Kadoya N, Sato K, Umezawa R, Jingu K, Takeda K

J Radiat Res　2023年7月18日

DOI： 10.1093/jrr/rrad052 　
Clinical impact of multimodal treatment including chemoradiotherapy, conversion surgery and postoperative chemotherapy for borderline resectable and unresectable locally advanced pancreatic cancer without disease progression after gemcitabine plus nab-paclitaxel. 国際誌

Rei Umezawa, Masamichi Mizuma, Kei Nakagawa, Takaya Yamamoto, Noriyoshi Takahashi, Yu Suzuki, Keita Kishida, So Omata, Michiaki Unno, Keiichi Jingu

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]　2023年7月4日

DOI： 10.1016/j.pan.2023.07.002 　

詳細を見る詳細を閉じる

BACKGROUND: The purpose of this study was to investigate treatment outcomes of chemoradiotherapy (CRT) using S-1 with or without conversion surgery after gemcitabine plus nab-paclitaxel (GnP) for borderline resectable (BR) and unresectable locally advanced (UR-LA) pancreatic cancer. METHODS: From 2016 to 2020, patients without disease progression after GnP for BR or UR-LA pancreatic cancer underwent CRT with S-1. If distant metastasis was not detected after CRT, conversion surgery and oral administration of S-1 as postoperative adjuvant chemotherapy for at least 6 months was performed. RESULTS: Forty patients were included in the present study. The median number of cycles of GnP was 6. Surgery was performed after CRT in 25 patients. The median progression-free survival (PFS) and overall survival (OS) periods from the start of radiotherapy were 24.6 and 27.4 months, respectively. The OS periods from the start of radiotherapy in patients who underwent conversion surgery and those who did not undergo conversion surgery were 41.3 and 16.8 months, respectively. The PFS periods from the start of radiotherapy in patients who underwent surgery and those who did not undergo surgery were 28.3 and 8.6 months, respectively. Patients who were able to receive S-1 after conversion surgery for more than 6 months had better OS than those who were not (p = 0.039), although there was no significant difference of PFS (p = 0.365). CONCLUSIONS: In BR/UR-LA pancreatic cancer without disease progression after GnP, multimodal treatment including CRT, conversion surgery and the scheduled postoperative chemotherapy may be effective.
Clinical impact of radiation-induced myocardial damage detected by cardiac magnetic resonance imaging and dose-volume histogram parameters of the left ventricle as prognostic factors of cardiac events after chemoradiotherapy for esophageal cancer. 国際誌

Rei Umezawa, Hideki Ota, Hidenobu Takagi, Noriyuki Kadoya, Yujiro Nakajima, Noriyoshi Takahashi, Takaya Yamamoto, Kei Takase, Keiichi Jingu

Journal of radiation research　64　(4)　702-710　2023年6月12日

DOI： 10.1093/jrr/rrad040 　

詳細を見る詳細を閉じる

This prospective study aimed to evaluate whether radiation (RT)-induced myocardial damage by cardiac magnetic resonance (CMR) imaging could be a predictor of cardiac events after chemoradiotherapy (CRT) for esophageal cancer and determine the dose-volume histogram (DVH) parameters of the left ventricle (LV) in predicting cardiac events. CMR imaging was performed before and 6 months after CRT in patients receiving definitive CRT. RT-induced myocardial damage was defined as abnormal CMR findings indicating myocardial fibrosis corresponding to an isodose line of ≥30 Gy. The cutoff values of the LV DVH parameters were calculated using the receiver operating characteristic curve based on the presence of RT-induced myocardial damage. The prognostic factors related to cardiac events of Grade 3 or higher were examined. Twenty-three patients were enrolled in the study. RT-induced myocardial damage by late gadolinium enhancement and/or an increase of 100 ms or higher in native T1 post-CRT was detected in 10 of the 23 patients. LV V45 was the best predictive factor for RT-induced myocardial damage with a cutoff value of 2.1% and an area under the curve of 0.75. The median follow-up period was 82.1 months. The 5- and 7-year cumulative incidences of cardiac events of Grade 3 or higher were 14.7 and 22.4%, respectively. RT-induced myocardial damage and LV V45 were significant risk factors (P = 0.015 and P = 0.013, respectively). RT-induced myocardial damage is a significant predictor of cardiac events. LV V45 is associated with RT-induced myocardial damage and subsequent cardiac events.
当院で行ったcT1N0M0食道扁平上皮癌に対する手術治療と化学放射線療法の比較検討

岡本宏史, 谷山裕亮, 佐藤千晃, 小澤洋平, 石田裕嵩, 小関健, 加藤伸史, 高橋紀善, 梅澤玲, 神宮啓一, 亀井尚

日本食道学会学術集会プログラム・抄録集　77回　132-132　2023年6月
出版者・発行元： (NPO)日本食道学会
Definitive radiotherapy consisting of external beam radiotherapy without central shielding and 3D image-guided brachytherapy for patients with cervical cancer: feasibility for Japanese patients and dose-response analyses for local control in the low-dose range. 国際誌

Takafumi Toita, Kentaro Wada, Shinya Sutani, Rei Umezawa, Hitoshi Maemoto, Noriko Ii, Tomoko Kawamura, Hitoshi Ikushima, Ryosuke Takenaka, Koji Konishi, Atsunori Yorozu, Keiichi Jingu, Takuro Ariga, Yoshihito Nomoto, Hideomi Yamashita

Japanese journal of clinical oncology　2023年3月27日

DOI： 10.1093/jjco/hyad022 　

詳細を見る詳細を閉じる

OBJECTIVE: To assess the feasibility of external beam radiotherapy without central shielding in definitive radiotherapy for Japanese patients with cervical cancer. METHODS: We retrospectively analysed the data of cervical cancer patients treated with definitive radiotherapy consisting of external beam radiotherapy without central shielding and three-dimensional-image-guided brachytherapy. RESULTS: The study included 167 patients (T1 + 2 = 108, T3 + 4 = 59) from eight Japanese institutions. For three-dimensional-image-guided brachytherapy, intra-cavitary and interstitial brachytherapy was utilized in 33 patients (20%). The median follow-up was 26.6 months (interquartile range, 20-43.2). The maximum rectal D2 (75 Gy)/bladder D2 (90 Gy) constraints were deviated by 6%/10% and 10%/5% for T1 + 2 and T3 + 4, respectively. The 2-year incidence of ≥grade 3 proctitis/cystitis was 4%/1% for T1 + 2 and 10%/2% for T3 + 4. The 2-year local progression-free survival was 89% for T1 + 2 and 82% for T3 + 4. For T1 + 2, the 2-year local progression-free survival for the high-risk clinical target volume D90 ≥ 68 Gy (indicated by receiver operating characteristic analysis; area under the curve = 0.711) was 92% versus 67% for <68 Gy (log-rank; P = 0.019). Cox multivariate analysis indicated that the high-risk clinical target volume D90 was one of independent predictors of local failure (P = 0.0006). For T3 + 4, the 2-year local progression-free survival was 87% for the high-risk clinical target volume <82 cm3 (area under the curve = 0.67) and 43% for ≥82 cm3 (P = 0.0004). Only the high-risk clinical target volume was an independent predictor of local failure (P = 0.0024). CONCLUSIONS: Definitive radiotherapy consisting of external beam radiotherapy without central shielding and three-dimensional-image-guided brachytherapy was feasible for Japanese patients with cervical cancer. Dose de-escalation from the current global standards is suggested for patients with T1 + 2 disease.
Cardiac impacts of postoperative radiotherapy for breast cancer in Japanese patients. 国際誌

Erika Segawa, Keiichi Jingu, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Noriyuki Kadoya, Ken Takeda

Journal of radiation research　2023年3月22日

DOI： 10.1093/jrr/rrad013 　

詳細を見る詳細を閉じる

Radiotherapy for breast cancer has attracted attention in Western countries because radiation to the heart can cause cardiac events. The purposes of this study were to evaluate the relationship between radiotherapy after breast-conserving surgery and the frequency of cardiac events in Japanese patients and to investigate the risk factors of cardiac events after postoperative radiotherapy in those patients. Female patients who received postoperative radiotherapy following breast-conserving surgery between 2007 and 2012 at our hospital were evaluated. In this study, we estimated the cumulative incidence of cardiac events including angina pectoris, myocardial infarction, ischemic heart disease, heart failure and cardiomyopathy after radiotherapy. Of 311 eligible patients, 7.1% of the patients had a smoking history, 20.3% of the patients were obese and 22.2% of the patients had hypertension. The median follow-up period was 118 months (interquartile range, 102-132 months). Twelve patients (3.9%) experienced cardiac events after treatment. The mean time to cardiac events was 126 months. The 10-year cumulative incidences of cardiac events after treatment were 4.2% and 4.3% for patients with left-sided and right-sided breast cancer, respectively, without a significant difference. Multivariate analysis showed that only hypertension was a risk factor for cardiac events (hazard ratio = 16.67, P = 0.0003). In conclusion, postoperative radiotherapy for breast cancer did not increase the incidence of cardiac events. Since at least 2007, postoperative radiotherapy for breast cancer has been safely performed without effects on the heart.
Hands-on seminar for image-guided adaptive brachytherapy and intracavitary/interstitial brachytherapy for uterine cervical cancer. 国際誌

Naoya Murakami, Koji Masui, Ken Yoshida, Shin-Ei Noda, Miho Watanabe, Tadashi Takenaka, Noriko Ii, Kazushige Atsumi, Rei Umezawa, Koji Inaba, Kotaro Iijima, Akiko Kubo, Hiroshi Igaki, Naoto Shikama, Hitoshi Ikushima

Japanese journal of clinical oncology　2023年2月21日

DOI： 10.1093/jjco/hyad012 　

詳細を見る詳細を閉じる

OBJECTIVE: Compared with the implementation speed of image-guided adaptive brachytherapy for uterine cervical cancer, that of intracavitary and interstitial brachytherapy is slow, possible because it requires more invasive procedure of inserting needles directly into tumours. To accelerate the implementation speed of intracavitary and interstitial brachytherapy, a first hands-on seminar for image-guided adaptive brachytherapy and intracavitary and interstitial brachytherapy for uterine cervical cancer was held on 26 November 2022, supported by Japanese Society for Radiology and Oncology. This article deals with this hands-on seminar and difference of degree of confidence of participants in starting intracavitary and interstitial brachytherapy before and after the seminar. METHODS: The seminar consisted of lectures regarding intracavitary and interstitial brachytherapy in the morning and hands-on practice of needle insertion and contouring, as well as dose calculation practice using the radiation treatment system in the evening. Prior to and following the seminar, participants completed a questionnaire asking about their level of confidence in performing intracavitary and interstitial brachytherapy, expressed between 0 and 10 (the higher the number, the stronger the confidence). RESULTS: A total of 15 physicians, six medical physicists and eight radiation technologists from 11 institutions attended the meeting. The median level of confidence before and after the seminar was 3 (range, 0-6) and 5.5 (range, 3-7), respectively, and a statistically significant improvement was observed (P<0.001). CONCLUSION: It was suggested that the hands-on seminar on intracavitary and interstitial brachytherapy for locally advanced uterine cervical cancer improved the level of confidence of the attendees and propelled their motivation, through which it is expected that the implementation of intracavitary and interstitial brachytherapy will be accelerated.
Development and validation of an [¹⁸F]FDG-PET/CT radiomic model for predicting progression-free survival for patients with stage II – III thoracic esophageal squamous cell carcinoma who are treated with definitive chemoradiotherapy

Noriyoshi Takahashi, Shohei Tanaka, Rei Umezawa, Kentaro Takanami, Kazuya Takeda, Takaya Yamamoto, Yu Suzuki, Yoshiyuki Katsuta, Noriyuki Kadoya, Keiichi Jingu

Acta Oncologica　62　(2)　1-7　2023年2月15日
出版者・発行元： Informa UK Limited
DOI： 10.1080/0284186x.2023.2178859 　

ISSN：0284-186X

eISSN：1651-226X
FDG-PET/CTでのRadiomics解析による胸部食道癌予後予測の検討

高橋紀善, 梅澤玲, 山本貴也, 石川陽二郎, 武田一也, 鈴木友, 岸田桂太, 寺村聡司, 神宮啓一

Japanese Journal of Radiology　41　(Suppl.)　3-3　2023年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
HPV陽性中咽頭癌に対する根治的化学放射線治療Real World Evidence

鈴木友, 梅澤玲, 山本貴也, 石川陽二郎, 高橋紀善, 武田一也, 岸田桂太, 寺村聡司, 神宮啓一

Japanese Journal of Radiology　41　(Suppl.)　3-3　2023年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
片側水腎症を伴ったdesmoid-type fibromatosisに対し放射線治療が著効した1例

石川陽二郎, 梅澤玲, 山本貴也, 高橋紀善, 武田一也, 鈴木友, 岸田桂太, 寺村聡司, 神宮啓一

Japanese Journal of Radiology　41　(Suppl.)　3-3　2023年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
膵炎を繰り返すIPMNに対して放射線治療を行った1例

針谷綾花, 高橋紀善, 梅澤玲, 山本貴也, 石川陽二郎, 武田一也, 鈴木友, 岸田桂太, 寺村聡司, 神宮啓一

Japanese Journal of Radiology　41　(Suppl.)　4-4　2023年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
食道神経内分泌癌に対して化学放射線療法を行い,局所制御を得た1例

関康宏, 梅澤玲, 山本貴也, 石川陽二郎, 高橋紀善, 武田一也, 鈴木友, 岸田桂太, 寺村聡司, 神宮啓一

Japanese Journal of Radiology　41　(Suppl.)　4-4　2023年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
肺定位放射線治療後の放射線肺障害の経時変化に関する検討

山本貴也, 勝田義之, 毛利詩菜, 梅澤玲, 石川陽二郎, 角谷倫之, 高橋紀善, 鈴木友, 武田一也, 岸田桂太, 神宮啓一

Japanese Journal of Radiology　41　(Suppl.)　8-8　2023年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
Salvage craniospinal irradiation for recurrent intracranial germinoma: a single institution analysis

Masayuki Kanamori, Yoshiteru Shimoda, Rei Umezawa, Osamu Iizuka, Shunji Mugikura, Kyoko Suzuki, Hisanori Ariga, Keiichi Jingu, Ryuta Saito, Yukihiko Sonoda, Toshihiro Kumabe, Teiji Tominaga

Journal of Radiation Research　64　(2)　428-437　2023年1月5日
出版者・発行元： Oxford University Press (OUP)
DOI： 10.1093/jrr/rrac095 　

ISSN：0449-3060

eISSN：1349-9157

詳細を見る詳細を閉じる

Abstract This study investigated the effectiveness and safety of low-dose salvage craniospinal irradiation (CSI) for recurrent germinoma. We retrospectively reviewed long-term tumor control and late adverse effects in 15 recurrent germinoma patients treated at our hospital between 1983 and 2019. Following the first recurrence of germinoma, seven were treated with 24–30 Gy of salvage CSI, three underwent non-CSI, and five were treated with only chemotherapy. CSI achieved a significantly better recurrence-free survival rate after the first recurrence compared to other strategies (100% vs 33%, p &lt; 0.001: log-rank test). To evaluate the safety of salvage CSI, we assessed the outcomes at the final follow-up of seven patients who received salvage CSI at first recurrence and three patients who received salvage CSI at second recurrence. The median follow-up period was 220 months after initial treatment. Five patients who received 40–50 Gy of radiation therapy or underwent multiple radiation therapy before salvage CSI were classified into Group A, whereas five patients treated with platinum-based chemotherapy and 24–32 Gy of radiation therapy to the primary site, whole ventricle, or whole brain were classified into Group B. In Group A, one had endocrine dysfunction and the other had visual dysfunction. None were socially independent. Meanwhile, in Group B, no endocrine or visual dysfunction was found, and three patients were socially independent. Salvage CSI achieved excellent tumor control in recurrent germinoma and was safe in patients initially treated with low-dose radiation therapy and chemotherapy.
Survival prediction nomogram for patients with vertebral bone metastases treated with palliative radiotherapy. 国際誌

Kazuya Takeda, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Yu Suzuki, Keita Kishida, So Omata, Keiichi Jingu

Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology　28　(5)　646-653　2023年

DOI： 10.5603/rpor.97512 　

詳細を見る詳細を閉じる

BACKGROUND: In the treatment of vertebral bone metastases, estimating patient prognosis is important to select the optimal treatment strategy. The purpose of this study was to identify prognostic factors for vertebral bone metastases treated with palliative radiotherapy and to establish a nomogram for predicting patient survival. MATERIALS AND METHODS: We analyzed patients who underwent palliative radiotherapy for vertebral bone metastasis between January 2010 and December 2020 at a single institution. Exclusion criteria were as follows: (1) primary bone malignancy, (2) stereotactic body radiotherapy, (3) concurrent radiotherapy to sites other than the vertebral bone, (4) radiotherapy to other sites within 12 weeks before or after the current radiotherapy, and (5) lack of more than half of blood test data before radiotherapy. RESULTS: A total of 487 patients met the inclusion criteria. Clinical and hematologic data were collected from the patient record system. Patients were divided into training and test groups in a 7:3 ratio. Multivariate Cox regression analysis in the training cohort revealed six significant factors, including a history of chemotherapy, primary site (breast cancer, prostate cancer, or hematologic malignancy), use of analgesics, neutrophil-lymphocyte ratio, serum albumin, and lactate dehydrogenase. A prognostic nomogram was developed and validated in the test cohort. The area under the curve (AUC) values in predicting survival at 6, 24, and 60 months were 0.83, 0.88, and 0.88 in the training cohort and 0.85, 0.81, and 0.79 in the test cohort, respectively. CONCLUSIONS: This nomogram may help to select the treatment strategy for vertebral bone metastases.
A Retrospective Study of Clinical Outcomes for Patients with Esophageal Cancer Who Were Treated with Radiotherapy Alone. 国際誌

Noriyoshi Takahashi, Rei Umezawa, Takaya Yamamoto, Kazuya Takeda, Yu Suzuki, Keita Kishida, So Omata, Yuta Sato, Hinako Harada, Yasuhiro Seki, Keiichi Jingu

Gastrointestinal tumors　10　(1)　57-66　2023年

DOI： 10.1159/000539173 　

詳細を見る詳細を閉じる

INTRODUCTION: Patients with esophageal cancer who are in a poor general condition receive radiotherapy alone, but outcomes are often unsatisfactory. The aim of this study was to clarify recent outcomes of radiotherapy alone for esophageal cancer. METHODS: Patients who underwent 50 Gy or more of radiotherapy without chemotherapy were retrospectively reviewed. Endpoints were overall survival (OS), disease-specific survival (DSS), local control (LC), and progression-free survival (PFS). Survival curves were drawn using the Kaplan-Meier method, and predictors were analyzed using the Cox proportional hazards model. RESULTS: Sixty-nine patients were included. The median follow-up period was 17.9 months. The 5-year OS, DSS, LC, and PFS rates were 33.2%, 49.8%, 46.2%, and 16.8%, respectively. In the multivariate Cox proportional hazard model, clinical stage was a significant predictor for OS (hazard ratio [HR]: 4.42, 95% confidence interval [CI]: 1.80-11.17, p = 0.001), DSS (HR: 2.08, 95% CI: 1.43-3.12, p = 0.0001), LC (HR: 1.86, 95% CI: 1.28-2.74, p = 0.001), and PFS (HR: 1.65, 95% CI: 1.25-2.18, p = 0.0004). Radiation dose was a significant predictor for LC (HR: 0.87, 95% CI: 0.78-0.97, p = 0.018) and tumor location was a significant predictor for PFS (HR: 1.55, 95% CI: 1.10-2.19, p = 0.018). In subgroup analysis, the 5-year OS, DSS, LC, and PFS rates for stage I were 60.0%, 80.0%, 71.9%, and 46.1%, respectively. CONCLUSIONS: Stage, radiation dose, and tumor location are significant predictors for outcomes. Patients with stage I esophageal cancer can be cured by radiotherapy alone.
Retrospective analysis of local recurrence pattern by computed tomography image-guided intracavitary and interstitial brachytherapy for locally advanced cervical cancer in a single Japanese institution. 国際誌

Rei Umezawa, Hideki Tokunaga, Takaya Yamamoto, Shogo Shigeta, Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Keita Kishida, Kengo Ito, Noriyuki Kadoya, Muneaki Shimada, Keiichi Jingu

Brachytherapy　22　(4)　477-486　2023年

DOI： 10.1016/j.brachy.2023.04.008 　

詳細を見る詳細を閉じる

PURPOSE: The purpose of this study was to investigate the treatment results with focus on local control (LC) by computed tomography (CT)-guided intracavity brachytherapy and interstitial brachytherapy (ICBT/ISBT) for locally advanced cervical cancer (LACC). METHODS AND MATERIALS: Patients with LACC undergoing ICBT/ISBT at least once in our institution between January 2017 and June 2019 were analyzed retrospectively. The primary endpoint was local control (LC), and the secondary endpoints were progression-free survival (PFS), overall survival (OS), and late toxicities. Differences between patient subgroups for prognostic factors in LC, PFS, and OS were analyzed using the log-rank test. The recurrence patterns of LC were also investigated. RESULTS: Forty-four patients were included in the present study. The median high-risk clinical target volume (HR-CTV) at the initial brachytherapy was 48.2 cc. The median total dose of HR-CTV D90 (EQD2) was 70.7 Gy. The median followup period was 39.4 months. The 3-year LC, PFS and OS rates in all patients were 88.2%, 56.6%, and 65.4% (95% CI 50.3-78.0%), respectively. Corpus invasion and large HR-CTV (70 cc or more) were significant prognostic factors in LC, PFS, and OS. Marginal recurrences at the fundus of the uterus were detected in 3 of 5 patients in whom local recurrence was observed. Late toxicities of Grade 3 or higher were detected in 3 patients (6.8%). CONCLUSIONS: Favorable LC was achieved by performing CT-guided ICBT/ISBT for LACC. The brachytherapy strategy for patients with corpus invasion or large HR-CTV may need to be reconsidered.
Clinical significance of completion of radium-223 treatment and acute adverse events in patients with metastatic castration-resistant prostate cancer. 国際誌

Kazuya Takeda, Yoshihide Kawasaki, Toru Sakayauchi, Chiaki Takahashi, Yu Katagiri, Takaya Tanabe, Yojiro Ishikawa, Keisuke Fujimoto, Masaki Kubozono, Maiko Kozumi, Keiko Abe, Kakutaro Narazaki, Shun Tasaka, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Yu Suzuki, Keita Kishida, So Omata, Akihiro Ito, Keiichi Jingu

Asia Oceania journal of nuclear medicine & biology　11　(1)　13-22　2023年

DOI： 10.22038/AOJNMB.2022.67136.1468 　

詳細を見る詳細を閉じる

OBJECTIVES: In the treatment of castration-resistant prostate cancer (CRPC) with bone metastases, radium-223 dichloride (Ra-223) is the only bone-targeted drug that shows survival benefits. Completing six courses of Ra-223 treatment is thought to be associated with better patient survival, but this treatment has a relatively high rate of acute adverse events. METHODS: This retrospective study included 85 patients from 12 institutions in Japan to investigate the clinical significance of the completion of Ra-223 treatment and acute adverse events in CRPC patients. RESULTS: Six courses of Ra-223 treatment were completed in 65.9% of the patients. Grade 3 or higher acute adverse events were observed in 27.1% of patients. The prostate specific antigen and alkaline phosphatase declined at 26.9% and 87.9%, respectively. The overall survival rates at 12 and 24 months were 80.7% and 63.2%, respectively. Both completion of six courses of Ra-223 treatment and absence of grade 3 or higher acute adverse events were associated with longer overall survival. In univariate analysis, factors related to the history of treatment (five or more hormone therapy agents and cytotoxic chemotherapy) and hematological parameters (Prostate specific antigen (PSA) doubling time, alkaline phosphatase, hemoglobin, albumin, and serum calcium) were associated with completing six courses of Ra-223 treatment without experiencing grade 3 or higher acute adverse events. Multivariate analysis showed that a history of chemotherapy, PSA doubling time, hemoglobin, and serum calcium showed statistical significance. We built a predictive score by these four factors. Patients with lower scores showed higher rates of treatment success (p<0.001) and longer overall survival (p<0.001) with statistical significance. CONCLUSIONS: Accomplishing six courses of Ra-223 treatment without grade 3 or higher acute adverse events was a prognostic factor in patients with mCRPC treated with Ra-223. We built a predictive score of treatment success and need future external validation.
Favorable response after radiation therapy for intraductal papillary mucinous neoplasms manifesting as acute recurrent pancreatitis: A case report. 国際誌

Ayaka Harigai, Kiyoshi Kume, Noriyoshi Takahashi, So Omata, Rei Umezawa, Keiichi Jingu, Atsushi Masamune

World journal of clinical cases　10　(30)　11116-11121　2022年10月26日

DOI： 10.12998/wjcc.v10.i30.11116 　

詳細を見る詳細を閉じる

BACKGROUND: There has been an increasing number of elderly patients with intraductal papillary mucinous neoplasm (IPMN), who are surgically intolerant and require less invasive treatment options, which are limited. In the present study, we report a case of IPMN presenting with acute recurrent pancreatitis (ARP), in which radiation therapy effectively prevented further attacks of ARP and reduced tumor volume. CASE SUMMARY: An 83-year-old man was referred to our hospital with an asymptomatic incidental pancreatic cyst. Endoscopic ultrasound imaging and magnetic resonance cholangiopancreatography revealed a multiloculated tumor in the head of the pancreas, with dilated pancreatic ducts and mural nodules. The patient was diagnosed with mixed-type IPMN, and five years later, he developed ARP. Several endoscopic pancreatic ductal balloon dilatations failed to prevent further ARP attacks. Surgery was considered clinically inappropriate because of his old age and comorbidities. He was referred to our department for radiation therapy targeted at those lesions causing intraductal hypertension and radiation was administered at a dose of 50 Gy. An magnetic resonance imaging scan taken ten weeks after treatment revealed a decrease in tumor size and improvement of pancreatic duct dilatation. Fourteen months later, he remains symptom-free from ARP. CONCLUSION: This case highlights the important role of radiation therapy in mitigating the signs and symptoms of ARP in patients with inoperable IPMN.
Chronic expanding hematoma of the left erector spinae muscle after stereotactic body radiotherapy for renal cell carcinoma: a case report. 国際誌

Yojiro Ishikawa, Takaya Yamamoto, Rei Umezawa, Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Keiichi Jingu

Journal of medical case reports　16　(1)　353-353　2022年10月3日

DOI： 10.1186/s13256-022-03612-3 　

詳細を見る詳細を閉じる

BACKGROUND: Hematomas that slowly increase in size for more than 1 month after the initial hemorrhage are referred to as chronic expanding hematomas. Chronic expanding hematoma can also occur after radiosurgery; however, there have been no reports about chronic expanding hematoma in the trunk after stereotactic body radiotherapy. We report a case of chronic expanding hematoma of the left erector spinae muscle after stereotactic body radiotherapy for renal cell carcinoma. CASE PRESENTATION: A 74-year-old Japanese male complained of back pain 7 years after stereotactic body radiotherapy for renal cell carcinoma of the left kidney. There was no history of surgery or trauma to his back. After stereotactic body radiotherapy, there was no acute or late complication of more than grade 2. The renal cell carcinoma did not show shrinkage or progression, and he was diagnosed with stable disease on computed tomography. The patient remains in a stable disease condition 7 years after treatment without surgery or chemotherapy; however, he came to the hospital with gradually worsening back pain for several months. Computed tomography revealed the left erector spinae muscle to be swollen compared with the contralateral side at the third lumbar level. Ultrasonography showed a tumor of 30 mm in size without blood flow in the left paraspinal muscle. Positron emission tomography-computed tomography revealed uptake in the left paraspinal muscle. Pathological examination showed radiation-induced chronic expanding hematoma. CONCLUSIONS: We present the first case report of chronic expanding hematoma of the left erector spinae muscle after stereotactic body radiotherapy for renal cell carcinoma. Usually, stereotactic body radiotherapy for renal cell carcinoma would be considered unlikely to cause chronic expanding hematoma, but the introduction of dialysis and antiplatelet drugs may have increased the risk.
胸部領域における新規開発した治療計画支援ソフトウェアの非剛体レジストレーションの精度評価

高橋春奈, 角谷倫之, 勝田義之, 田中祥平, 新井一弘, 山本貴也, 梅澤玲, 神宮啓一

日本放射線技術学会雑誌　78　(10)　1187-1193　2022年10月
出版者・発行元： (公社)日本放射線技術学会
ISSN：0369-4305

eISSN：1881-4883
80歳以上の食道癌でも放射線治療に化学療法併用は必要か? SEER分析

神宮啓一, 高橋紀善, 梅澤玲, 山本貴也, 武田一也, 鈴木友, 岸田桂太, 尾股聡

日本食道学会学術集会プログラム・抄録集　76回　153-153　2022年9月
出版者・発行元： (NPO)日本食道学会
[Evaluation of Accuracy of Deformable Image Registration with Newly Developed Treatment Planning Support Software for Thoracic Images].

Haruna Takahashi, Noriyuki Kadoya, Yoshiyuki Katsuta, Shohei Tanaka, Kazuhiro Arai, Takaya Yamamoto, Rei Umezawa, Keiichi Jingu

Nihon Hoshasen Gijutsu Gakkai zasshi　78　(10)　1187-1193　2022年8月24日

DOI： 10.6009/jjrt.2022-1308 　

詳細を見る詳細を閉じる

This study evaluated accuracy of deformable image registration (DIR) with twelve parameter settings for thoracic images. We used peak-inhale and peak-exhale images for ten patients provided by DIR-lab. We used a prototype version of iCView software (ITEM Corporation) with DIR to perform intensity, structure, and hybrid-based DIR with the twelve parameter settings. DIR accuracy was evaluated by a target registration error (TRE) using 300 bronchial bifurcations and the Dice similarity coefficient (DSC) of the lungs. For twelve parameter settings, TRE ranged from 2.83 mm to 5.27 mm, whereas DSC ranged from 0.96 to 0.98. These results demonstrated that DIR accuracy differed among parameter settings and show that appropriate parameter settings are required for clinical practice.
Comparison of acute gastrointestinal toxicities between 3-dimensional conformal radiotherapy and intensity-modulated radiotherapy including prophylactic regions in chemoradiotherapy with S-1 for pancreatic cancer-importance of dose volume histogram parameters in the stomach as the predictive factors. 国際誌

Rei Umezawa, Kei Nakagawa, Masamichi Mizuma, Yoshiyuki Katsuta, Shohei Tanaka, Noriyuki Kadoya, Yu Suzuki, Kazuya Takeda, Noriyoshi Takahashi, Takaya Yamamoto, Michiaki Unno, Keiichi Jingu

Journal of radiation research　63　(6)　856-865　2022年8月20日

DOI： 10.1093/jrr/rrac049 　

詳細を見る詳細を閉じる

The purpose of this study was to compare acute gastrointestinal (GI) toxicities in patients who underwent 3-dimensional conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT) in chemoradiotherapy (CRT) with S-1 including prophylactic regions for pancreatic cancer. We also investigated the predictive factor of acute GI toxicities in dose volume histogram (DVH) parameters. Patients who received CRT with S-1 for pancreatic cancer between January 2014 and March 2021 were included. Radiotherapy (RT) with a total dose of 50-54 Gy was delivered. We examined the differences in the frequencies of acute GI toxicity of grade 2 or higher and DVH parameters of the stomach (ST) and duodenum (DU) between the 3DCRT group and the IMRT group. The RT-related predictive factors of acute GI toxicities were investigated by univariate and multivariate analyses. There were 25 patients in the 3DCRT group and 31 patients in the IMRT group. The frequencies of acute GI toxicity of G2 or higher were 36% in the 3DCRT group and 9.7% in the IMRT group (p = 0.035). ST V50 was the most predictive factor (p = 0.001), and the incidences of acute GI toxicity of G2 or higher in ST V50 ≥ 4.1 cc and < 4.1cc were 43.7% and 7.7%, respectively. ST V40 was also a significant predictive factor of acute GI toxicity (p = 0.002). IMRT could reduce acute GI toxicities in CRT with S-1 including prophylactic regions for pancreatic cancer. Acute GI toxicities may be affected by moderate to high doses to the ST.
Stereotactic Radiosurgery for Lung Cancer with a Risk-Adapted Strategy Using the Volumetric Modulated Arc Therapy Technique: A Single Arm Phase II Study

Takaya Yamamoto, Yu Katagiri, Yoko Tsukita, Haruo Matsushita, Rei Umezawa, Yoshiyuki Katsuta, Noriyuki Kadoya, Noriyoshi Takahashi, Yu Suzuki, Kazuya Takeda, Keita Kishida, So Omata, Eisaku Miyauchi, Ryota Saito, Keiichi Jingu

Cancers　14　(16)　3993-3993　2022年8月18日
出版者・発行元： MDPI AG
DOI： 10.3390/cancers14163993 　

eISSN：2072-6694

詳細を見る詳細を閉じる

Purpose: A phase II study carried out to assess the efficacy of a risk-adapted strategy of stereotactic radiosurgery (SRS) for lung cancer. The primary endpoint was 3-year local recurrence, and the secondary endpoints were overall survival (OS), disease-free survival (DFS), rate of start of systemic therapy or best supportive care (SST-BSC), and toxicity. Materials and Methods: Eligible patients fulfilled the following criteria: performance status of 2 or less, forced expiratory volume in 1 s of 700 mL or more, and tumor not located in central or attached to the chest wall. Twenty-eight Gy was prescribed for primary lung cancers with diameters of 3 cm or less and 30 Gy was prescribed for primary lung cancers with diameters of 3.1–5.0 cm or solitary metastatic lung cancer diameters of 5 cm or less. Results: Twenty-one patients were analyzed. The patients included 7 patients with adenocarcinoma, 2 patients with squamous cell carcinoma, 1 patient with metastasis, and 11 patients with clinical diagnosis. The median tumor diameter was 1.9 cm. SRS was prescribed at 28 Gy for 18 tumors and 30 Gy for 3 tumors. During the median follow-up period of 38.9 months for survivors, 1 patient had local recurrence, 7 patients had regional or distant metastasis, and 5 patients died. The 3-year local recurrence, SST-BSC, DFS, and OS rates were 5.3% (95% confidence interval [CI]: 0.3–22.2%), 20.1% (95% CI: 6.0–40.2%), 59.2% (95% CI: 34.4–77.3%), and 78.2% (95% CI: 51.4–91.3%), respectively. The 95% CI upper value of local recurrence was lower than the null local recurrence probability. There was no severe toxicity, and grade 2 radiation pneumonitis occurred in 1 patient. Conclusions: Patients who received SRS for lung cancer had a low rate of 3-year local recurrence and tolerable toxicity.
An Asian multi-national, multi-institutional, retrospective study on image-guided brachytherapy in cervical adenocarcinoma and adenosquamous carcinoma. 国際誌

Noriyuki Okonogi, Naoya Murakami, Ken Ando, Masumi Murata, Kazutoshi Murata, Tomomi Aoshika, Shingo Kato, Anneyuko I Saito, Joo-Young Kim, Yasuo Yoshioka, Shuhei Sekii, Kayoko Tsujino, Chairat Lowanichkiattikul, Poompis Pattaranutaporn, Yuko Kaneyasu, Tomio Nakagawa, Miho Watanabe, Takashi Uno, Rei Umezawa, Keiichi Jingu, Ayae Kanemoto, Masaru Wakatsuki, Katsuyuki Shirai, Hiroshi Igaki, Tatsuya Ohno, Jun Itami

Journal of contemporary brachytherapy　14　(4)　311-320　2022年8月

DOI： 10.5114/jcb.2022.119451 　

詳細を見る詳細を閉じる

Purpose: There are limited reports on outcomes of three-dimensional image-guided brachytherapy (3D-IGBT) for cervical adenocarcinoma in Asia. In a multi-institutional retrospective study, we assessed the clinical outcomes of three-dimensional image-guided brachytherapy for cervical adenocarcinoma or adenosquamous carcinoma (CA/CAC) in Asian countries. Material and methods: Patients who had undergone definitive radiation therapy/concurrent chemoradiotherapy for untreated cervical cancer between 2000 and 2016 were registered. Those who had undergone 3D-IGBT for histologically proven CA/CAC were included. Data on patients' characteristics and treatment were collected, including tumor reduction rate (defined as a percentage of reduction in tumor size before brachytherapy compared with that at diagnosis) and high-risk clinical target volume D90. Overall survival (OS), local control (LC), and progression-free survival (PFS) rates were calculated using Kaplan-Meier method. Late toxicities were assessed using common terminology criteria for adverse events version 4.0. Results: Anonymized data of 498 patients were collected. Of the 498 patients, 36 patients met inclusion criteria. The median follow-up period was 39 months. The 3-year OS, LC, and PFS rates were 68.4%, 68.5%, and 44.4%, respectively. After treatment, five patients had tumor re-growth without complete disappearance of the tumor. Two patients developed grade 3 vaginal toxicity or grade 4 rectal toxicity; none developed other severe late toxicities. A tumor reduction rate of > 26.3% was the only significant factor in multivariate analyses, and was associated with significantly better OS (p = 0.018), LC (p = 0.022), and PFS (p = 0.013). There were no significant trends in local control or dose to high-risk clinical target volume D90. Conclusions: LC rate of CA/CAC was insufficient despite 3D-IGBT. Meanwhile, tumor reduction rate was associated with LC, OS, and PFS rates. Therefore, CA/CAC may require a different treatment strategy than that applied in cervical squamous cell carcinoma.
The benefit of concurrent chemotherapy with radiotherapy for esophageal cancer is limited in Asian patients aged 80 years or older: a SEER database analysis.

Keiichi Jingu, Noriyoshi Takahashi, Rei Umezawa, Takaya Yamamoto, Kazuya Takeda, Yu Suzuki, Keita Kishida, So Omata, Yuta Sato, Hinako Harada, Ayaka Harigai

Esophagus : official journal of the Japan Esophageal Society　19　(4)　653-659　2022年7月2日

DOI： 10.1007/s10388-022-00938-1 　

詳細を見る詳細を閉じる

PURPOSE: To evaluate the benefit of concurrent chemotherapy with radiotherapy (RT) for esophageal cancer in Asian patients aged ≥ 80 years using the Surveillance, Epidemiology, and End Results (SEER) database. MATERIALS AND METHODS: Among more than 7000 patients with squamous cell carcinoma or adenocarcinoma who were treated by RT without surgery for esophageal cancer in the SEER database, 2047 patients aged ≥ 80 years were analyzed. Patients who received chemoradiotherapy (CRT group) and patients who received RT alone (RT alone group) were matched with a propensity score. RESULTS: The median observation period for survivors was 57 months. The 3-year and 5-year overall survival rates in all patients were 15.2% and 8.5%, respectively. The 3-year and 5-year cause-specific survival rates in all patients were 20.8% and 14.5%, respectively. After propensity score matching, the overall survival rate in the CRT group was significantly higher than that in the RT alone group (5-year overall survival rates: 11.9% and 3.2%, respectively, p < 0.001). In 108 Asian or Pacific Islander patients, there was no significant difference (5-year overall survival rates: 13.5% and 0%, respectively, p = 0.291), although the overall survival rate in the CRT group was significantly higher than that in the RT alone group in any other race. CONCLUSIONS: It is controversial whether CRT is beneficial for Asian or Pacific Islander patients aged 80 years or older with esophageal cancer based on Analysis of data in SEER database.
放射線治療における膵臓変位推定の為の2D断層画像駆動型複数臓器接触シミュレーション

原裕貴, 角谷倫之, 三目直登, 家永直人, 梅澤玲, 神宮啓一, 黒田嘉宏

日本医用画像工学会大会予稿集　41回　86-87　2022年7月
出版者・発行元： (一社)日本医用画像工学会
子宮頸癌に対して治療強度低減は可能か?

村上直也, 安藤謙, 青鹿友美, 加藤眞吾, 小此木範之, 吉岡靖生, 関井修平, 兼安祐子, 渡辺未歩, 梅澤玲, 金本彩恵, 若月優, 白井克幸, 井垣浩, 伊丹純

日本婦人科腫瘍学会学術講演会プログラム・抄録集　64回　191-191　2022年7月
出版者・発行元： (公社)日本婦人科腫瘍学会
Brachytherapy for primary nasal vestibule cancer using Au-198 grains. 国際誌

Hinako Harada, Yojiro Ishikawa, Shohei Tanaka, Keita Kishida, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Keiichi Jingu

International cancer conference journal　11　(3)　184-187　2022年7月

DOI： 10.1007/s13691-022-00546-x 　

詳細を見る詳細を閉じる

Radiation therapy (RT) is one of the definitive treatments for early-stage nasal vestibular carcinoma and has similar local control rates to resection surgery. There are various methods, including external beam RT and brachytherapy. This report describes a case who showed local control for more than 5 years after brachytherapy alone using Au-198 grains for nasal vestibular carcinoma. A 68-year-old Japanese man complained of swelling and pain in his left nasal cavity. He was diagnosed with squamous cell carcinoma (SCC) (cT1N0M0, stage I). An elevated mass of 8 mm in long diameter was found inside the left nasal cavity. Since the patient selected brachytherapy, nine Au-198 grains 185 mBq were permanently injected percutaneously under local anesthesia, and 85 Gy was prescribed. Grade three dermatitis was observed as an acute adverse event. After 2 years, mild telangiectasia of the left nasal skin and epilation of nasal hair in the left nasal cavity was regarded as late adverse events. The patient continues to keep a complete response for 5 years. For small nasal vestibular SCC, brachytherapy with Au-198 grains might be a good option.
An Asian multi-national multi-institutional retrospective study comparing intracavitary versus the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical carcinoma. 国際誌

Naoya Murakami, Ken Ando, Masumi Murata, Kazutoshi Murata, Tatsuya Ohno, Tomomi Aoshika, Shingo Kato, Noriyuki Okonogi, Anneyuko I Saito, Joo-Young Kim, Yasuo Yoshioka, Shuhei Sekii, Kayoko Tsujino, Chairat Lowanichkiattikul, Poompis Pattaranutaporn, Yuko Kaneyasu, Tomio Nakagawa, Miho Watanabe, Takashi Uno, Rei Umezawa, Keiichi Jingu, Ayae Kanemoto, Masaru Wakatsuki, Katsuyuki Shirai, Hiroshi Igaki, Jun Itami

Journal of radiation research　63　(3)　412-427　2022年5月18日

DOI： 10.1093/jrr/rrac014 　

詳細を見る詳細を閉じる

This study is an international multi-institutional retrospective study comparing the clinical outcomes between intracavitary brachytherapy (ICBT) and the hybrid of intracavitary and interstitial brachytherapy (HBT) for locally advanced cervical cancer patients treated with definitive radiation therapy. Locally advanced cervical cancer, the initial size of which is larger than 4 cm and treated by concurrent chemoradiotherapy and image-guided adaptive brachytherapy, were eligible for this retrospective study. Patients who received HBT at least once were included in the HBT group, and patients who received only ICBT were included in the ICBT group. Anonymized data from 469 patients from 13 institutions in Japan, one from Korea and one from Thailand, were analyzed. Two hundred eighty and 189 patients were included in the ICBT group and the HBT group, respectively. Patients in the HBT group had more advanced stage, non-Scc histopathology, a higher rate of uterine body involvement, larger tumor at diagnosis, larger tumor before brachytherapy and a lower tumor reduction ratio. With a median follow-up of 51.3 months (2.1-139.9 months), 4-y local control (LC), progression-free survival (PFS) and overall survival (OS) for the entire patient population were 88.2%, 64.2% and 83%, respectively. The HBT group received a higher HR-CTV D90 than that of the ICBT group (68.8 Gy vs 65.6 Gy, P = 0.001). In multivariate analysis, the non-Scc histological subtype, HR-CTV D95 ≤ 60 Gy, reduction ratio ≤ 29% and total treatment time (TTT) ≥ 9 weeks were identified as the independent adverse prognostic factors for LC. Regarding LC, no difference was found between ICBT and HBT (4-y LC 89.3% vs 86.8%, P = 0.314). After adjustment for confounding factors by propensity score matching, no advantage of applying HBT was demonstrated regarding LC, PFS, or OS. Despite the fact that HBT patients had more adverse clinical factors than ICBT patients, HBT delivered a higher dose to HR-CTV and resulted in comparable LC.
Patterns of failure after salvage chemoradiotherapy for postoperative loco-regional recurrent esophageal cancer: 20-year experience in a single institution in Japan.

Keiichi Jingu, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Keita Kishida, So Omata, Yuta Sato, Noriyuki Kadoya

Esophagus : official journal of the Japan Esophageal Society　19　(4)　639-644　2022年5月16日

DOI： 10.1007/s10388-022-00922-9 　

詳細を見る詳細を閉じる

PURPOSE: The purpose of the present study was to evaluate patterns of recurrence after salvage chemoradiotherapy (SCRT) for postoperative loco-regional recurrent esophageal cancer. METHODS: We reviewed records for 114 patients with postoperative loco-regional recurrent esophageal cancer treated by platinum-based chemoradiotherapy between 2000 and 2020, and we evaluated the patterns of failure in patients who had recurrence again or who had been observed for 2 years or more after SCRT at the last observation date. RESULTS: One hundred and three patients were enrolled in this study. The median observation period for survivors was 60 months. Fifty-three patients died of esophageal cancer and nine patients died of other diseases. The 5-year overall survival rate, cause-specific survival rate and disease-control rate were 43.7%, 45.3% and 37.0%, respectively. Sixty-five patients had failure after SCRT. In those patients, 26 patients had only distant organ or non-regional lymph node metastases, 26 patients had only loco-regional failure, and 13 patients had both. Of those 65 patients, 64 patients showed failure within 42 months after SCRT. Of 39 patients with loco-regional failure, failure in the irradiated field was observed in 28 patients. Of those 28 patients, 27 patients showed failure within 24 months and the other patient showed failure at 26.5 months. CONCLUSIONS: The patterns of failure after SCRT for patients with postoperative loco-regional recurrent esophageal cancer were shown. The patterns of failure suggest that follow-up for at least 4 years after SCRT should be performed for those patients.
Palliative radiotherapy for gastric cancer bleeding: a multi-institutional retrospective study. 国際誌

Kazuya Takeda, Toru Sakayauchi, Masaki Kubozono, Yu Katagiri, Rei Umezawa, Takaya Yamamoto, Yojiro Ishikawa, Noriyoshi Takahashi, Yu Suzuki, Keita Kishida, Keiichi Jingu

BMC palliative care　21　(1)　52-52　2022年4月12日

DOI： 10.1186/s12904-022-00943-2 　

詳細を見る詳細を閉じる

BACKGROUND: Palliative radiotherapy for gastric cancer bleeding has been reported to be a safe and effective treatment, but predictive factors for achievement of hemostasis and overall survival have not been established. METHODS: In this retrospective study, 120 courses of palliative radiotherapy for gastric cancer bleeding in 117 patients in 4 institutes in Japan were reviewed with approval of the ethical committee in each institute. The rate of achieving hemostasis was evaluated by 50% or more reduction of red blood cell transfusion before and after the start of radiotherapy, elevation of blood hemoglobin concentration in a period of 4 weeks from the start of radiotherapy or improvement of subjective or objective clinical symptoms in a period of 4 weeks from the start of radiotherapy. Predictive factors for overall survival and achieving hemostasis were investigated with the Cox hazards model. RESULTS: The median overall survival period was 3.7 months. Multivariate analysis showed that absence of metastatic disease, higher biological effective dose, higher serum albumin level, lower blood urea nitrogen level and lower neutrophil-to-lymphocyte ratio (NLR) were associated with longer overall survival. Elevation of hemoglobin concentration in a period of 4 weeks from the start of radiotherapy (mean concentration: 8.2 g/dL vs. 8.9 g/dL, p = 0.006) and decrease in the amount of red cell transfusion from a 4-week period before to a 4-week period after the start of radiotherapy (mean amount: 716 mL vs. 230 mL, p < 0.0001) were observed. The overall rate of achievement of hemostasis was 59.6%. In multivariate analysis, higher biological effective dose was associated with achievement of hemostasis. Grade 2 or higher acute adverse effects related to radiotherapy were observed in 17.5% of cases in 120 treatment courses. Six cases (5.0%) had grade 3 or 4 adverse effects including gastric penetration in 1 patient and anorexia requiring total parental nutrition in 3 patients. No grade 5 adverse effects were observed. CONCLUSIONS: Palliative radiotherapy for gastric cancer bleeding seems to be an effective and safe treatment strategy. Higher treatment dose was associated with longer overall survival and a hemostatic effect. Some hematological parameters may predict overall survival, and they would be helpful for deciding the treatment strategy.
Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice. 国際誌

Takaya Yamamoto, Yoko Tsukita, Yu Katagiri, Haruo Matsushita, Rei Umezawa, Yojiro Ishikawa, Noriyoshi Takahashi, Yu Suzuki, Kazuya Takeda, Eisaku Miyauchi, Ryota Saito, Yoshiyuki Katsuta, Noriyuki Kadoya, Keiichi Jingu

BMC cancer　22　(1)　364-364　2022年4月4日

DOI： 10.1186/s12885-022-09354-1 　

詳細を見る詳細を閉じる

BACKGROUND: In clinical practice, the effect of durvalumab and radiation pneumonitis (RP) on survival after intensity-modulated radiotherapy (IMRT) is not fully understood. The purpose of this retrospective study was to investigate factors related to distant metastasis-free survival (DMFS), progression-free survival (PFS) and overall survival (OS) after IMRT for locally advanced non-small cell lung cancer (LA-NSCLC). METHODS: All patients who were treated with conventional fractionated IMRT for LA-NSCLC between April 2016 and March 2021 were eligible. Time-to-event data were assessed by using the Kaplan-Meier estimator, and the Cox proportional hazards model was used for prognostic factor analyses. Factors that emerged after the start of IMRT, such as durvalumab administration or the development of RP, were analysed as time-dependent covariates. RESULTS: A total of 68 consecutive patients treated with conventional fractionated IMRT for LA-NSCLC were analysed. Sixty-six patients completed radiotherapy, 50 patients received concurrent chemotherapy, and 36 patients received adjuvant durvalumab. During the median follow-up period of 14.3 months, 23 patients died, and tumour progression occurred in 37 patients, including 28 patients with distant metastases. The 1-year DMFS rate, PFS rate and OS rate were 59.9%, 48.7% and 84.2%, respectively. Grade 2 RP occurred in 16 patients, grade 3 in 6 patients and grade 5 in 1 patient. The 1-year cumulative incidences of grade 2 or higher RP and grade 3 or higher RP were 33.8% and 10.3%, respectively. The results of multivariate analyses showed that durvalumab had a significantly lower hazard ratio (HR) for DMFS, PFS and OS (HR 0.31, p < 0.01; HR 0.33, p < 0.01 and HR 0.32, p = 0.02), respectively. Grade 2 or higher RP showed significance for DMFS and a nonsignificant trend for OS (HR 2.28, p = 0.04 and HR 2.12, p = 0.13), respectively, whereas a higher percentage of lung volume receiving 20 Gy or higher was significant for PFS (HR 2.25, p = 0.01). CONCLUSIONS: In clinical practice, durvalumab administration following IMRT with concomitant chemotherapy showed a significant survival benefit. Reducing the risk of grade 2 or higher RP would also be beneficial.
Differential abscopal effect in extracranial and intracranial lesions after radiotherapy alone for vertebral bone metastasis of unknown primary: a case report. 国際誌

Yojiro Ishikawa, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Keiichi Jingu

Journal of medical case reports　16　(1)　94-94　2022年3月6日

DOI： 10.1186/s13256-022-03321-x 　

詳細を見る詳細を閉じる

BACKGROUND: The abscopal effect is a phenomenon in which a tumor located far from irradiated lesions regresses. We have experienced a case in which both intracranial and extracranial lesions showed an abscopal effect after radiotherapy for spinal metastases of unknown primary. We report the differential abscopal effect in extracranial and intracranial lesions. CASE PRESENTATION: A 57-year-old Japanese man was diagnosed with multiple lung nodules, bone metastases, and brain metastases. The results of pathological examination at the previous hospital he visited suggested adenocarcinoma of the lung. However, there was a possibility that the biopsy specimen was inadequate. Radiation therapy was performed on the ninth thoracic vertebra for a total dose of 39 Gy in 13 fractions because the lesion in the ninth thoracic vertebra was destructively extending. After thorough examination, the primary lesion could not be identified, and we made diagnosis of cancer of unknown primary. The patient did not want to receive systemic chemotherapy; however, all of the lesions except for the brain metastases had spontaneously shrunk 2 months after radiation therapy. Although the brain metastases had partially shrunk, whole-brain radiotherapy for a total dose of 36 Gy in 12 fractions was performed. Fifteen months after initial radiation therapy, the brain metastasis recurred, and Gamma Knife radiosurgery was additionally performed. The brain metastases disappeared after the radiosurgery. During a period of 30 months after radiation therapy for the ninth vertebra, the lesions of the trunk all maintained their shrinkage without systemic chemotherapy. Right cervical lymph node metastasis and brain metastases occurred 30 months after the initial radiation therapy. A biopsy of the right cervical lymph node led to the diagnosis of clear cell carcinoma. Although we considered additional radiation therapy or chemotherapy, the patient died 3 months after the progression of recurrence lesions. DISCUSSION AND CONCLUSIONS: We report a rare case in which radiotherapy alone for an extracranial metastatic lesion of a vertebra resulted in an abscopal effect on both extracranial and intracranial lesions. Notably, the abscopal effect in the intracranial lesions was weaker than that in the extracranial lesions.
肺癌照射後再発に対して定位照射が著効した1例

佐藤雄太, 松下晴雄, 梅澤玲, 山本貴也, 石川陽二郎, 高橋紀善, 武田一也, 神宮啓一

Japanese Journal of Radiology　40　(Suppl.)　2-2　2022年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
中央遮蔽を併用しなかった局所進行子宮頸癌に対する放射線治療成績

梅澤玲, 松下晴雄, 山本貴也, 石川陽二郎, 高橋紀善, 武田一也, 神宮啓一

Japanese Journal of Radiology　40　(Suppl.)　3-3　2022年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
頭頸部がんに対するIMRT後の口腔内QOLの長期的変化 3D-CRTと比較して

神宮啓一, 高橋紀善, 田坂俊, 松下晴雄, 梅澤玲, 山本貴也, 石川陽二郎, 武田一也

Japanese Journal of Radiology　40　(Suppl.)　3-3　2022年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
80歳以上の高齢食道癌患者における放射線治療の予後因子の検討

高橋紀善, 梅澤玲, 岸田桂太, 山本貴也, 石川陽二郎, 武田一也, 鈴木友, 川端広聖, 寺村聡司, 神宮啓一

Japanese Journal of Radiology　40　(Suppl.)　6-6　2022年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
局所型前立腺癌に対する根治的IMRT後の重篤な晩期尿路障害に関連する臨床因子

武田賢, 梅澤玲, 石川陽二郎, 山本貴也, 高橋紀善, 武田一也, 角谷倫之, 松下晴雄, 神宮啓一, 山下慎一, 三塚浩二, 伊藤明宏, 荒井陽一, 高井良尋

Japanese Journal of Radiology　40　(Suppl.)　6-6　2022年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
頬粘膜癌に対してIr-RALSを用いたモールド照射を施行した1例

原田日南子, 神宮啓一, 松下晴雄, 梅澤玲, 山本貴也, 石川陽二郎, 高橋紀善, 武田一也, 鈴木友, 石河理沙, 小関健由

Japanese Journal of Radiology　40　(Suppl.)　8-8　2022年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
Radiation Therapy for Advanced Mucinous Carcinoma of the Breast With a Malignant Wound: A Case Report. 国際誌

Yojiro Ishikawa, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Keita Kishida, Kengo Ito, Maiko Kozumi, Kaneki Koyama, Keiichi Jingu

Cureus　14　(2)　e22017　2022年2月

DOI： 10.7759/cureus.22017 　

詳細を見る詳細を閉じる

Patients with breast cancer who refuse standard treatment often suffer from malignant wounds due to the growth of local tumors. However, treatment strategies for patients with unresectable locally advanced breast cancer who refuse standard treatment remain unclear. Usually, such cases are treated with palliative irradiation and do not achieve local control by irradiation alone. This is the first case report discussing the role of high-dose local irradiation and the treatment course for a patient with a massive breast tumor (mucinous adenocarcinoma) who refused standard treatment. A 44-year-old female was diagnosed with mucinous carcinoma of the breast in the right breast (cT1N0M0, cStage I). She refused standard treatment for six years. She visited the emergency department because of acute bleeding from the right breast with malignant wounds. Macroscopically, the tumor in the right breast measured over 20 cm in diameter. The tumor was exudative, exhibited ulceration and slight bleeding, and emitted an odor. Imaging findings showed multiple lymph nodes and bone metastases, and the final diagnosis was stage IV breast cancer (cT4bN1M1). Although the surgeon recommended chemotherapy for breast cancer, the patient refused chemotherapy or other therapy due to concerns regarding treatment-related complications. Considering the symptoms of advanced breast cancer with malignant wounds, she finally agreed to receive radiation therapy (RT). We performed RT at 70 Gy in 35 fractions over seven weeks. The tumor-associated symptoms disappeared after RT. Three months after RT, the tumor had almost disappeared. We administered luteinizing hormone-releasing hormone agonists after RT. Two years after RT, she died due to multiple liver metastases and ascites; however, there was no disease progression in the right breast. High-dose RT for locally advanced mucinous carcinoma of the breast with malignant wounds is considered an effective therapeutic option.
Long-Term Survival Following Palliative Chemoradiotherapy in an Elderly Patient With Advanced Squamous Cell Carcinoma in the Right Mandibular Gingiva. 国際誌

Yojiro Ishikawa, Rei Umezawa, Takaya Yamamoto, Kengo Ito, Keiichi Jingu

Cureus　14　(2)　e22142　2022年2月

DOI： 10.7759/cureus.22142 　

詳細を見る詳細を閉じる

Advanced squamous cell carcinoma (SCC) of the mandibular gingiva in elderly patients is difficult to cure. The treatment policy for elderly patients with advanced SCC of the mandibular gingiva has not been clear. We report a case of right mandibular gingival carcinoma that was successfully treated by palliative chemoradiotherapy. An 83-year-old female complained of pain and an ulcer in her right mandibular gingiva. Oral examination revealed a lesion of about 20 mm in size in the right mandibular gingiva. A diagnosis of SCC in the right mandibular gingiva was made by histology. Imaging findings revealed some right neck lymph node metastases. Based on these findings, a clinical diagnosis before treatment was SCC in the right mandibular gingiva (cT4aN2bM0, stage IV) by the 7th edition of the Union of International Cancer Control. She refused to receive definitive surgery or chemoradiotherapy due to concerns about the invasiveness of these definitive therapies and requested palliative chemoradiotherapy. We delivered S-1 (a combination of tegafur, gimeracil, and oteracil) and radiation therapy (RT) to the primary tumor alone with 30 Gy in 10 fractions using 4-megavoltage equipment via a multiple leaf collimator by three-dimensional RT. Although we could not complete the delivery of S-1 because of an acute side effect, the palliative chemoradiotherapy resulted in a complete response, and the lymph node metastases also disappeared. The patient remains in complete remission for 5 years without surgery or chemotherapy. Palliative chemoradiotherapy for elderly patients with mandibular gingival carcinoma is considered to be one of the therapeutic options.
Radiation recall phenomenon after administration of the mRNA-1273 SARS-CoV-2 vaccine. 国際誌

Yojiro Ishikawa, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Keiichi Jingu

International cancer conference journal　11　(1)　1-5　2022年1月9日

DOI： 10.1007/s13691-021-00528-5 　

詳細を見る詳細を閉じる

Several types of SARS-CoV-2 vaccine have been developed. However, the relationship between SARS-CoV-2 vaccine and radiation therapy (RT) is unclear. Recently, there have been some reports of radiation recall phenomenon (RRP) caused by a SARS-CoV-2 vaccine. We report a case of RRP after administration of the mRNA-1273 SARS-CoV-2 vaccine. A 51-year-old female was diagnosed with breast cancer (cT4N1M0, cStage IIIB) and underwent breast total mastectomy with axillary lymph node dissection after neoadjuvant chemotherapy. After mastectomy, the patient received RT with 50 Gy in 25 fractions. An acute side effect of grade 2 dermatitis according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. occurred after RT. The patient had not started any new systemic medication after RT; however, the patient received the mRNA-1273 SARS-CoV-2 vaccine (Moderna) 1 month after the end of the initial RT. Seven days after vaccination, the patient had a skin reaction with burning sensation and redness. This skin reaction was induced in an area corresponding to the irradiation field of the chest wall. There was no skin reaction in areas other than that described. The reaction was cured within 1 week with topical hydrocortisone. This report is an interesting case report with a RPP after administration of the mRNA-1273 SARS-CoV-2 vaccine.
Longitudinal analyses and predictive factors of radiation-induced lung toxicity-related parameters after stereotactic radiotherapy for lung cancer. 国際誌

Takaya Yamamoto, Yoshiyuki Katsuta, Kiyokazu Sato, Yoko Tsukita, Rei Umezawa, Noriyoshi Takahashi, Yu Suzuki, Kazuya Takeda, Keita Kishida, So Omata, Eisaku Miyauchi, Ryota Saito, Noriyuki Kadoya, Keiichi Jingu

PloS one　17　(12)　e0278707　2022年

DOI： 10.1371/journal.pone.0278707 　

詳細を見る詳細を閉じる

BACKGROUND AND PURPOSE: The purpose of this prospective study was to investigate changes in longitudinal parameters after stereotactic radiotherapy for lung cancer and to identify possible pretreatment factors related to radiation-induced lung toxicity and the decline in pulmonary function after radiotherapy. MATERIALS AND METHODS: Protocol-specified examinations, including 4-D CT, laboratory tests, pulmonary function tests (PFTs) and body composition measurements, were performed before SRT and at 1 month, 4 months and 12 months after stereotactic radiotherapy. Longitudinal differences were tested by using repeated-measures analysis of variance. Correlations were examined by using the Pearson product-moment correlation coefficient (r). RESULTS: Sixteen patients were analyzed in this study. During a median follow-up period of 26.6 months, grade 1 and 2 lung toxicity occurred in 11 patients and 1 patient, respectively. The mean Hounsfield units (HU) and standard deviation (SD) of the whole lung, as well as sialylated carbohydrate antigen KL-6 (KL-6) and surfactant protein-D (SP-D), peaked at 4 months after radiotherapy (p = 0.11, p<0.01, p = 0.04 and p<0.01, respectively). At 4 months, lung V20 Gy (%) and V40 Gy (%) were correlated with changes in SP-D, whereas changes in the mean HU of the lung were related to body mass index and lean body mass index (r = 0.54, p = 0.02; r = 0.57, p = 0.01; r = 0.69, p<0.01; and r = 0.69, p<0.01, respectively). The parameters of PFTs gradually declined over time. When regarding the change in PFTs from pretreatment to 12 months, lung V5 Gy (cc) showed significant correlations with diffusion capacity for carbon monoxide (DLCO), DLCO/alveolar volume and the relative change in DLCO (r = -0.72, p<0.01; r = -0.73, p<0.01; and r = -0.63, p = 0.01, respectively). CONCLUSIONS: The results indicated that some parameters peaked at 4 months, but PFTs were the lowest at 12 months. Significant correlations between lung V5 Gy (cc) and changes in DLCO and DLCO/alveolar volume were observed.
The Impact of Histological Subtype on Survival Outcome of Patients with Stage IIB-IVA Cervical Cancer Who Received Definitive Radiotherapy.

Shuko Miyahara, Keita Tsuji, Muneaki Shimada, Yusuke Shibuya, Shogo Shigeta, Tomoyuki Nagai, Rei Umezawa, Hideki Tokunaga, Keiichi Jingu, Nobuo Yaegashi

The Tohoku journal of experimental medicine　255　(4)　303-313　2021年12月

DOI： 10.1620/tjem.255.303 　

詳細を見る詳細を閉じる

The impact of histologic subtype on definitive radiotherapy for patients with locally advanced cervical cancer remains unclear. The aim of this retrospective analysis was to assess clinicopathological findings and clinical outcome by histological type in patients with stage IIB-IVA cervical cancer. Ninety-two patients with stage IIB-IVA [International Federation of Gynecology and Obstetrics (FIGO) 2008] cervical cancer, who underwent definitive radiotherapy between 2013 to 2018, were identified as eligible for this study. The clinical information of the eligible patients was obtained from medical records of our hospital. Seventy-eight patients underwent concurrent chemoradiotherapy, and the remaining 14 patients received radiotherapy alone. Of 92 patients, 83 had squamous cell carcinoma (SCC) and 9 had non-SCC histology. Progression-free survival (PFS) rate of patients with non-SCC was significantly worse than of those with SCC (2-year PFS: 62.0% vs. 12.5%, p = 0.0020), but overall survival (OS) rate did not statistically differ between the two subtypes (2-year OS: 82.4% vs. 62.5%, p = 0.2157). Pelvic failure-free (PFF) rate of patients with non-SCC histology was significantly worse than of those with non-SCC (2-year PFF; 88.2% vs. 25.0%, p < 0.0001). In univariate analysis, non-SCC histology was associated with PFS rate, although there was no association with OS rate. In multivariate analysis, non-SCC histology and lymph node metastasis were independent prognostic factors for shorter PFS. In patients with stage IIB-IVA cervical cancer who underwent definitive radiotherapy, patients with non-SCC showed significantly worse PFS rate than those with SCC.
Hyperfractionated radiotherapy for re-irradiation of recurrent esophageal cancer. 国際誌

Kazuya Takeda, Haruo Matsushita, Rei Umezawa, Takaya Yamamoto, Yojiro Ishikawa, Noriyoshi Takahashi, Yu Suzuki, Keiichi Jingu

Radiation oncology journal　39　(4)　265-269　2021年12月

DOI： 10.3857/roj.2021.00325 　

詳細を見る詳細を閉じる

PURPOSE: Re-irradiation is a treatment option for recurrent esophageal cancer patients with a history of radiotherapy, but there is a risk of severe late adverse effects. This study focused on the efficacy and safety of re-irradiation using hyperfractionated radiotherapy. MATERIALS AND METHODS: Twenty-six patients who underwent re-irradiation by the hyperfraction technique using twice-daily irradiation of 1.2 Gy per fraction for recurrent esophageal cancer were retrospectively included in this study. The overall survival period after the start of secondary radiotherapy and the occurrence of late adverse effects were investigated. RESULTS: Of 26 patients, 21 (81%) received re-irradiation with definitive intention and 21 (81%) underwent concurrent chemotherapy. The median re-irradiation dose was 60 Gy in 50 fractions in 25 treatment days, and the median accumulated irradiation dose in equivalent dose in 2 Gy per fraction was 85.4 Gy with an α/β value of 3. The median interval between two courses of radiotherapy was 21.0 months. The median overall survival period was 15.8 months and the 1-year and 3-year overall survival rates were 64.3% and 28.3%, respectively. Higher dose of re-irradiation and concurrent chemotherapy significantly improved survival (p < 0.001 and p = 0.019, respectively). Severe late adverse effects with the Common Terminology Criteria for Adverse Events grade 3 or higher were observed in 5 (19.2%) patients, and 2 (7.7%) of them developed a grade 5 late adverse effect. CONCLUSION: High-dose re-irradiation using a hyperfractionated schedule with concurrent chemotherapy might be related to good prognosis, while the rate of late severe adverse effects is not high compared with the rates in past reports.
Successful treatment with radiation therapy for desmoid-type fibromatosis with unilateral hydronephrosis: a case report. 国際誌

Yojiro Ishikawa, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Keiichi Jingu

Journal of medical case reports　15　(1)　540-540　2021年10月27日

DOI： 10.1186/s13256-021-03088-7 　

詳細を見る詳細を閉じる

BACKGROUND: Desmoid-type fibromatosis is a rare disease that can result in hydronephrosis. Hydronephrosis associated with desmoid-type fibromatosis often requires surgery or ureteral stent insertion. Although radiation therapy is recommended for inoperable cases of desmoid-type fibromatosis, there has been no report of treatment for hydronephrosis associated with desmoid-type fibromatosis by radiation therapy alone. We herein report a case of successful treatment for inoperable recurrence of desmoid-type fibromatosis with unilateral hydronephrosis by radiation therapy alone. CASE PRESENTATION: A 43-year-old Japanese female underwent resection of desmoid-type fibromatosis in the right inguinal region and combined resection of the right external iliac vein 5 years before. Other treatment was not performed because of her pregnancy. Four years after surgery, desmoid-type fibromatosis recurred in the right pelvic wall. Cyclooxygenase-2 selective inhibitor treatment was given for 1 year, but her desmoid-type fibromatosis enlarged to more than 10 cm, and she had swelling of her right leg and hydronephrosis of her right kidney. The patient received 50.4 Gy in 28 fractions of prophylactic irradiation using 10 MV X-ray and 9 Gy in five fractions of a sequential boost for the recurrent desmoid-type fibromatosis. Although there was temporary tumor progression at 1 month after radiation therapy, slow regression of the tumor was seen. At 5 years after radiation therapy, there was no disease progression or severe complications. CONCLUSION: We experienced successful treatment for an inoperable case of desmoid-type fibromatosis with hydronephrosis. Moderate-dose radiation therapy alone is an effective and feasible approach for the management of hydronephrosis associated with desmoid-type fibromatosis.
頭頸部がんに対する根治放射線治療後の口腔関連QOL長期的推移

神宮啓一, 高橋紀善, 田坂俊, 梅澤玲, 山本貴也, 石川陽二郎, 武田一也, 鈴木友, 角谷倫之, 松下晴雄

頭頸部癌　47　(3)　290-294　2021年10月
出版者・発行元： (一社)日本頭頸部癌学会
ISSN：1349-5747

eISSN：1881-8382
膵癌に対する予防域を含めた放射線治療における3DCRTとIMRTでの急性期有害事象の比較

梅澤玲, 中川圭, 水間正道, 山本貴也, 石川陽二郎, 海野倫明, 神宮啓一

日本癌治療学会学術集会抄録集　59回　O52-6　2021年10月
出版者・発行元： (一社)日本癌治療学会
Clinical outcomes and prognostic factors for esophageal cancer in patients aged 80 years or older who were treated with definitive radiotherapy and chemoradiotherapy.

Noriyoshi Takahashi, Rei Umezawa, Keita Kishida, Takaya Yamamoto, Yojiro Ishikawa, Kazuya Takeda, Yu Suzuki, Kousei Kawabata, Satoshi Teramura, Keiichi Jingu

Esophagus : official journal of the Japan Esophageal Society　19　(1)　129-136　2021年9月2日

DOI： 10.1007/s10388-021-00876-4 　

詳細を見る詳細を閉じる

OBJECTIVE: Aging of populations has been rapidly increasing worldwide. The aim of this study was to identify prognostic factors of overall survival (OS) and progression-free survival (PFS) in patients aged 80 years or older who had esophageal cancer and received radiotherapy. METHODS: Patients aged 80 years or older who received radiotherapy between 2004 and 2015 were retrospectively reviewed. Pretreatment age, gender, performance status, Charlson comorbidity index score, tumor location, histology, clinical stage, results of blood tests and treatment methods were obtained to determine prognostic factors of OS and PFS. Survival curves were drawn using the Kaplan-Meier method and prognostic factors were analyzed using Cox's hazards model. RESULTS: Ninety-two patients were included. Thirty-five patients were treated with chemo-radiotherapy. The median follow-up period was 19.0 months. The 3-year OS and PFS rates were 44.7% and 28.4%, respectively. In multivariate analysis, clinical stage (hazard ratio [HR] 2.28, 95% confidence interval [CI] 1.40-3.73, p = 0.001) and the geriatric nutritional risk index (GNRI, HR 0.95, 95% CI 0.92-0.97, p < 0.001) were significant prognostic factors of OS. Clinical stage (HR 2.06, 95% CI 1.34-3.18, p = 0.001), tumor location (HR 2.04, 95% CI 1.39-3.01, p < 0.001) and GNRI (HR 0.96, 95% CI 0.94-0.99, p = 0.003) were significant prognostic factors of PFS. CONCLUSION: Clinical stage and GNRI were significant prognostic factors of OS and PFS. Tumor location was a significant prognostic factor of PFS. These prognostic factors might be useful for decision-making for elderly patients with esophageal cancer.
高齢食道癌患者における放射線治療の治療効果と予後因子の研究

高橋紀善, 梅澤玲, 神宮啓一

日本食道学会学術集会プログラム・抄録集　75回　295-295　2021年9月
出版者・発行元： (NPO)日本食道学会
最先端医療の今早期食道癌に対する心筋線量軽減による心毒性低下を図った高精度放射線治療の検討

梅澤玲, 神宮啓一

Medical Science Digest　47　(10)　541-544　2021年9月
出版者・発行元： (株)ニュー・サイエンス社
ISSN：1347-4340
Clinical predictors of severe late urinary toxicity after curative intensity-modulated radiation therapy for localized prostate cancer. 国際誌

Ken Takeda, Rei Umezawa, Yojiro Ishikawa, Takaya Yamamoto, Noriyoshi Takahashi, Kazuya Takeda, Noriyuki Kadoya, Haruo Matsushita, Yoshihide Kawasaki, Koji Mitsuzuka, Akihiro Ito, Yoichi Arai, Yoshihiro Takai, Keiichi Jingu

Journal of radiation research　2021年8月31日

DOI： 10.1093/jrr/rrab074 　

詳細を見る詳細を閉じる

Intractable late urinary toxicity is a serious complication after radiotherapy for patients with localized prostate cancer (LPC). We assessed clinical factors correlated with severe late urinary toxicity in LPC treated with curative image-guided intensity-modulated radiation therapy (IMRT). A total of 452 patients with LPC treated with IMRT between 2002 and 2016 were retrospectively analyzed. Among them, 432 patients received androgen deprivation therapy (ADT). The median total irradiated doses were 80 (range, 76-80) Gy. Each daily dose was 2 Gy per fraction. The median follow-up was 83 (range, 4-210) months. Late urinary toxicity was scored according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03. Grade 3 late urinary toxicity was observed in 27 patients. No cases with grade ≥ 4 late urinary toxicity were observed. The 5-, 10-, and 12.5-year grade 3 late urinary toxicity-free survival rates were 97%, 91.8% and 88.1%, respectively. Age, risk classification, total irradiated dose, ADT duration, antithrombotic therapy (AT), cardiovascular disease, hypertension (HT), diabetes mellitus (DM), dyslipidemia (DL), prior transurethral resection of the prostate (TURP) and prior high-intensity focused ultrasound (HIFU) were investigated for correlations with grade 3 late urinary toxicity. In univariate analysis, AT and prior HIFU and no other studied factors, were correlated with grade 3 late urinary toxicity. AT and prior HIFU appear to be predictive of grade 3 late urinary toxicity. Patients with LPC with these relevant clinical factors should be carefully followed up by sharing detailed information with the urology department.
膵癌診療ガイドライン2022の改訂作業の概況(放射線療法)

伊藤芳紀, 中村聡明, 大栗隆行, 染谷正則, 篠藤誠, 梅澤玲, 稲葉浩二, 土屋高旭, 小野幸果

膵臓　36　(3)　A94-A94　2021年8月
出版者・発行元： (一社)日本膵臓学会
ISSN：0913-0071

eISSN：1881-2805
Why not de-intensification for uterine cervical cancer? 国際誌

Naoya Murakami, Ken Ando, Masumi Murata, Kazutoshi Murata, Tatsuya Ohno, Tomomi Aoshika, Shingo Kato, Noriyuki Okonogi, Anneyuko I Saito, Joo-Young Kim, Yasuko Kumai, Yasuo Yoshioka, Shuhei Sekii, Kayoko Tsujino, Chairat Lowanichkiattikul, Poompis Pattaranutaporn, Yuko Kaneyasu, Tomio Nakagawa, Miho Watanabe, Takashi Uno, Rei Umezawa, Keiichi Jingu, Ayae Kanemoto, Masaru Wakatsuki, Katsuyuki Shirai, Hiroshi Igaki, Jun Itami

Gynecologic oncology　163　(1)　105-109　2021年7月19日

DOI： 10.1016/j.ygyno.2021.07.021 　

詳細を見る詳細を閉じる

OBJECTIVE: The majority of uterine cervical cancer is known to be related to human papillomavirus (HPV), and HPV-related tumors are known to be radio-sensitive. In the management of HPV-related oropharyngeal cancer, de-intensification of treatment has been attempted; however, no such attempt is performed in the management of cervical cancer. The aim of this study was to identify a group of patients who can safely be treated by de-escalated treatment intensity. METHODS: From the Asian international multi-institutional retrospective study involving 13 Japanese, one Thailand, and one Korean institutions based on 469 patients, squamous cell carcinoma (Scc), tumor reduction ratio ≥29%, tumor size before brachytherapy ≤4 cm, and total treatment time (TTT) <9 weeks were identified as factors having an influence on local control. Based on these findings, low-risk patients having these four factors were extracted, and treatment outcomes categorized in 10 Gy increment of CTVHR D90 were compared. RESULTS: Among 469 patients, 162 patients (34.5%) met the criteria of low-risk group, and 63, 41, 43, and 15 patients were categorized in CTVHR D90 50-60 Gy, 60-70 Gy, 70-80 Gy, and >80 Gy, respectively. While 4-y progression-free survival ranged from 66 to 80%, 4-y local control was consistently over 90% in every dose group. Rectum and bladder D2cc and incidence of late adverse events decreased as CTVHR D90 decreased. CONCLUSIONS: The low-risk patients achieved favorable local control with CTVHR D90 <80 Gy. A personalized treatment strategy based on tumor response could also be adopted for cervical cancer.
IMRT improves local control in patients with nasopharyngeal carcinoma compared with conventional radiotherapy: propensity score-matched analysis. 国際誌

Zichang Ma, Rei Umezawa, Takaya Yamamoto, Yojiro Ishikawa, Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Liuwei Tang, Kengo Ito, Noriyuki Kadoya, Keiichi Jingu

Japanese journal of clinical oncology　51　(9)　1444-1451　2021年7月12日

DOI： 10.1093/jjco/hyab100 　

詳細を見る詳細を閉じる

BACKGROUND: It is still controversial whether intensity-modulated radiotherapy has an obvious advantage over conventional radiotherapy. The purposes of this study were to evaluate prognostic factors in pre-treatment characteristics for nasopharyngeal carcinoma and to compare treatment outcomes in patients who received intensity-modulated radiotherapy and patients who received two-dimensional radiotherapy or three-dimensional radiotherapy. METHODS: We reviewed patients with nasopharyngeal carcinoma who received chemoradiotherapy in our hospital during the period from 2000 to 2017, and we excluded patients who had a history of surgery for nasopharyngeal carcinoma and those who had distant metastases before treatment. A total of 72 patients who were treated by radiotherapy with concurrent chemotherapy were enrolled. All of the patients were irradiated with a total dose of 58-70 Gy. Overall survival, locoregional control and progression-free survival rates were compared in the groups treated by intensity-modulated radiotherapy and two-dimensional/three-dimensional radiotherapy. Propensity score matching was performed to homogenize the two groups. RESULTS: The median follow-up period was 62.5 months. After propensity score matching, in patients treated with intensity-modulated radiotherapy, the 5-year rate of overall survival, locoregional control and progression-free survival were 73.5, 95.2 and 72.7%, respectively. In patients treated with two-dimensional/three-dimensional radiotherapy, the 5-year rate of overall survival, locoregional control and progression-free survival were 69.1, 67.7 and 51.8%, respectively. There was a significant difference between the groups only in locoregional control. Late toxicities of grade 2 or higher were occurred in 38.5 and 24.2% of the patients treated by two-dimensional/three-dimensional radiotherapy and intensity-modulated radiotherapy, respectively. CONCLUSIONS: Our results suggested that intensity-modulated radiotherapy is more effective than two-dimensional/three-dimensional radiotherapy in patients with nasopharyngeal carcinoma, especially in locoregional control.
A Pilot Study of Synchronization of Respiration-Induced Motions in the Duodenum and Stomach for the Primary Tumor in Radiation Therapy for Pancreatic Cancer Using 4-Dimensional Computed Tomography

Rei Umezawa, Akihisa Wakita, Yoshiyuki Katsuta, Yoshinori Ito, Satoshi Nakamura, Hiroyuki Okamoto, Noriyuki kadoya, Kana Takahashi, Koji Inaba, Naoya Murakami, Hiroshi Igaki, Keiichi Jingu, Jun Itami

Advances in Radiation Oncology　6　(4)　100730-100730　2021年7月

DOI： 10.1016/j.adro.2021.100730 　

eISSN：2452-1094
Evaluation of the dosimetric impact of heart function-based volumetric modulated arc therapy planning in patients with esophageal cancer.

Shohei Tanaka, Noriyuki Kadoya, Rei Umezawa, Hikaru Nemoto, Yoshiyuki Katsuta, Kengo Ito, Ken Takeda, Keiichi Jingu

Radiological physics and technology　14　(3)　279-287　2021年6月8日

DOI： 10.1007/s12194-021-00623-5 　

詳細を見る詳細を閉じる

Radiotherapy for esophageal cancer entails high-dose irradiation of the myocardium owing to its close anatomical proximity to the esophagus. This study aimed to evaluate the dosimetric impact of functional avoidance planning for the myocardium with volumetric-modulated arc therapy (VMAT) in patients with esophageal cancer and determine the feasibility of functional planning. Ten patients with early stage esophageal cancer were included in this study. The prescribed dose was 60 Gy administered in 30 fractions. An experienced physician contoured the left ventricle (LV) of the myocardium. For each patient, an anatomical plan (non-LV-sparing plan) and a functional plan (LV-sparing plan) were created using the VMAT. In the functional plan, the mean percentage of LV volume receiving a dose of ≥ 30 and ≥ 40 Gy was 6.0% ± 6.7% and 2.4% ± 2.7%, respectively, whereas in the anatomical plan, they were 11.7% ± 13.1% and 4.9% ± 6.5%, respectively. There were no significant differences with respect to the dose to the hottest 1 cm3 of the planning target volume (PTV) and the minimum dose of the gross tumor volume and the dosimetric parameters of other normal tissues between the anatomical and functional plans. We compared the anatomical and functional plans of patients with esophageal cancer undergoing VMAT. Our results demonstrated that the functional plan reduced the dose to the LV with no significant differences in the organs at risk and PTV, indicating that avoidance planning can be safely performed when administering VMAT in patients with esophageal cancer.
Differences in patterns of recurrence of squamous cell carcinoma and adenocarcinoma after radiotherapy for stage III non-small cell lung cancer.

Yu Katagiri, Keiichi Jingu, Takaya Yamamoto, Haruo Matsushita, Rei Umezawa, Yojiro Ishikawa, Noriyoshi Takahashi, Kazuya Takeda, Shun Tasaka, Noriyuki Kadoya

Japanese journal of radiology　39　(6)　611-617　2021年6月

DOI： 10.1007/s11604-021-01091-y 　

詳細を見る詳細を閉じる

PURPOSE: To evaluate the differences in patterns of recurrence and treatment results by histology after definitive radiotherapy for stage III non-small cell lung cancer (NSCLC) in Japan. MATERIALS AND METHODS: Patients with stage III NSCLC who underwent definitive radiotherapy between 2000 and 2016 in our institution were included. A total of 217 patients were enrolled. Propensity score matching was used to exclude the following confounding factors: (1) age (≥70 years or <70 years), (2) gender, (3) T factor, (4) N factor, (5) Eastern Cooperative Oncology Group performance status score and (6) smoking status (Brinkman index ≥400 or <400). RESULTS: The median observation period for survivors was 55.1 months. After propensity score matching, the Sqcc and adenocarcinoma groups each included 62 paired patients. There was no significant difference in OS or PFS between the adenocarcinoma and Sqcc groups. However, rates of recurrence in the GTV-primary site (p = 0.009) and GTV-lymph node site (p = 0.037) were significantly higher in patients with Sqcc than in patients with adenocarcinoma. New metastatic recurrence was more frequent in patients with adenocarcinoma than in patients with Sqcc (p = 0.025). CONCLUSION: There were significant differences in patterns of recurrence after definitive (chemo)radiotherapy between patients with Sqcc and patients with adenocarcinoma.
Treatment results of radiotherapy to both the prostate and metastatic sites in patients with bone metastatic prostate cancer. 国際誌

Koji Inaba, Keisuke Tsuchida, Tairo Kashihara, Rei Umezawa, Kana Takahashi, Kae Okuma, Naoya Murakami, Yoshinori Ito, Hiroshi Igaki, Minako Sumi, Yuko Nakayama, Yasuo Shinoda, Tomohiko Hara, Yoshiyuki Matsui, Motokiyo Komiyama, Hiroyuki Fujimoto, Jun Itami

Journal of radiation research　62　(3)　511-516　2021年5月12日

DOI： 10.1093/jrr/rraa056 　

詳細を見る詳細を閉じる

Although systemic therapy is the standard treatment for metastatic prostate cancer, a randomized controlled trial showed radiotherapy to the prostate improved overall survival of metastatic prostate cancer patients with the low metastatic burden. Additionally, a randomized phase II trial showed that metastasis-directed therapy for oligo-recurrent prostate cancer improved androgen-deprivation therapy (ADT)-free survival. Therefore, administering radiotherapy to both prostate and metastatic regions might result in better outcomes. Thus, we report the treatment results of radiotherapy to both prostate and metastatic regions. Our institutional database was searched for patients who received radiotherapy to the prostate and metastatic regions. We summarized patient characteristics and treatment efficacy and performed statistical analysis to find possible prognostic factors. A total of 35 patients were included in this study. The median age was 66 years, and the median initial prostate-specific antigen (PSA) level was 32 ng/ml. The Gleason score was 7 in 10 patients, 8 in 13 patients, and 9 in 12 patients. The median radiotherapy dose was 72 Gy to the prostate and 50 Gy to the metastatic bone region. The 8-year overall survival, cause-specific survival, progression-free survival, and freedom from biochemical failure rate were 81, 85, 53, and 57%. Among the 35 patients, 12 were disease-free even after ADT was discontinued. In selected patients with metastatic prostate cancer, ADT and radiotherapy to the prostate and metastatic sites were effective. Patients with good response to ADT may benefit from radiotherapy to both prostate and metastatic regions.
Stereotactic body radiotherapy for kidney cancer: a 10-year experience from a single institute. 国際誌

Takaya Yamamoto, Yoshihide Kawasaki, Rei Umezawa, Noriyuki Kadoya, Haruo Matsushita, Kazuya Takeda, Yojiro Ishikawa, Noriyoshi Takahashi, Yu Suzuki, Ken Takeda, Kousei Kawabata, Akihiro Ito, Keiichi Jingu

Journal of radiation research　62　(3)　533-539　2021年5月12日

DOI： 10.1093/jrr/rrab031 　

詳細を見る詳細を閉じる

The purpose of this retrospective study was to investigate survival outcomes and irradiated tumor control (local control [LC]) and locoregional control (LRC) after stereotactic body radiotherapy (SBRT) for T1 or recurrent T1 (rT1) kidney cancer. Twenty-nine nonconsecutive patients with 30 tumors were included. SBRT doses of 70 Gy, 60 Gy or 50 Gy in 10 fractions were prescribed with a linear accelerator using daily image guidance. The Kaplan-Meier method was used to estimate time-to-event outcomes, and the log-rank test was used to compare survival curves between groups divided by each possible factor. The median follow-up periods for all patients and survivors were 57 months and 69.6 months, respectively. The five-year LC rate, LRC rate, progression-free survival (PFS) rate, disease-specific survival (DSS) rate and overall survival (OS) rate were 94%, 88%, 50%, 96% and 68%, respectively. No significant factor was related to OS and PFS. Three of 24 non-hemodialysis (HD) patients had new-onset-HD because of the progression of underlying kidney disease. Grade 3 or higher toxicities from SBRT did not occur. In conclusion, SBRT for kidney cancer provided a high rate of LC, LRC and DSS with minimal toxicities, but patient selection and indication for SBRT should be done carefully considering the relatively low OS rate.
放射線治療

神宮啓一, 梅澤玲, 山本貴也, 石川陽二郎, 高橋紀善, 武田一也, 鈴木友, 寺村聡司, 尾股聡

日本気管食道科学会会報　72　(2)　84-87　2021年4月
出版者・発行元： (NPO)日本気管食道科学会
ISSN：0029-0645

eISSN：1880-6848
Comparison of predictive performance for toxicity by accumulative dose of DVH parameter addition and DIR addition for cervical cancer patients. 国際誌

Yuya Miyasaka, Noriyuki Kadoya, Rei Umezawa, Yoshiki Takayama, Kengo Ito, Takaya Yamamoto, Shohei Tanaka, Suguru Dobashi, Ken Takeda, Kenji Nemoto, Takeo Iwai, Keiichi Jingu

Journal of radiation research　62　(1)　155-162　2021年1月1日

DOI： 10.1093/jrr/rraa099 　

詳細を見る詳細を閉じる

We compared predictive performance between dose volume histogram (DVH) parameter addition and deformable image registration (DIR) addition for gastrointestinal (GI) toxicity in cervical cancer patients. A total of 59 patients receiving brachytherapy and external beam radiotherapy were analyzed retrospectively. The accumulative dose was calculated by three methods: conventional DVH parameter addition, full DIR addition and partial DIR addition. ${D}_{2{cm}^3}$, ${D}_{1{cm}^3}$ and ${D}_{0.1{cm}^3}$ (minimum doses to the most exposed 2 cm3, 1cm3 and 0.1 cm3 of tissue, respectively) of the rectum and sigmoid were calculated by each method. V50, V60 and V70 Gy (volume irradiated over 50, 60 and 70 Gy, respectively) were calculated in full DIR addition. The DVH parameters were compared between toxicity (≥grade1) and non-toxicity groups. The area under the curve (AUC) of the receiver operating characteristic (ROC) curves were compared to evaluate the predictive performance of each method. The differences between toxicity and non-toxicity groups in ${D}_{2{cm}^3}$ were 0.2, 5.7 and 3.1 Gy for the DVH parameter addition, full DIR addition and partial DIR addition, respectively. The AUCs of ${D}_{2{cm}^3}$ were 0.51, 0.67 and 0.57 for DVH parameter addition, full DIR addition and partial DIR addition, respectively. In full DIR addition, the difference in dose between toxicity and non-toxicity was the largest and AUC was the highest. AUCs of V50, V60 and V70 Gy were 0.51, 0.63 and 0.62, respectively, and V60 and V70 were high values close to the value of ${D}_{2{cm}^3}$ of the full DIR addition. Our results suggested that the full DIR addition may have the potential to predict toxicity more accurately than the conventional DVH parameter addition, and that it could be more effective to accumulate to all pelvic irradiation by DIR.
The Long-Term Recovery of Parotid Glands in Nasopharyngeal Carcinoma Treated by Intensity-Modulated Radiotherapy. 国際誌

Shun Tasaka, Keiichi Jingu, Noriyoshi Takahashi, Rei Umezawa, Takaya Yamamoto, Yojiro Ishikawa, Kazuya Takeda, Yu Suzuki, Noriyuki Kadoya

Frontiers in oncology　11　665837-665837　2021年

DOI： 10.3389/fonc.2021.665837 　

詳細を見る詳細を閉じる

Background: Xerostomia is one of the most common adverse events of radiotherapy in head and neck cancer patients. There have been many reports on functional changes of the parotid gland after radiation therapy, but there have been few reports on the volume of the parotid gland and its relationship with oral quality of life (QOL) and even fewer reports on longitudinal change of the parotid gland volume. The purpose of this study was to evaluate the long-term change of the parotid gland volume after intensity-modulated radiotherapy (IMRT) for nasopharyngeal carcinoma and the relationship between parotid irradiation dose and xerostomia symptoms. Methods: We retrospectively analyzed 26 patients with nasopharyngeal cancer treated by IMRT. Longitudinal changes of parotid gland volumes after IMRT were evaluated on CT images. The parotid gland volumes in each period were converted to the ratio to parotid gland volumes before radiotherapy (relative parotid volume). Dunnett's test was used to evaluate the longitudinal changes in relative parotid volumes at 0-6, 7-18, 19-30, 31-42, 43-54 and 55-66 months after IMRT. We assessed xerostomia 3 years or more after IMRT by measuring the degree of oral moisture using a moisture-checking device (Mucus, Life Co., Ltd.) and oral QOL evaluation by GOHAI (General Oral Health Assessment Index). Results: The relative parotid volumes during radiotherapy and at 0-6, 7-18, 19-30, 31-42, 43-54 and 55-66 months after IMRT were 75.2 ± 14.3%, 67.2 ± 11.4%, 68.5 ± 15.9%, 72.4 ± 14.8%, 73.0 ± 13.8%, 76.2 ± 17.5%, and 77.1% ± 17.3%, respectively. The parotid volume had recovered significantly at 43-54 and 55-66 months after IMRT, especially in parotids receiving less than 40 Gy as the mean dose. The mean irradiated dose for bilateral parotids showed negative correlations with oral QOL score and oral moisture after a long period. Conclusions: The parotid volume recovered gradually but had not reached a plateau even 3 years after radiotherapy, especially in parotids receiving less than 40 Gy as the mean dose.
Dose-dependent Radiation-induced Myocardial Damage in Esophageal Cancer Treated with Chemoradiotherapy: A Prospective Cardiac Magnetic Resonance Imaging Study 査読有り

Rei Umezawa, Noriyuki Kadoya, Hideki Ota, Yujiro Nakajima, Masahide Saito, Hidenobu Takagi, Kentaro Takanami, Noriyoshi Takahashi, Yojiro Ishikawa, Takaya Yamamoto, Haruo Matsushita, Ken Takeda, Kei Takase, Keiichi Jingu

Advances in Radiation Oncology　5　(6)　1170-1178　2020年8月
出版者・発行元： Elsevier BV
DOI： 10.1016/j.adro.2020.07.012 　

ISSN：2452-1094
局所進行直腸癌に対するTS-1/CPT-11併用術前化学放射線療法の多施設共同臨床第II相試験の長期成績 SAMRAI-2

宮本裕士, 馬場秀夫, 大屋夏生, 佐藤武郎, 早川和重, 冨田尚裕, 的場周一郎, 肥田侯矢, 西舘敏彦, 坂田耕一, 内藤剛, 梅澤玲, 久保亜貴子, 有賀久哲, 笹野仲史, 竹内正弘, 坂井義治, 渡邊昌彦

日本大腸肛門病学会雑誌　73　(7)　325-325　2020年7月
出版者・発行元： (一社)日本大腸肛門病学会
ISSN：0047-1801

eISSN：1882-9619
A long-term survival case following salvage stereotactic radiotherapy for local recurrence after definitive chemoradiotherapy for stage III non-small cell lung cancer 査読有り

Yuta Sato, Keiichi Jingu, Rei Umezawa, Takaya Yamamoto, Yojiro Ishikawa, Kazuya Takeda, Yu Suzuki, Haruo Matsushita

INTERNATIONAL CANCER CONFERENCE JOURNAL　2020年7月

DOI： 10.1007/s13691-020-00431-5 　

ISSN：2192-3183
Clinical experience of pelvic radiotherapy or chemoradiotherapy for postoperative uterine cervical cancer using intensity-modulated radiation therapy. 国際誌査読有り

Takaya Yamamoto, Rei Umezawa, Hideki Tokunaga, Masaki Kubozono, Maiko Kozumi, Noriyoshi Takahashi, Haruo Matsushita, Noriyuki Kadoya, Kengo Ito, Kiyokazu Sato, Keita Tsuji, Muneaki Shimada, Keiichi Jingu

Journal of radiation research　61　(3)　470-478　2020年5月22日

DOI： 10.1093/jrr/rraa004 　

詳細を見る詳細を閉じる

The purpose of this study was to reveal treatment outcomes and toxicity after pelvic intensity-modulated radiotherapy (IMRT) for postoperative uterine cervical cancer of Japanese patients. Consecutive patients who were treated with pelvic IMRT for postoperative cervical cancer in our institute were retrospectively analyzed. Relapse-free survival (RFS) and overall survival (OS) were calculated using the Kaplan-Meier estimator, and log-rank tests were used to compare differences. From the database, 62 patients were identified. The pathology was squamous cell carcinoma in 44 patients and other pathology in 18 patients. Of the 62 patients, 35 had high-risk prognostic factors and 27 patients had intermediate-risk prognostic factors. The prescribed radiation doses were 50 Gy in 25 fractions for 58 patients and 50.4 Gy in 28 fractions for 4 patients. One patient received a vaginal cuff boost. Chemotherapy was administered in 36 patients. During the median follow-up period of 50.9 months, there was no locoregional failure. Six patients in the high-risk group relapsed, but none of the patients in the intermediate-risk group relapsed (P = 0.02). The 3-year OS and RFS rates were 98.2% and 90.9%, respectively. Significant factors related to RFS were squamous cell carcinoma pathology (P = 0.02), pathological T stage (P = 0.04), surgical margin status (P < 0.01) and multiple lymph nodes metastases (P < 0.01). Grade 3 or more toxicity occurred in 6 patients. Four patients had obstruction of the intestine, and 2 patients had stenosis of the urinary tract. In clinical practice, the use of pelvic IMRT for postoperative cervical cancer of Japanese patients showed a low rate of toxicity without decreasing the efficacy.
How Much Was the Elective Lymph Node Region Covered in Involved-Field Radiation Therapy for Locally Advanced Pancreatic Cancer? Evaluation of Overlap Between Gross Target Volume and Celiac Artery–Superior Mesenteric Artery Lymph Node Regions

Rei Umezawa, Yoshinori Ito, Akihisa Wakita, Satoshi Nakamura, Hiroyuki Okamoto, Kana Takahashi, Koji Inaba, Naoya Murakami, Hiroshi Igaki, Keiichi Jingu, Jun Itami

Advances in Radiation Oncology　5　(3)　377-387　2020年5月

DOI： 10.1016/j.adro.2019.08.014 　

eISSN：2452-1094
Quantitative analysis of intra-fractional variation in CT-based image guided brachytherapy for cervical cancer patients. 国際誌査読有り

Yuya Miyasaka, Noriyuki Kadoya, Kengo Ito, Rei Umezawa, Masaki Kubozono, Takaya Yamamoto, Yujiro Nakajima, Masahide Saito, Yoshiki Takayama, Kenji Nemoto, Takeo Iwai, Keiichi Jingu

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)　73　164-172　2020年5月

DOI： 10.1016/j.ejmp.2020.04.009 　

詳細を見る詳細を閉じる

We quantified intra-fractional dose variation and organ movement during CT-based 3D-image guided brachytherapy (3D-IGBT) in cervical cancer patients. Fifteen patients who underwent CT-based 3D-IGBT were studied. For all patients, pre-delivery CT for treatment planning after applicator insertion and post-delivery CT after dose delivery without changing the applicator position were acquired. Pre- and post-delivery CT were rigidly fused by matching the inserted applicator and planned dose on pre-delivery CT (pre-delivery dose) was mapped on post-delivery CT (post-delivery dose). D2, D1, and D0.1 cm3 of the rectum and bladder were compared between pre- and post-delivery doses with contours on each CT image. Organ movement and deformation was evaluated using deformation vector fields calculated by deformable image registration between pre- and post-delivery CT. We also evaluated dose variation and DVF between with and without a catheter to control filling. Differences in all DVH parameters were <±3% in physical dose and ± 5% in EQD2. However, a > 15% dose difference was found in 13.8% of the fractions in rectum D2 cm3 and in 11.1% of those in bladder D2 cm3. The mean value of DVF for bladder was larger than that of rectum, especially for the superior-inferior (S-I) direction. Insertion catheters in bladder reduced mean dose and DVF variation compared with that of without catheters. In fraction groups with large dose increasing, DVF in the S-I direction was significantly larger than that of other fraction groups. Our results indicated that preparation is needed to reduce changes in the S-I direction affect dose variation.
Risk factors of severe benign cicatricial stricture after definitive chemoradiation for localized T3 esophageal carcinoma 査読有り

Satomi NT, Honma Y, Nagashima K, Umezawa R, Ito Y, Hirano H, Shoji H, Takashima A, Iwasa S, Kato K, Hamaguchi T, Itami J, Boku N

Anticancer Research　40　(2)　1071-1077　2020年1月

DOI： 10.21873/anticanres.14045 　
FDG-PET might not contribute to improving survival in patients with locally advanced inoperable esophageal cancer. 査読有り

Keiichi Jingu, Rei Umezawa, Takaya Yamamoto, Kazuya Takeda, Yojiro Ishikawa, Noriyoshi Takahashi, Noriyuki Kadoya, Haruo Matsushita

International journal of clinical oncology　24　(8)　927-933　2019年8月

DOI： 10.1007/s10147-019-01428-8 　

ISSN：1341-9625

詳細を見る詳細を閉じる

BACKGROUND: In Japan, positron emission tomography using 18F-fluorodeoxyglucose (FDG-PET) has been covered by the national health insurance for esophageal cancer since 2006. FDG-PET is commonly performed in advanced esophageal cancer. The aim of this study was to determine the effect of FDG-PET on survival in patients with locally advanced inoperable esophageal cancer. METHODS: We retrospectively reviewed all patients with cT4 and without M1 esophageal cancer on CT in our institution between 2000 and 2014, and data for 78 patients who meet the eligibility criteria described below were used for analysis in this study. The eligibility criteria included (1) cT4 esophageal cancer without distant metastases or M1 lymph node metastasis (UICC 2002), (2) histologically proven squamous cell carcinoma, (3) 20-79 years of age, (4) having undergone at least 1 cycle of concomitant chemotherapy, (5) having been irradiated with 50 Gy or more, and (6) no other active malignant tumor during treatment. RESULTS: Two patients were excluded because abdominal lymph node metastases or neck lymph node metastases were detected by FDG-PET. In 78 eligible patients, FDG-PET was not performed before treatment in 41 of the 78 patients and was performed in the other patients. The median observation period was 68 months. The 3-year and 5-year overall survival rates in 78 patients were 36.9% and 30.8%, respectively. There was no significant difference in overall survival or progression-free survival between patients in whom FDG-PET was performed and those in whom FDG-PET was not performed (12.0 months vs. 11.0 months, p = 0.920 and 6.0 months vs. 6.0 months, p = 0.844, respectively). CONCLUSIONS: Compared with only CT, additional information from FDG-PET is not associated with improving survival in patients with locally advanced esophageal cancer. Our results suggest that FDG-PET might not have much meaning for survival in locally advanced esophageal cancer.
Hyaluronate gel injection for rectum dose reduction in gynecologic high-dose-rate brachytherapy: initial Japanese experience. 国際誌査読有り

Tairo Kashihara, Naoya Murakami, Nikolaos Tselis, Kazuma Kobayashi, Keisuke Tsuchida, Satoshi Shima, Koji Masui, Ken Yoshida, Kana Takahashi, Koji Inaba, Rei Umezawa, Hiroshi Igaki, Yoshinori Ito, Tomoyasu Kato, Takashi Uno, Jun Itami

Journal of radiation research　60　(4)　501-508　2019年7月1日

DOI： 10.1093/jrr/rrz016 　

ISSN：0449-3060

詳細を見る詳細を閉じる

Perirectal hyaluronate gel injection (HGI) appears to be a promising technique for healthy tissue dose sparing in pelvic radiotherapy. In this analysis, we report our initial experience of HGI in gynecologic brachytherapy, focusing on its safety and effectiveness for dose reduction to the rectum. Between July 2013 and May 2014, 36 patients received HGI for primary/salvage gynecologic brachytherapy. Dosimetric effect analysis was based on pre- and post-HGI computed tomography dataset registration with corresponding dose-volume histogram evaluation. The maximum dose to the most exposed 0.1 cm3 (D0.1cm3) and 2.0 cm3 (D2.0cm3) were used as index values for rectum and bladder dose evaluation. The dose indexes for target volume (TV) coverage were TV D90/V100. In all cases, HGI was well tolerated, with no acute or late adverse events documented at a median follow-up of 220 days (range, 18-1046 days). Rectum D2.0cm3 and D0.1cm3 were significantly decreased by HGI (P < 0.001 and P = 0.003, respectively), with no significant impact on dosimetric parameters of bladder and TV coverage. Factors correlating negatively with the dosimetric effect of HGI were an increasing number of interstitial catheters (P = 0.003) as well as Lcranial100% (P = 0.014) and Lcranial80% (P = 0.001) [i.e. the length from the anal verge to the most cranial point at which the 100% and 80% isodose lines, respectively, crossed the rectum]. The concept of HGI for gynecologic brachytherapy is plausible, and our initial experience indicates it to be an effective technique for rectal dose reduction in radiotherapy of intrapelvic tumours.
放射線療法の進歩と明日への提言

伊藤芳紀, 澁谷景子, 中村聡明, 大栗隆行, 染谷正則, 堀正和, 高橋昌太郎, 篠藤誠, 梅澤玲

膵臓　34　(3)　A16-A16　2019年6月
出版者・発行元： (一社)日本膵臓学会
ISSN：0913-0071

eISSN：1881-2805
Predictors of severe late urinary toxicity after curative radiotherapy for localised prostatecancer 査読有り

K.Takeda, Y.Takayama, N.Kadoya, H.Takagi, K.Ito, T.Chiba, K.Sato, S.Dobashi, R.Umezawa, T.Yamamoto, Y.Ishikawa, K.Takeda, H.Matsushita, Y.Kawasaki, K.Mitsuduka, K.Jingu

Radiother Oncol　133　(supplement 1)　S823-S824　2019年4月
Dose escalation of external beam radiotherapy for high-risk prostate cancer-Impact of multiple high-risk factor. 国際誌

Rei Umezawa, Koji Inaba, Satoshi Nakamura, Akihisa Wakita, Hiroyuki Okamoto, Keisuke Tsuchida, Tairo Kashihara, Kazuma Kobayashi, Ken Harada, Kana Takahashi, Naoya Murakami, Yoshinori Ito, Hiroshi Igaki, Keiichi Jingu, Jun Itami

Asian journal of urology　6　(2)　192-199　2019年4月

DOI： 10.1016/j.ajur.2017.07.002 　
A hybrid technique of intracavitary and interstitial brachytherapy for locally advanced cervical cancer: initial outcomes of a single-institute experience. 国際誌査読有り

Naoya Murakami, Kazuma Kobayashi, Satoshi Shima, Keisuke Tsuchida, Tairo Kashihara, Nikolaos Tselis, Rei Umezawa, Kana Takahashi, Koji Inaba, Yoshinori Ito, Hiroshi Igaki, Yuko Nakayama, Koji Masui, Ken Yoshida, Tomoyasu Kato, Jun Itami

BMC cancer　19　(1)　221-221　2019年3月12日

DOI： 10.1186/s12885-019-5430-x 　

詳細を見る詳細を閉じる

BACKGROUND: Locally advanced uterine cervical cancer (LAUCC) with lateral tumor extension may not always be covered adequately by conventional intracavitary brachytherapy (ICBT). Hybrid intracavitary and interstitial brachytherapy (HBT) seems to be an effective alternative by improving anatomy-oriented dose optimisation. The purpose of this study was to report initial clinical result for LAUCC treated by HBT. METHODS: Between January 2012 and November 2015, 42 patients with LAUCC (T1b2-4a) were treated with primary radiation therapy including HBT. Patients with distant metastasis other than para-aortic lymph node spread were excluded from this study. A retrospective analysis was performed for toxicity evaluation and oncological outcome calculation. RESULTS: Median follow-up was 23.2 months (range 13.2-71.4). Two-year overall survival, progression free survival, and local control rate were 81.6, 54.4, and 80.2%, respectively. Seven patients experienced local recurrence (16.6%). Of those, five were confined to the uterus and two at the parametria. Late adverse events ≥ grade 3 were seen in 3 patients. CONCLUSIONS: HBT can generate favorable local control in tumors which cannot be adequately covered by ICBT.
Automated noncoplanar treatment planning strategy in stereotactic radiosurgery of multiple cranial metastases: HyperArc and CyberKnife dose distributions. 査読有り

Kadoya N, Abe Y, Kajikawa T, Ito K, Yamamoto T, Umezawa R, Chiba T, Katsuta Y, Takayama Y, Kato T, Kikuchi Y, Jingu K

Medical dosimetry : official journal of the American Association of Medical Dosimetrists　2019年2月

DOI： 10.1016/j.meddos.2019.02.004 　

ISSN：0958-3947
Hypofractionated Radiotherapy for Anaplastic Thyroid Carcinoma: 15 Years of Experience in a Single Institution. 国際誌査読有り

Noriyoshi Takahashi, Haruo Matsushita, Rei Umezawa, Takaya Yamamoto, Yojiro Ishikawa, Yu Katagiri, Shun Tasaka, Kazuya Takeda, Katsuya Fukui, Noriyuki Kadoya, Kengo Ito, Keiichi Jingu

European thyroid journal　8　(1)　24-30　2019年1月

DOI： 10.1159/000493315 　

ISSN：2235-0640

詳細を見る詳細を閉じる

Background: Anaplastic thyroid carcinoma (ATC) is a rare cancer and has a poor prognosis. Several radiation protocols have been reported, but the results were not satisfactory. Objective: The aim of this study was to determine the effect of hypofractionated radiotherapy. Methods: Thirty-three patients who received radiotherapy for ATC between January 2000 and December 2014 were retrospectively included. We defined hypofractionated radiotherapy as a single dose ≥5 Gy. Results: Nineteen patients were treated with hypofractionated radiotherapy. Twenty-eight patients died, and 27 of those patients died from ATC. Sixteen patients died from distant metastasis and 6 from local recurrence. In the hypofractionated radiotherapy group, local recurrence occurred in 5 patients and 1 of them died from active bleeding from a local tumor. There was local recurrence in 7 patients who received the other protocol, and 5 of them died from asphyxiation, active bleeding, or uncontrollable growth of a local tumor on the neck. The median overall survival (OS) was 5 months. In multivariate analysis, patients who received an equivalent dose in 2-Gy fractions (EQD2) ≥50 Gy had significantly better OS (p = 0.016). In univariate analysis, patients who received hypofractionated radiotherapy did not have significantly better OS (p = 0.872) or local control (p = 0.090). The χ2 test showed that significantly fewer patients died from local recurrence in the hypofractionated radiotherapy group (p = 0.025). Conclusions: Multivariate analysis showed that an EQD2 ≥50 Gy resulted in better OS, and hypofractionated radiotherapy decreased the rate of mortality from local recurrence.
Left Ventricular T1 Mapping during Chemotherapy-Radiation Therapy: Serial Assessment of Participants with Esophageal Cancer. 国際誌査読有り

Hidenobu Takagi, Hideki Ota, Rei Umezawa, Tomoyoshi Kimura, Noriyuki Kadoya, Satoshi Higuchi, Wenyu Sun, Yujiro Nakajima, Masahide Saito, Yoshiaki Komori, Keiichi Jingu, Kei Takase

Radiology　289　(2)　347-354　2018年11月

DOI： 10.1148/radiol.2018172076 　

ISSN：0033-8419

詳細を見る詳細を閉じる

Purpose To assess changes in left ventricular function and tissue composition by using MRI after chemotherapy-radiation therapy in participants with esophageal cancer. Materials and Methods Between January 2013 and April 2015, this prospective study enrolled 24 participants (42% women; mean age, 63 years; range, 49-73 years) scheduled for chemotherapy-radiation therapy. 3.0-T MRI examinations were performed before, at 0.5 year, and at 1.5 years after chemotherapy-radiation therapy. Myocardial native T1, postcontrast T1, and extracellular volume were measured in basal septum (as irradiated areas) and apical lateral wall (as nonirradiated areas). Left ventricular function, prevalence of late gadolinium enhancement, and T1 and extracellular volume values were compared over the follow-up period by using Friedman or Cochran Q tests, followed by Dunn test. Results In 14 participants who were followed up for 1.5 years, native T1 and extracellular volume in the septum were elevated at 0.5 year compared with baseline (1183 msec ± 46 [standard deviation] vs 1257 msec ± 35; 26% ± 3 vs 32% ± 3; adjusted P < .01 for both), but not in the lateral wall. Left ventricular stroke volume index and late gadolinium enhancement changed at 1.5 years compared with baseline (41 mL/m2 ± 11 vs 36 mL/m2 ± 9; P = .046; 7% [one of 14] vs 78% [11 of 14]; P < .01). Other measures of left ventricular function did not change during the follow-up period (P > .10 for all). Conclusion Native T1 and extracellular volume could detect early changes in myocardium at 0.5 year after chemotherapy-radiation therapy, whereas left ventricular stroke volume index and late gadolinium enhancement showed abnormality at 1.5 years. © RSNA, 2018 Online supplemental material is available for this article.
Whole-body total lesion glycolysis is an independent predictor in patients with esophageal cancer treated with definitive chemoradiotherapy 査読有り

Noriyoshi Takahashi, Rei Umezawa, Kentaro Takanami, Takaya Yamamoto, Youjirou Ishikawa, Maiko Kozumi, Kazuya Takeda, Noriyuki Kadoya, Keiichi Jingu

Radiotherapy and Oncology　129　(1)　161-165　2018年10月
出版者・発行元： Elsevier {BV}
DOI： 10.1016/j.radonc.2017.10.019 　

ISSN：0167-8140

eISSN：1879-0887
Impact of change in serum albumin level during and after chemoradiotherapy in patients with locally advanced esophageal cancer. 査読有り

Kazuya Takeda, Rei Umezawa, Noriyoshi Takahashi, Haruo Matsushita, Maiko Kozumi, Yojiro Ishikawa, Takaya Yamamoto, Ken Takeda, Keiichi Jingu

Esophagus : official journal of the Japan Esophageal Society　15　(3)　190-197　2018年7月

DOI： 10.1007/s10388-018-0612-1 　

ISSN：1612-9059

eISSN：1612-9067
Oesophageal squamous cell carcinoma: histogram-derived ADC parameters are not predictive of tumour response to chemoradiotherapy 査読有り

Maiko Kozumi, Hideki Ota, Takaya Yamamoto, Rei Umezawa, Haruo Matsushita, Yojiro Ishikawa, Noriyoshi Takahashi, Tomonori Matsuura, Kei Takase, Keiichi Jingu

European Radiology　28　(10)　1-10　2018年5月3日
出版者・発行元： Springer Verlag
DOI： 10.1007/s00330-018-5439-6 　

ISSN：1432-1084 0938-7994
Importance of the site of positive surgical margin in salvage external beam radiation therapy for biochemical recurrence of prostate cancer after radical prostatectomy. 国際誌査読有り

Tairo Kashihara, Satoshi Nakamura, Akihisa Wakita, Hiroyuki Okamoto, Koji Inaba, Rei Umezawa, Satoshi Shima, Keisuke Tsuchida, Kazuma Kobayashi, Kana Takahashi, Naoya Murakami, Yoshinori Ito, Hiroshi Igaki, Hiroyuki Fujimoto, Takashi Uno, Jun Itami

Cancer medicine　7　(5)　1723-1730　2018年5月

DOI： 10.1002/cam4.1408 　

詳細を見る詳細を閉じる

The aim of this study was to examine long-term outcomes in patients who received salvage radiotherapy (SRT) for biochemical recurrence (BRec) of prostate cancer after radical prostatectomy (RP). One hundred and twenty patients with prostate cancer who underwent SRT for BRec after RP without evidence of clinical disease were identified in our institution from 2002 to 2014. Prescription doses to prostate beds were 64.8 Gy with a fractional dose of 1.8 Gy in 96.7% of the patients. In three-dimensional conformal radiation therapy (3D-CRT), the seminal vesicle bed (SVB) was not included in the radiation fields. The prognostic factors for BRec-free survival (BRFS) and incidence of acute and late toxicities were investigated. Median follow-up duration after SRT was 64.9 months. The 5-year rates of BRFS, overall survival (OS), cause-specific survival (CSS), and clinical recurrence-free survival (CRFS) were 39.2%, 98.3%, 97.0%, and 91.9%, respectively. Only two patients experienced late grade 3 toxicity of hematuria. Multivariate analysis revealed that BRFS was significantly favorable in patients with prostate-specific antigen (PSA) values <0.5 ng/mL at the initiation of SRT and pathological Gleason score not including Gleason grade 5. In patients treated with 3D-CRT, a positive surgical margin at the base of the prostate influenced BRFS unfavorably in comparison with positive surgical margins at other sites. SRT for patients with BRec after RP was performed very safely in our institution. However, to improve BRFS, adequate inclusion of the SVB appears mandatory, especially in cases of positive surgical margins at the base of the prostate.
Long-term Results of External Beam Radiotherapy for Prostate Cancer with Prostate-specific Antigen of More Than 50 ng/ml and Without Evidence of Lymph Node or Distant Metastasis. 国際誌査読有り

Rei Umezawa, Koji Inaba, Satoshi Nakamura, Akihisa Wakita, Hiroyuki Okamoto, Satoshi Shima, Keisuke Tsuchida, Tairo Kashihara, Kazuma Kobayashi, Ken Harada, Kana Takahashi, Naoya Murakami, Yoshinori Ito, Hiroshi Igaki, Keiichi Jingu, Jun Itami

Anticancer research　38　(4)　2303-2309　2018年4月

DOI： 10.21873/anticanres.12475 　

ISSN：0250-7005

eISSN：1791-7530

詳細を見る詳細を閉じる

BACKGROUND/AIM: To evaluate long-term treatment outcomes of external beam radiotherapy for prostate cancer with a pretreatment prostate-specific antigen (PSA) level of more than 50 ng/ml and without evidence of lymph node or distant metastasis. PATIENTS AND METHODS: Definitive radiotherapy of 66 Gy or 72 Gy in combination with androgen deprivation therapy (ADT) was performed. PSA relapse-free survival (PRFS), distant metastasis-free survival (DMFS), cause-specific survival (CSS), and overall survival (OS) were evaluated. The impact of prognostic factors on PRFS, DMFS, CSS, and OS was analyzed in univariate and multivariate analyses. RESULTS: One hundred twenty patients with a median follow-up period of 92.6 months were analyzed in this study. The median duration of ADT was 11.0 months. The 5- and 8-year PRFS rates in all patients were 65.1% and 48.5%, respectively. The 8-year DMFS, CSS, and OS rates in all patients were 84.0%, 93.4%, and 81.6%, respectively. Both in univariate and multivariate analyses, Gleason score (GS) and radiotherapy dose were significant prognostic factors (p=0.015 and 0.001). There was no significant difference between each prognostic factor in DMFS, CSS, and OS. CONCLUSION: We might have indicated the significance of definitive radiotherapy even for prostate cancer with PSA of more than 50 ng/ml and without evidence of metastasis.
Image-guided interstitial high-dose-rate brachytherapy for locally recurrent uterine cervical cancer: A single-institution study 査読有り

Rei Umezawa, Naoya Murakami, Satoshi Nakamura, Akihisa Wakita, Hiroyuki Okamoto, Keisuke Tsuchida, Tairo Kashihara, Kazuma Kobayashi, Ken Harada, Kana Takahashi, Koji Inaba, Yoshinori Ito, Hiroshi Igaki, Koji Masui, Ken Yoshida, Keiichi Jingu, Nikolaos Tselis, Jun Itami

Brachytherapy　17　(2)　368-376　2018年3月1日
出版者・発行元： Elsevier Inc.
DOI： 10.1016/j.brachy.2017.11.011 　

ISSN：1873-1449 1538-4721
Impact of a commercially available model-based dose calculation algorithm on treatment planning of high-dose-rate brachytherapy in patients with cervical cancer. 国際誌査読有り

Kota Abe, Noriyuki Kadoya, Shinya Sato, Shimpei Hashimoto, Yujiro Nakajima, Yuya Miyasaka, Kengo Ito, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Ken Takeda, Keiichi Jingu

Journal of radiation research　59　(2)　198-206　2018年3月1日

DOI： 10.1093/jrr/rrx081 　

ISSN：0449-3060

詳細を見る詳細を閉じる

We evaluated the impact of model-based dose calculation algorithms (MBDCAs) on high-dose-rate brachytherapy (HDR-BT) treatment planning for patients with cervical cancer. Seven patients with cervical cancer treated using HDR-BT were studied. Tandem and ovoid applicators were used in four patients, a vaginal cylinder in one, and interstitial needles in the remaining two patients. MBDCAs were applied to the Advanced Collapsed cone Engine (ACE; Elekta, Stockholm, Sweden). All plans, which were originally calculated using TG-43, were re-calculated using both ACE and Monte Carlo (MC) simulations. Air was used as the rectal material. The mean difference in the rectum D2cm3 between ACErec-air and MCrec-air was 8.60 ± 4.64%, whereas that in the bladder D2cm3 was -2.80 ± 1.21%. Conversely, in the small group analysis (n = 4) using water instead of air as the rectal material, the mean difference in the rectum D2cm3 between TG-43 and ACErec-air was 11.87 ± 2.65%, whereas that between TG-43 and ACErec-water was 0.81 ± 2.04%, indicating that the use of water as the rectal material reduced the difference in D2cm3 between TG-43 and ACE. Our results suggested that the differences in the dose-volume histogram (DVH) parameters of TG-43 and ACE were large for the rectum when considerable air (gas) volume was present in it, and that this difference was reduced when the air (gas) volume was reduced. Also, ACE exhibited better dose calculation accuracy than that of TG-43 in this situation. Thus, ACE may be able to calculate the dose more accurately than TG-43 for HDR-BT in treating cervical cancers, particularly for patients with considerable air (gas) volume in the rectum.
II・III期食道癌CRTにおける血液検査データと予後との関連

武田一也, 松下晴雄, 久保園正樹, 田邊隆哉, 石川陽二郎, 山本貴也, 古積麻衣子, 高橋紀善, 片桐佑, 田坂俊, 福井勝哉, 鈴木友, 角谷倫之, 伊藤謙吾, 千葉瑞己, 神宮啓一, 武田賢, 土橋卓, 梅澤玲

Japanese Journal of Radiology　36　(Suppl.)　5-5　2018年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
Stereotactic Radiotherapy for Oligometastases in Lymph Nodes-A Review. 国際誌査読有り

Haruo Matsushita, Keiichi Jingu, Rei Umezawa, Takaya Yamamoto, Yojiro Ishikawa, Noriyoshi Takahashi, Yu Katagiri, Noriyuki Kadoya

Technology in cancer research & treatment　17　1533033818803597-1533033818803597　2018年1月1日

DOI： 10.1177/1533033818803597 　

ISSN：1533-0346

詳細を見る詳細を閉じる

In recent years, the concept of oligometastases has become accepted and reports on stereotactic body radiotherapy as a treatment method have been published. Lesions in the brain, lung, and liver have been reported as target lesions. However, lymph node oligometastases could be a good candidate for stereotactic body radiotherapy as well. In this study, the usability of stereotactic body radiotherapy for oligometastases to lymph nodes is assessed by researching for each primary site. As a result, we could consider that stereotactic body radiotherapy could be almost well applied for lymph node oligometastases from the breast, gynecological organs, and prostate. However, doubts remain concerning the usefulness of stereotactic body radiotherapy for cervical node metastases from head and neck cancer or for mediastinal node metastases from lung or esophageal cancer since late toxicities have occurred with a large radiation dose at hypofractionation to major vessels or the central respiratory tract, especially in patients with irradiation histories. In addition, high-dose irradiation is required to control lymph node metastases from colorectal cancer due to its radioresistance, and severe late adverse events would therefore occur in adjacent organs such as the gastrointestinal tract. In cases of lymph node oligometastases with a primary tumor in the stomach or esophagus, stereotactic body radiotherapy should be used limitedly at present because this patient population is not so large and these metastases are often located close to organs at risk. Because of the varied status of recurrence and varied conditions of patients, it is difficult to determine the optimal dose for tumor control. It might be reasonable to determine the treatment dose individually based on dose constraints of adjacent organs. The oligometastatic state is becoming more frequently identified with more sensitive methods of detecting such oligometastases. In addition, there seems to be another type of oligometastases, so-called induced oligometastases, following successful systemic treatment. To determine the optimal indication of stereotactic body radiotherapy for lymph node oligometastases, further investigation about the mechanisms of oligometastases and further clinical studies including a phase III study are needed.
Assessment and agreement of the CT appearance pattern and its severity grading of radiation-induced lung injury after stereotactic body radiotherapy for lung cancer. 国際誌査読有り

Takaya Yamamoto, Noriyuki Kadoya, Yohei Morishita, Yoshinao Sato, Haruo Matsushita, Rei Umezawa, Yojiro Ishikawa, Noriyoshi Takahashi, Yu Katagiri, Ken Takeda, Keiichi Jingu

PloS one　13　(10)　e0204734　2018年

DOI： 10.1371/journal.pone.0204734 　

詳細を見る詳細を閉じる

PURPOSE: Radiographic severity of radiation-induced lung injury (RILI) has not been well-studied. The goal of this study was to assess the CT appearance pattern and severity of RILI without consideration of the clinical presentation. MATERIAL AND METHODS: A total of 49 patients, 41 with primary lung cancer and 8 with metastatic lung cancer, were treated by 4-fraction stereotactic body radiotherapy (SBRT). RILI after SBRT was separately assessed by two observers. The early and late CT appearance patterns and CT-based severity grading were explored. RESULTS: The median follow-up period was 39.0 months. In the early CT findings of observers 1 and 2, there was diffuse consolidation in 15 and 8, diffuse ground glass opacity (GGO) in 0 and 0, patchy consolidation and GGO in 17 and 20, patchy GGO in 3 and 3, and no changes in 10 and 14, respectively (kappa = 0.61). In late CT findings of observer 1 and 2, there were modified conventional pattern in 28 and 24, mass-like pattern in 8 and 11, scar-like pattern in 12 and 12, and no changes in 1 and 2, respectively (kappa = 0.63). In the results of the CT-based grading by observers 1 and 2, there were grade 0 in 1 and 2, grade 1 in 10 and 14, grade 2 in 31 and 29, grade 3 in 7 and 4, and none of grade 4 or more, respectively (kappa = 0.66). According to multivariate analyses (MVA), the significant predicting factors of grade 2 or more CT-based RILI were age (p = 0.01), oxygen dependence (p = 0.03) and interstitial shadow (p = 0.03). CONCLUSIONS: The agreement of the CT appearance and CT-based grading between two observers was good. These indicators may be able to provide us with more objective information and a better understanding of RILI.
Prognostic Value of Radiation Pneumonitis After Stereotactic Body Radiotherapy: Effect of Pulmonary Emphysema Quantitated Using CT Images. 査読有り

Yamamoto T, Kadoya N, Sato Y, Matsushita H, Umezawa R, Kubozono M, Ishikawa Y, Kozumi M, Takahashi N, Morishita Y, Katagiri Y, Sato K, Ito K, Takeda K, Jingu K

Clinical lung cancer　19　(1)　e85-e90　2018年1月1日
出版者・発行元：
DOI： 10.1016/j.cllc.2017.05.022 　

ISSN：1938-0690 1525-7304

eISSN：1938-0690
Stereotactic Radiotherapy for Pulmonary Oligometastases From Colorectal Cancer: A Systematic Review and Meta-Analysis. 国際誌査読有り

Keiichi Jingu, Haruo Matsushita, Takaya Yamamoto, Rei Umezawa, Yojiro Ishikawa, Noriyoshi Takahashi, Yu Katagiri, Kazuya Takeda, Noriyuki Kadoya

Technology in cancer research & treatment　17　1533033818794936-1533033818794936　2018年1月1日

DOI： 10.1177/1533033818794936 　

ISSN：1533-0346

eISSN：1533-0338
Clinicopathological features and pathological evaluation of preoperative treatment of patients with resectable esophageal carcinosarcoma

Yuki Katsuya, Yoshitaka Honma, Hirokazu Taniguchi, Ken Kato, Natsuko Okita, Atsuo Takashima, Satoru Iwasa, Tetsuya Hamaguchi, Narikazu Boku, Rei Umezawa, Koji Inaba, Yoshinori Ito, Jun Itami, Kazuo Koyanagi, Hiroyasu Igaki, Yuji Tachimori

ESOPHAGUS　14　(4)　317-323　2017年10月

DOI： 10.1007/s10388-017-0579-3 　

ISSN：1612-9059

eISSN：1612-9067
Native T1値と細胞外容積分画を用いた放射線心筋障害の評価

高木英誠, 大田英揮, 梅沢玲, 神宮啓一, 高瀬圭

日独医報　62　(1)　82-82　2017年9月
出版者・発行元：バイエル薬品(株)
ISSN：0912-0351
Evaluation of rectum and bladder dose accumulation from external beam radiotherapy and brachytherapy for cervical cancer using two different deformable image registration techniques 査読有り

Noriyuki Kadoya, YuYa Miyasaka, Takaya Yamamoto, Yoshihiro Kuroda, Kengo Ito, Mizuki Chiba, Yujiro Nakajima, Noriyoshi Takahashi, Masaki Kubozono, Rei Umezawa, Suguru Dobashi, Ken Takeda, Keiichi Jingu

JOURNAL OF RADIATION RESEARCH　58　(5)　720-728　2017年9月

DOI： 10.1093/jrr/rrx028 　

ISSN：0449-3060

eISSN：1349-9157
Radiation-induced heart disease after treatment for esophageal cancer

Keiichi Jingu, Rei Umezawa, Katsuya Fukui

ESOPHAGUS　14　(3)　215-220　2017年7月

DOI： 10.1007/s10388-017-0569-5 　

ISSN：1612-9059

eISSN：1612-9067
A management method for the statistical results of patient-specific quality assurance for intensity-modulated radiation therapy 査読有り

Satoshi Nakamura, Hiroyuki Okamoto, Akihisa Wakita, Rei Umezawa, Kana Takahashi, Koji Inaba, Naoya Murakami, Toru Kato, Hiroshi Igaki, Yoshinori Ito, Yoshihisa Abe, Jun Itami

JOURNAL OF RADIATION RESEARCH　58　(4)　572-578　2017年7月

DOI： 10.1093/jrr/rrw107 　

ISSN：0449-3060

eISSN：1349-9157
Outcomes of surgery followed by local brain radiotherapy compared with surgery followed by whole brain radiotherapy for single brain metastasis 査読有り

Hiroshi Igaki, Ken Harada, Rei Umezawa, Yasuji Miyakita, Makoto Ohno, Masamichi Takahashi, Minako Sumi, Koji Inaba, Naoya Murakami, Yoshinori Ito, Yoshitaka Narita, Jun Itami

TUMORI　103　(4)　367-373　2017年7月

DOI： 10.5301/tj.5000657 　

ISSN：0300-8916

eISSN：2038-2529
Clinical Outcomes of Resectable Esophageal Cancer with Supraclavicular Lymph Node Metastases Treated with Curative Intent 査読有り

Yoshitaka Honma, Nobukazu Hokamura, Kengo Nagashima, Kazuki Sudo, Hirokazu Shoji, Satoru Iwasa, Atsuo Takashima, Ken Kato, Tetsuya Hamaguchi, Narikazu Boku, Rei Umezawa, Yoshinori Ito, Jun Itami, Kazuo Koyanagi, Hiroyasu Igaki, Yuji Tachimori

ANTICANCER RESEARCH　37　(7)　3741-3749　2017年7月

DOI： 10.21873/anticanres.11748 　

ISSN：0250-7005

eISSN：1791-7530
Ⅲ期食道癌CRTにおける血液検査データと予後との関連

武田一也, 梅澤玲, 松下晴雄, 久保園正樹, 田邊隆哉, 石川陽二郎, 山本貴也, 古積麻衣子, 高橋紀善, 片桐佑, 田坂俊, 福井勝哉, 鈴木友, 角谷倫之, 伊藤謙吾, 千葉瑞己, 土橋卓, 武田賢, 神宮啓一

東北医誌　129　(1)　72-73　2017年6月
Elective nodal irradiation is not necessary in chemoradiotherapy for postoperative loco-regional recurrent esophageal cancer 査読有り

Keiichi Jingu, Rei Umezawa, Takaya Yamamoto, Haruo Matsushita, Youjirou Ishikawa, Maiko Kozumi, Masaki Kubozono, Noriyoshi Takahashi, Noriyuki Kadoya, Ken Takeda

JAPANESE JOURNAL OF CLINICAL ONCOLOGY　47　(3)　200-205　2017年3月

DOI： 10.1093/jjco/hyw195 　

ISSN：0368-2811

eISSN：1465-3621
Metabolic tumor volume on FDG-PET/CT is a possible prognostic factor for Stage I lung cancer patients treated with stereotactic body radiation therapy: a retrospective clinical study 査読有り

Noriyoshi Takahashi, Takaya Yamamoto, Haruo Matsushita, Toshiyuki Sugawara, Masaki Kubozono, Rei Umezawa, Yojiro Ishikawa, Maiko Kozumi, Yu Katagiri, Syun Tasaka, Kazuya Takeda, Ken Takeda, Suguru Dobashi, Keiichi Jingu

JOURNAL OF RADIATION RESEARCH　57　(6)　655-661　2016年11月

DOI： 10.1093/jrr/rrw048 　

ISSN：0449-3060

eISSN：1349-9157
In vivo spatial correlation between F-18-BPA and F-18-FDG uptakes in head and neck cancer 査読有り

Kazuma Kobayashi, Hiroaki Kurihara, Yoshiaki Watanabe, Naoya Murakami, Koji Inaba, Satoshi Nakamura, Akihisa Wakita, Hiroyuki Okamoto, Rei Umezawa, Kana Takahashi, Hiroshi Igaki, Yoshinori Ito, Seiichi Yoshimoto, Naoyuki Shigematsu, Jun Itami

APPLIED RADIATION AND ISOTOPES　115　138-146　2016年9月

DOI： 10.1016/j.apradiso.2016.05.026 　

ISSN：0969-8043
Long-term observations of radiation-induced creatinine clearance reduction and renal parenchymal volume atrophy.

Inaba K, Okamoto H, Wakita A, Tsuchida K, Kashihara T, Kobayashi K, Harada K, Kitaguchi M, Sekii S, Umezawa R, Takahashi K, Murakami N, Ito Y, Igaki H, Uno T, Itami J

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology　120　(1)　145-9　2016年7月

DOI： 10.1016/j.radonc.2016.04.022 　

ISSN：1879-0887
Long-term observations of radiation-induced creatinine clearance reduction and renal parenchymal volume atrophy 査読有り

Koji Inaba, Hiroyuki Okamoto, Akihisa Wakita, Keisuke Tsuchida, Tairo Kashihara, Kazuma Kobayashi, Ken Harada, Mayuka Kitaguchi, Shuhei Sekii, Rei Umezawa, Kana Takahashi, Naoya Murakami, Yoshinori Ito, Hiroshi Igaki, Takashi Uno, Jun Itami

RADIOTHERAPY AND ONCOLOGY　120　(1)　145-149　2016年7月

DOI： 10.1016/j.radonc.2016.04.022 　

ISSN：0167-8140
Evaluation of four-dimensional computed tomography (4D-CT)-based pulmonary ventilation: The high correlation between 4D-CT ventilation and Kr-81m-planar images was found 査読有り

Takayuki Kanai, Noriyuki Kadoya, Kengo Ito, Kazuma Kishi, Suguru Dobashi, Takaya Yamamoto, Rei Umezawa, Haruo Matsushita, Ken Takeda, Keiichi Jingu

RADIOTHERAPY AND ONCOLOGY　119　(3)　444-448　2016年6月

DOI： 10.1016/j.radonc.2016.04.030 　

ISSN：0167-8140
Salvage High-dose-rate Interstitial Brachytherapy for Pelvic Recurrent Cervical Carcinoma After Hysterectomy 査読有り

Naoya Murakami, Tomoyasu Kato, Yuichiro Miyamoto, Satoshi Nakamura, Akihisa Wakita, Hiroyuki Okamoto, Keisuke Tsuchida, Tairo Kashihara, Kazuma Kobayashi, Ken Harada, Mayuka Kitaguchi, Shuhei Sekii, Kana Takahashi, Rei Umezawa, Koji Inaba, Yoshinori Ito, Hiroshi Igaki, Jun Itami

ANTICANCER RESEARCH　36　(5)　2413-2421　2016年5月

ISSN：0250-7005

eISSN：1791-7530
After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer 査読有り

Satoshi Nakamura, Naoya Murakami, Koji Inaba, Akihisa Wakita, Kazuma Kobayashi, Kana Takahashi, Hiroyuki Okamoto, Rei Umezawa, Madoka Morota, Minako Sumi, Hiroshi Igaki, Yoshinori Ito, Jun Itami

BMC CANCER　16　296　2016年5月

DOI： 10.1186/s12885-016-2329-7 　

ISSN：1471-2407
Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma 査読有り

Takaya Yamamoto, Noriyuki Kadoya, Ken Takeda, Haruo Matsushita, Rei Umezawa, Kiyokazu Sato, Masaki Kubozono, Kengo Ito, Yojiro Ishikawa, Maiko Kozumi, Noriyoshi Takahashi, Yu Katagiri, Hiroshi Onishi, Keiichi Jingu

RADIATION ONCOLOGY　11　72　2016年5月

DOI： 10.1186/s13014-016-0651-5 　

ISSN：1748-717X
Clinical and volumetric prognostic factors in external beam radiotherapy for head and neck cancer 査読有り

K. Takeda, H. Matsushita, T. Ogawa, S. Dobashi, Y. Ishizawa, K. Chida, N. Kadoya, K. Ito, M. Chiba, M. Kubozono, R. Umezawa, Y. Shirata, Y. Ishikawa, T. Yamamoto, M. Kozumi, T. Tanabe, N. Takahashi, Y. Katagiri, S. Tazaka, K. Takeda, K. Sato, Y. Katori, K. Jingu

Radiother Oncol　119　(1)　504-505　2016年4月
Chemoradiotherapy for T4 and/or M1 lymph node esophageal cancer: experience since 2000 at a high-volume center in Japan 査読有り

Keiichi Jingu, Rei Umezawa, Haruo Matsushita, Toshiyuki Sugawara, Masaki Kubozono, Takaya Yamamoto, Youjirou Ishikawa, Maiko Kozumi, Noriyoshi Takahashi, Yu Katagiri, Noriyuki Kadoya, Ken Takeda

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY　21　(2)　276-282　2016年4月

DOI： 10.1007/s10147-015-0896-2 　

ISSN：1341-9625

eISSN：1437-7772
Association between radiation dose to the heart and myocardial fatty acid metabolic impairment due to chemoradiation-therapy: Prospective study using I-123 BMIPP SPECT/CT 査読有り

Kentaro Takanami, Akira Arai, Rei Umezawa, Takashi Takeuchi, Noriynki Kadoya, Yasuyuki Taki, Keiichi Jingu, Kei Takase

RADIOTHERAPY AND ONCOLOGY　119　(1)　77-83　2016年4月

DOI： 10.1016/j.radonc.2016.01.024 　

ISSN：0167-8140
Patterns of recurrence after selective postoperative radiation therapy for patients with head and neck squamous cell carcinoma 査読有り

Naoya Murakami, Fumihiko Matsumoto, Seiichi Yoshimoto, Yoshinori Ito, Taisuke Mori, Takao Ueno, Keisuke Tuchida, Tairo Kashihara, Kazuma Kobayashi, Ken Harada, Mayuka Kitaguchi, Shuhei Sekii, Rei Umezawa, Kana Takahashi, Koji Inaba, Hiroshi Igaki, Jun Itami

BMC CANCER　16　192　2016年3月

DOI： 10.1186/s12885-016-2229-x 　

ISSN：1471-2407
Dose reconstruction technique using non-rigid registration to evaluate spatial correspondence between high-dose region and late radiation toxicity: a case of tracheobronchial stenosis after external beam radiotherapy combined with endotracheal brachytherapy for tracheal cancer 査読有り

Kazuma Kobayashi, Naoya Murakami, Koji Inaba, Akihisa Wakita, Satoshi Nakamura, Hiroyuki Okamoto, Jun Sato, Rei Umezawa, Kana Takahashi, Hiroshi Igaki, Yoshinori Ito, Naoyuki Shigematsu, Jun Itami

JOURNAL OF CONTEMPORARY BRACHYTHERAPY　8　(2)　156-163　2016年3月

DOI： 10.5114/jcb.2016.59688 　

ISSN：1689-832X

eISSN：2081-2841
A total EQD(2) greater than 85 Gy for trachea and main bronchus D-2cc being associated with severe late complications after definitive endobronchial brachytherapy (vol 7, pg 363, 2015) 査読有り

Naoya Murakami, Kazuma Kobayashi, Satoshi Nakamura, Akihisa Wakita, Hiroyuki Okamoto, Keisuke Tsuchida, Tairo Kashihara, Ken Harada, Mayuka Yamada, Shuhei Sekii, Kana Takahashi, Rei Umezawa, Koji Inaba, Yoshinori Ito, Hiroshi Igaki, Jun Itami

JOURNAL OF CONTEMPORARY BRACHYTHERAPY　8　(2)　164-164　2016年3月

DOI： 10.5114/jcb.2016.59694 　

ISSN：1689-832X

eISSN：2081-2841
Assessment of Myocardial Metabolic Disorder Associated with Mediastinal Radiotherapy-a pilot study-

梅澤玲, 高浪健太郎, 松下晴雄, 菅原俊幸, 久保園正樹, 山本貴也, 石川陽二郎, 片桐佑, 古積麻衣子, 高橋紀善, 角谷倫之, 木田智士, 伊藤謙吾, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　34　4-4　2016年2月25日
前立腺癌74Gy照射の治療成績

石川陽二郎, 松下晴雄, 菅原俊幸, 梅澤玲, 久保園正樹, 山本貴也, 片桐佑, 古積麻衣子, 高橋紀善, 角谷倫之, 木田智士, 伊藤謙吾, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　34　(Suppl.)　5-5　2016年2月25日
出版者・発行元：
ISSN：1867-1071

eISSN：1867-108X
縦隔へ40Gy以上照射された根治的放射線治療後、異時性肺癌に対する定位放射線治療成績の検討

山本貴也, 松下晴雄, 菅原俊幸, 梅澤玲, 久保園正樹, 石川陽二郎, 古積麻衣子, 片桐佑, 高橋紀善, 角谷倫之, 伊藤謙吾, 木田智士, 神宮啓一, 土橋卓, 武田賢

Japanese Journal of Radiology　34　(Suppl.)　9-9　2016年2月25日
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
胸部食道癌Ⅱ/Ⅲ期に対する根治的化学放射線治療成績-予後因子の検討-

梅澤玲, 松下晴雄, 菅原俊幸, 久保園正樹, 山本貴也, 石川陽二郎, 片桐佑, 古積麻衣子, 高橋紀善, 角谷倫之, 木田智士, 伊藤謙吾, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　34　(Suppl.)　9-9　2016年2月25日
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
FDG-PET/CTでのMetabolic tumor volumeを用いた肺定位放射線治療に対する予後予測の検討

高橋紀善, 松下晴雄, 菅原俊幸, 梅澤玲, 久保園正樹, 石川陽二郎, 山本貴也, 片桐佑, 古積麻衣子, 角谷倫之, 木田智士, 伊藤謙吾, 神宮啓一, 土橋卓, 武田賢

Japanese Journal of Radiology　34　(Suppl.)　9-9　2016年2月25日
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
３D-IGBTにおける独立線量計算の有効性の検討

伊藤謙吾, 角谷倫之, 木田智士, 高橋紀善, 古積麻衣子, 山本貴也, 石川陽二郎, 梅澤玲, 久保園正樹, 菅原俊幸, 松下晴雄, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　34　(Suppl.)　10-10　2016年2月25日
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
手術不適応非小細胞肺癌Ⅲ期に対する放射線治療成績-東北大学病院200例超の解析結果

片桐佑, 松下晴雄, 菅原俊幸, 梅澤玲, 久保園正樹, 山本貴也, 石川陽二郎, 古積麻衣子, 高橋紀善, 角谷倫之, 木田智士, 伊藤謙吾, 神宮啓一, 土橋卓, 武田賢

Japanese Journal of Radiology　34　(Suppl.)　11-11　2016年2月25日
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
The role of interstitial brachytherapy in the management of primary radiation therapy for uterine cervical cancer 査読有り

Naoya Murakami, Kazuma Kobayashi, Tomoyasu Kato, Satoshi Nakamura, Akihisa Wakita, Hiroyuki Okamoto, Satoshi Shima, Keisuke Tsuchida, Tairo Kashihara, Ken Harada, Kana Takahashi, Rei Umezawa, Koji Inaba, Yoshinori Ito, Hiroshi Igaki, Jun Itami

JOURNAL OF CONTEMPORARY BRACHYTHERAPY　8　(5)　391-398　2016年

DOI： 10.5114/jcb.2016.62938 　

ISSN：1689-832X

eISSN：2081-2841
Dosimetric variations due to interfraction organ deformation in cervical cancer brachytherapy 査読有り

Kazuma Kobayashi, Naoya Murakami, Akihisa Wakita, Satoshi Nakamura, Hiroyuki Okamoto, Rei Umezawa, Kana Takahashi, Koji Inaba, Hiroshi Igaki, Yoshinori Ito, Naoyuki Shigematsu, Jun Itami

RADIOTHERAPY AND ONCOLOGY　117　(3)　555-558　2015年12月

DOI： 10.1016/j.radonc.2015.08.017 　

ISSN：0167-8140
Radiation Therapy Is a Reasonable Option for Improving the Prognosis in Hepatocellular Carcinoma 査読有り

Yasuteru Kondo, Osamu Kimura, Takayuki Kogure, Masashi Ninomiya, Rei Umezawa, Toshiyuki Sugawara, Haruo Matsushita, Keiichi Jingu, Yu Nakagome, Tomoaki Iwata, Tatsuki Morosawa, Yasuyuki Fujisaka, Takao Iwasaki, Tooru Shimosegawa

TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE　237　(4)　249-257　2015年12月

DOI： 10.1620/tjem.237.249 　

ISSN：0040-8727

eISSN：1349-3329
Metabolic Tumor Volume and Total Lesion Glycolysis on FDG-PET/CT Are Possible Prognostic Factors for Stage I Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy 査読有り

Takahashi, N, Yamamoto, T, Jingu, K, Matsushita, H, Sugawara, T, Kubozono, M, Umezawa, R, Ishikawa, Y, Kozumi, M, Katagiri, Y, Takeda, K

Int J Radiat Oncol Biol Phys　93　(3)　426-426　2015年11月
Evaluation of Prognostic Factors in Clinical Blood Examinations in Patients Undergoing Chemoradiation Therapy for Stage II-III Thoracic Esophageal Cancer 査読有り

Umezawa, R, Matsushita, H, Sugawara, T, Kubozono, M, Yamamoto, T, Ishikawa, Y, Kozumi, M, Takahashi, N, Katagiri, Y, Kadoya, N, Takeda, K, Jingu, K

Int J Radiat Oncol Biol Phys　93　(3)　152-153　2015年11月
Formula corrected maximal standardized uptake value in FDG-PET for partial volume effect and motion artifact is not a prognostic factor in stage I non-small cell lung cancer treated with stereotactic body radiotherapy 査読有り

Takaya Yamamoto, Noriyuki Kadoya, Yuko Shirata, Tomohiro Kaneta, Masashi Koto, Rei Umezawa, Youjirou Ishikawa, Masaki Kubozono, Toshiyuki Sugawara, Haruo Matsushita, Keiko Abe, Ken Takeda, Keiichi Jingu

ANNALS OF NUCLEAR MEDICINE　29　(8)　666-673　2015年10月

DOI： 10.1007/s12149-015-0991-5 　

ISSN：0914-7187

eISSN：1864-6433
Long-term results of chemoradiotherapy for stage II-III thoracic esophageal cancer in a single institution after 2000-with a focus on comparison of three protocols- 査読有り

Rei Umezawa, Keiichi Jingu, Haruo Matsushita, Toshiyuki Sugawara, Masaki Kubozono, Takaya Yamamoto, Yojiro Ishikawa, Maiko Kozumi, Noriyoshi Takahashi, Yu Katagiri, Noriyuki Kadoya, Ken Takeda, Hisanori Ariga, Kenji Nemoto, Shogo Yamada

BMC CANCER　15　813　2015年10月

DOI： 10.1186/s12885-015-1836-2 　

ISSN：1471-2407
Dosimetric impact of 4-dimensional computed tomography ventilation imaging-based functional treatment planning for stereotactic body radiation therapy with 3-dimensional conformal radiation therapy 査読有り

Noriyuki Kadoya, Sang Yong Cho, Takayuki Kanai, Yusuke Onozato, Kengo Ito, Suguru Dobashi, Takaya Yamamoto, Rei Umezawa, Haruo Matsushita, Ken Takeda, Keiichi Jingu

Practical Radiation Oncology　5　(5)　e505-e512　2015年9月1日
出版者・発行元： Elsevier Inc.
DOI： 10.1016/j.prro.2015.03.001 　

ISSN：1879-8500
A total EQD(2) greater than 85 Gy for trachea and main bronchus D-2cc being associated with severe late complications after definitive endobronchial brachytherapy 査読有り

Naoya Murakami, Kazuma Kobayashi, Satoshi Nakamura, Akihisa Wakita, Hiroyuki Okamoto, Keisuke Tsuchida, Tairo Kashihara, Ken Harada, Mayuka Yamada, Shuhei Sekii, Kana Takahashi, Rei Umezawa, Koji Inaba, Yoshinori Ito, Hiroshi Igaki, Jun Itami

JOURNAL OF CONTEMPORARY BRACHYTHERAPY　7　(5)　363-368　2015年9月

DOI： 10.5114/jcb.2015.54968 　

ISSN：1689-832X

eISSN：2081-2841
Radiotherapy for thyroid cancer 査読有り

Keiichi Jingu, Shin Maruoka, Rei Umezawa, Noriyoshi Takahashi

Japanese Journal of Cancer and Chemotherapy　42　(6)　666-669　2015年6月1日
出版者・発行元： Japanese Journal of Cancer and Chemotherapy Publishers Inc.
ISSN：0385-0684
Assessment of myocardial metabolic disorder associated with mediastinal radiotherapy for esophageal cancer -a pilot study- 査読有り

Rei Umezawa, Kentaro Takanami, Noriyuki Kadoya, Yujiro Nakajima, Masahide Saito, Hideki Ota, Haruo Matsushita, Toshiyuki Sugawara, Masaki Kubozono, Takaya Yamamoto, Yojiro Ishikawa, Ken Takeda, Yasuyuki Taki, Kei Takase, Keiichi Jingu

RADIATION ONCOLOGY　10　96　2015年4月

DOI： 10.1186/s13014-015-0410-z 　

ISSN：1748-717X
[Current status and prospects of radiotherapy for gallbladder cancer]. 査読有り

Jingu K, Umezawa R

Nihon rinsho. Japanese journal of clinical medicine　73 Suppl 3　590-594　2015年3月

ISSN：0047-1852
甲状腺MALTリンパ腫に対し放射線治療を行い長期経過観察中の症例査読有り

平塚裕介, 松下晴雄, 菅原俊幸, 梅澤玲, 久保園正樹, 阿部恵子, 山本貴也, 古積麻衣子, 高橋紀善, 角谷倫之, 藤田幸男, 伊藤謙吾, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　33　3-3　2015年2月
乳癌上腕骨転移照射後の上腕浮腫、末梢神経障害に対し200回超の高気圧酸素療法(HBO)を施行、奏効している症例査読有り

松下晴雄, 菅原俊幸, 梅澤玲, 久保園正樹, 阿部恵子, 山本貴也, 古積麻衣子, 高橋紀善, 角谷倫之, 藤田幸男, 伊藤謙吾, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　33　5-5　2015年2月
当院での乳房温存術後boost(追加)照射について査読有り

松下晴雄, 菅原俊幸, 梅澤玲, 久保園正樹, 阿部恵子, 藤本俊裕, 山本貴也, 石川陽二郎, 古積麻衣子, 高橋紀善, 角谷倫之, 藤田幸男, 伊藤謙吾, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　33　(Suppl.)　12-12　2015年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
4D-CTとdeformable image registrationを用いた肺機能イメージングの開発と治療計画への応用査読有り

角谷倫之, 藤田幸男, 伊藤謙吾, 高橋紀善, 古積麻衣子, 山本貴也, 阿部恵子, 梅澤玲, 久保園正樹, 菅原俊幸, 松下晴雄, 神宮啓一, 土橋卓, 武田賢

Japanese Journal of Radiology　33　12-12　2015年2月
骨軟部悪性腫瘍に対する放射線治療成績査読有り

古積麻衣子, 松下晴雄, 菅原俊幸, 久保園正樹, 梅澤玲, 阿部恵子, 山本貴也, 角谷倫之, 藤田幸男, 伊藤謙吾, 高橋紀善, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　33　5-5　2015年2月
VariSeedを用いたAu-198密封小線源治療の線量分布計算査読有り

伊藤謙吾, 角谷倫之, 藤田幸男, 高橋紀善, 古積麻衣子, 山本貴也, 阿部恵子, 梅澤玲, 久保園正樹, 菅原俊幸, 松下晴雄, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　33　4-4　2015年2月
東北大学病院における食道腺癌に対する放射線治療経験査読有り

高橋紀善, 松下晴雄, 菅原俊幸, 梅澤玲, 久保園正樹, 阿部恵子, 山本貴也, 古積麻衣子, 角谷倫之, 藤田幸男, 伊藤謙吾, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　33　3-3　2015年2月
モンテカルロ法を用いた四次元線量分布計算コードの開発査読有り

藤田幸男, 角谷倫之, 伊藤謙吾, 高橋紀善, 古積麻衣子, 山本貴也, 阿部恵子, 梅澤玲, 久保園正樹, 菅原俊幸, 松下晴雄, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　33　3-3　2015年2月
Impact of tumor attachment to the pleura measured by a pretreatment CT image on outcome of stage I NSCLC treated with stereotactic body radiotherapy 査読有り

Takaya Yamamoto, Noriyuki Kadoya, Yuko Shirata, Masashi Koto, Kiyokazu Sato, Haruo Matsushita, Toshiyuki Sugawara, Rei Umezawa, Masaki Kubozono, Yojiro Ishikawa, Maiko Kozumi, Noriyoshi Takahashi, Kengo Ito, Yu Katagiri, Ken Takeda, Keiichi Jingu

RADIATION ONCOLOGY　10　35　2015年2月

DOI： 10.1186/s13014-015-0343-6 　

ISSN：1748-717X
Clinical Factors Relating to Cervical Body Volume Reduction during Curative External Beam Radiation Therapy for Head and Neck Cancer 査読有り

Takeda K, Dobashi S, Komori S, Chida K, Kadoya N, Kida S, Ito K, Sugawara T, Kubozono M, Umezawa R, Ishikawa Y, Yamamoto T, Kozumi M, Takahashi N, Katagiri Y, Onozato Y, Kanai T, Sato K, Kishi K, Matsushita H, Ogawa T, Katori Y, Jingu K

J Nucl Med Radiat Ther　(6)　203　2014年12月
Evaluation of accuracy of B-spline transformation-based deformable image registration with different parameter settings for thoracic images 査読有り

Takayuki Kanai, Noriyuki Kadoya, Kengo Ito, Yusuke Onozato, Sang Yong Cho, Kazuma Kishi, Suguru Dobashi, Rei Umezawa, Haruo Matsushita, Ken Takeda, Keiichi Jingu

JOURNAL OF RADIATION RESEARCH　55　(6)　1163-1170　2014年11月

DOI： 10.1093/jrr/rru062 　

ISSN：0449-3060

eISSN：1349-9157
Clinical Factors With Respect to Cervical Body Volume Reduction During Definitive External Beam Radiation Therapy for Hypopharyngeal Squamous Cell Carcinoma 査読有り

K. Takeda, S. Dobashi, S. Komori, K. Chida, N. Kadoya, K. Itoh, T. Sugawara, M. Kubozono, R. Umezawa, Y. Ishikawa, T. Yamamoto, T. Fujimoto, M. Kozumi, Y. Onozato, T. Suzuki, H. Matsushita, K. Jingu

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　90　(1)　S532-S533　2014年9月

ISSN：0360-3016

eISSN：1879-355X
Dosimetric Impact of 4D-CT Ventilation Imaging-Based Functional Treatment Planning for Stereotactic Body Radiation Therapy 査読有り

Kadoya N, Cho S, Kanai T, Ito K, Onozato Y, Kishi K, Dobashi S, Yamamoto T, Umezawa R, Takeda K, Jingu K

Int J Radiat Oncol Biol Phys　90　(1)　145-145　2014年9月
Long-Term Results of Chemoradiation Therapy for Stage II-III Thoracic Esophageal Cancer: Comparison of 3 Protocols 査読有り

Umezawa R, Jingu K, Sugawara T, Kubozono M, Abe K, Fujimoto T, Yamamoto T, Ishikawa Y, Kozumi M, Kadoya N, Takeda K, Matsushita H

Int J Radiat Oncol Biol Phys　90　(1)　340-340　2014年9月
Even Local Control of Metastatic Lung Tumors Is Worse Than That of Primary Lung Cancer in Patients Treated With Stereotactic Body Radiation Therapy 査読有り

Takahashi N, Yamamoto T, Shirata Y, Matsushita H, Sugawara T, Kubozono M, Umezawa R, Fujimoto S, Ishikawa Y, Kozumi M, Abe K, Takeda K, Jingu K

Int J Radiat Oncol Biol Phys　90　(1)　617-617　2014年9月
Dose–Volume Constraints in Rectum in Patients with Prostate Cancer after 74-Gy 3-Dimensional Conformal Radiotherapy. 査読有り

Ishikawa Y, Kadoya N, Matsushita H, Sugawara T, Kubozono M, Umezawa R, Yamamoto T, Kozumi M, Takeda K, Jingu K

J Radiol Radiat Ther　2014年7月
Evaluation of On-Board kV Cone Beam Computed Tomographye-Based Dose Calculation With Deformable Image Registration Using Hounsfield Unit Modifications 査読有り

Yusuke Onozato, Noriyuki Kadoya, Yukio Fujita, Kazuhiro Arai, Suguru Dobashi, Ken Takeda, Kazuma Kishi, Rei Umezawa, Haruo Matsushita, Keiichi Jingu

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　89　(2)　416-423　2014年6月

DOI： 10.1016/j.ijrobp.2014.02.007 　

ISSN：0360-3016

eISSN：1879-355X
Outcomes after stereotactic body radiotherapy for lung tumors, with emphasis on comparison of primary lung cancer and metastatic lung tumors 査読有り

Takaya Yamamoto, Keiichi Jingu, Yuko Shirata, Masashi Koto, Haruo Matsushita, Toshiyuki Sugawara, Masaki Kubozono, Rei Umezawa, Keiko Abe, Noriyuki Kadoya, Youjirou Ishikawa, Maiko Kozumi, Noriyoshi Takahashi, Ken Takeda, Yoshihiro Takai

BMC CANCER　14　464　2014年6月

DOI： 10.1186/1471-2407-14-464 　

ISSN：1471-2407
頭頸部癌術後予防照射の検討東北大、宮城がんセンター症例の検討

松下晴雄, 菅原俊幸, 久保園正樹, 梅沢玲, 阿部恵子, 角谷倫之, 藤田幸男, 白田佑子, 田邊隆哉, 山本貴也, 神宮啓一, 武田賢, 土橋卓, 和田仁, 藤本俊裕, 古積麻衣子, 塩見美帆

Japanese Journalof Radiology　32　13-13　2014年2月
食道癌術後再発に対する放射線化学療法予後因子多変量解析結果

神宮啓一, 松下晴雄, 菅原俊幸, 久保園正樹, 梅澤玲, 阿部恵子, 角谷倫之, 藤田幸男, 田邊隆之, 白田佑子, 山本貴也, 武田賢, 土橋卓, 根本建二

Japanese Journalof Radiology　32　13-13　2014年2月
I期非小細胞肺癌定位照射の予後因子

白田佑子, 久保園正樹, 菅原俊幸, 松下晴雄, 阿部恵子, 梅澤玲, 角谷倫之, 藤田幸男, 田邊隆哉, 山本貴也, 土橋卓, 神宮啓一, 武田賢, 小藤昌志

Japanese Journal of Radiology　32　6-6　2014年2月
前立腺癌体外照射における前立腺sizeと晩期直腸出血の検討

山本貴也, 松下晴雄, 菅原俊幸, 久保園正樹, 梅澤玲, 阿部恵子, 角谷倫之, 藤田幸男, 白田佑子, 田邊隆哉, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　32　6-6　2014年2月
呼吸性移動によるSUVmaxの減弱に対する補正法の検討

角谷倫之, 藤田幸男, 山本貴也, 白田佑子, 阿部恵子, 梅澤玲, 久保園正樹, 菅原俊幸, 松下晴雄, 神宮啓一, 土橋卓, 武田賢, 金田朋洋

Japanese Journal of Radiology　32　7-7　2014年2月
食道悪性黒色腫の2例

木下知, 松下晴雄, 菅原俊幸, 久保園正樹, 梅澤玲, 阿部恵子, 角谷倫之, 藤田幸男, 白田佑子, 田邊隆哉, 山本貴也, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　32　(Suppl.)　12-12　2014年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
MRI findings of-radiation-induced myocardial damage in patients with oesophageal cancer 査読有り

Umezawa R, Ota H, Takanami K, Ichinose A, Matsushita H, Saito H, Takase K, Jingu K

Clinical Radiology　69　(12)　1273-1279　2014年

DOI： 10.1016/j.crad.2014.08.010 　

ISSN：0009-9260

eISSN：1365-229X
Assessment of Myocardial Metabolic Disorder Associated With Mediastinal Radiation Therapy for Esophageal Cancer 査読有り

Umezawa R, Takanami K, Ota H, Kaneta T, Kadoya N, Fujita Y, Arai A, Arai K, Matsushita H, Takase K, Jingu K

International Journal of Radiation Oncology Biology Physics　90　S205　2014年

DOI： 10.1016/j.ijrobp.2014.05.762 　
Evaluation of various deformable image registration algorithms for thoracic images 査読有り

Noriyuki Kadoya, Yukio Fujita, Yoshiyuki Katsuta, Suguru Dobashi, Ken Takeda, Kazuma Kishi, Masaki Kubozono, Rei Umezawa, Toshiyuki Sugawara, Haruo Matsushita, Keiichi Jingu

JOURNAL OF RADIATION RESEARCH　55　(1)　175-182　2014年1月

DOI： 10.1093/jrr/rrt093 　

ISSN：0449-3060

eISSN：1349-9157
Reassessing the Prognostic Value of the Maximum Standardized Uptake Value (SUVmax) in FDG-PET by Correcting for the Partial Volume Effect and Respiratory Motion Blur in Stage I Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy 査読有り

T. Yamamoto, N. Kadoya, Y. Shirata, R. Umezawa, M. Kubozono, T. Sugawara, T. Kaneta, H. Matsushita, K. Takeda, K. Jingu

Int J Radiat Oncol Biol Phys　87　(2)　S523-S523　2013年10月
Magnetic Resonance Imaging Findings of Radiation-Induced Myocardial Damage in Patients With Esophageal Cancer 査読有り

R. Umezawa, K. Jingu, K. Takase, H. Ota, K. Takanami, T. Kaneta, K. Takeda, H. Matsushita, S. Takahashi

Int J Radiat Oncol Biol Phys　87　(2)　S291-S292　2013年10月
Prognostic Factors for Patients With Loco-Regional Recurrent Esophageal Cancer Who Were Treated With Chemoradiation Therapy: Results of Multivariate Analysis 査読有り

K. Jingu, H. Matsushita, K. Takeda, R. Umezawa, T. Sugawara, M. Kubozono, K. Abe, N. Kadoya

Int J Radiat Oncol Biol Phys　87　(2)　S284-S284　2013年10月
Investigation of correction method of recovery effect and motion blur for SUV quantification in FDG PET/CT in patients with early lung cancer 査読有り

Noriyuki Kadoya, Yukio Fujita, Kengo Ito, Suguru DObashi, Ken Takeda, Kazuma Kishi, Takaya Yamamoto, Rei Umezawa, Toshiyuki Sugawara, Tomohiro Kaneta, Haruo Matsushita, Keiichi Jingu

J Nucl Med Radiat Ther　4　(4)　2013年9月

DOI： 10.4172/2155-9619.1000162 　
Evaluation of radiation-induced myocardial damage using iodine-123 β-methyl-iodophenyl pentadecanoic acid scintigraphy. 査読有り

Umezawa R, Takase K, Jingu K, Takanami K, Ota H, Kaneta T, Takeda K, Matsushita H, Ariga H, Takahashi S, Yamada S

Journal of radiation research　54　(5)　880-889　2013年9月

DOI： 10.1093/jrr/rrt011 　

ISSN：0449-3060
Results of chemoradiotherapy for stage I esophageal cancer in medically inoperable patients compared with results in operable patients

K. Jingu, H. Matsushita, K. Takeda, K. Narazaki, H. Ariga, R. Umezawa, T. Sugawara, G. Miyata, K. Onodera, K. Nemoto, S. Yamada

Diseases of the Esophagus　26　522-527　2013年7月1日

DOI： 10.1111/j.1442-2050.2012.01396.x 　

ISSN：1120-8694
東日本大震災における東北大学放射線治療科の活動報告

山本貴也, 神宮啓一, 松下晴雄, 菅原俊幸, 久保園正樹, 梅澤玲, 清水栄二, 山田章吾, 武田賢, 有賀久哲

Japanese Journal of Radiology　31　(1)　4-4　2013年2月
I期非小細胞肺癌に対する定位放射線治療成績と予後因子の検討

山本貴也, 角谷倫之, 白田佑子, 松下晴雄, 菅原俊幸, 梅澤玲, 阿部恵子, 神宮啓一, 武田賢, 土橋卓

日本医学放射線学会学術集会抄録集　72　271-271　2013年2月
二次発がんを生じた後に不幸な経過をたどった若年性上咽頭癌の1例

古積麻衣子, 松下晴雄, 菅原俊幸, 神宮啓一, 清水栄二, 梅澤玲, 阿部恵子, 白田佑子, 石川陽二郎, 山本貴也, 角谷倫之, 藤田幸男, 武田賢, 土橋卓, 久保園正樹, 有賀久哲, 山田章吾

Japanese Journal of Radiology　31　(Suppl.I)　12-12　2013年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
術後食道癌孤立性リンパ節転移再発に対する放射線化学療法治療長期成績

神宮啓一, 松下晴雄, 菅原俊幸, 久保園正樹, 清水栄二, 梅澤玲, 阿部恵子, 白田佑子, 石川陽二郎, 山本貴也, 古積麻衣子, 山田章吾, 武田賢, 有賀久哲, 根本建二

Japanese Journal of Radiology　31　(Suppl.I)　11-11　2013年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
原発不明頭頸部扁平上皮癌の検討

菅原俊幸, 松下晴雄, 神宮啓一, 清水栄二, 阿部恵子, 梅澤玲, 山本貴也, 石川陽二郎, 古積麻衣子, 角谷倫之, 藤田幸男, 武田賢, 土橋卓, 久保園正樹, 小川芳弘, 山田章吾

Japanese Journal of Radiology　31　(Suppl.I)　10-10　2013年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
頭頸部癌術後予防照射の検討

松下晴雄, 菅原俊幸, 神宮啓一, 清水栄二, 梅澤玲, 阿部恵子, 白田佑子, 石川陽二郎, 山本貴也, 古積麻衣子, 角谷倫之, 藤田幸男, 武田賢, 土橋卓, 久保園正樹, 有賀久哲, 山田章吾

Japanese Journal of Radiology　31　(Suppl.I)　10-10　2013年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
前立腺癌74Gy照射による直腸障害の検討

石川陽二郎, 角谷倫之, 藤田幸男, 神宮啓一, 松下晴雄, 菅原俊幸, 久保園正樹, 梅澤玲, 清水栄二, 阿部恵子, 白田佑子, 古積麻衣子, 山田章吾, 武田賢, 有賀久哲

Japanese Journal of Radiology　31　(Suppl.I)　3-3　2013年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
stage I食道癌に対する放射線化学療法手術可能と不可症例の長期成績比較

神宮啓一, 松下晴雄, 菅原俊幸, 久保園正樹, 梅澤玲, 清水栄二, 阿部恵子, 白田佑子, 石川陽二郎, 山本貴也, 古積麻衣子, 武田賢, 山田章吾, 根本建二, 有賀久哲

Japanese Journal of Radiology　31　(Suppl.I)　2-2　2013年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study 査読有り

Keiichi Jingu, Haruo Matsushita, Ken Takeda, Rei Umezawa, Chiaki Takahashi, Toshiyuki Sugawara, Masaki Kubozono, Keiko Abe, Takaya Tanabe, Yuko Shirata, Takaya Yamamoto, Youjirou Ishikawa, Kenji Nemoto

BMC CANCER　12　542　2012年11月

DOI： 10.1186/1471-2407-12-542 　

ISSN：1471-2407
Intraoperative Radiotherapy for Pancreatic Cancer: 30-Year Experience in a Single Institution in Japan 査読有り

Keiichi Jingu, Takaya Tanabe, Kenji Nemoto, Hisanori Ariga, Rei Umezawa, Yoshihiro Ogawa, Ken Takeda, Masashi Koto, Toshiyuki Sugawara, Masaki Kubozono, Eiji Shimizu, Keiko Abe, Shogo Yamada

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　83　(4)　E507-E511　2012年7月

DOI： 10.1016/j.ijrobp.2012.01.024 　

ISSN：0360-3016
Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan 査読有り

Ken Takeda, Yoshihiro Takai, Kakutaro Narazaki, Masatoshi Mitsuya, Rei Umezawa, Noriyuki Kadoya, Yukio Fujita, Toshiyuki Sugawara, Masaki Kubozono, Eiji Shimizu, Keiko Abe, Yuko Shirata, Yohjiro Ishikawa, Takaya Yamamoto, Maiko Kozumi, Suguru Dobashi, Haruo Matsushita, Koichi Chida, Shigeto Ishidoya, Yoichi Arai, Keiichi Jingu, Shogo Yamada

RADIATION ONCOLOGY　7　105　2012年7月

DOI： 10.1186/1748-717X-7-105 　

ISSN：1748-717X
DOES IMRT INCREASE LOCO-REGIONAL FAILURE IN PATIENTS WITH NASOPHARYNGEAL CANCER? A FIRST REPORT 査読有り

K. Jingu, K. Abe, M. Koto, K. Fujimoto, H. Matsushita, T.Sugawara, R. Umezawa, N. Kadoya, K. Takeda, S.Yamada

Radiother Oncol　103　447-448　2012年5月
Long-Term Results of Radiochemotherapy for Solitary Lymph Node Metastasis After Curative Resection of Esophageal Cancer 査読有り

Keiichi Jingu, Hisanori Ariga, Kenji Nemoto, Kakutaro Narazaki, Rei Umezawa, Ken Takeda, Masashi Koto, Toshiyuki Sugawara, Masaki Kubozono, Go Miyata, Ko Onodera, Shogo Yamada

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　83　(1)　172-177　2012年5月

DOI： 10.1016/j.ijrobp.2011.06.1978 　

ISSN：0360-3016
前立腺癌に対する外照射(non-IMRT)による高線量処方時の直腸線量制限

石川陽二郎, 角谷倫之, 藤田幸男, 神宮啓一, 松下晴雄, 菅原俊幸, 梅澤玲, 阿部恵子, 山田章吾, 武田賢

日本医学放射線学会学術集会抄録集　71　286-287　2012年2月
放射線誘発性髄膜腫に対し過分割放射線治療を行った1例

山本貴也, 神宮啓一, 有賀久哲, 武田賢, 菅原俊幸, 久保園正樹, 梅澤玲, 清水栄二, 阿部恵子, 白田佑子, 田邊隆哉, 石川陽二郎, 山田章吾

Japanese Journal of Radiology　30　(Suppl.I)　14-14　2012年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/ml 査読有り

Rei Umezawa, Hisanori Ariga, Yoshihiro Ogawa, Keiichi Jingu, Haruo Matsushita, Ken Takeda, Keisuke Fujimoto, Toru Sakayauchi, Toshiyuki Sugawara, Masaki Kubozono, Kakutaro Narazaki, Eiji Shimizu, Yoshihiro Takai, Shogo Yamada

RADIATION ONCOLOGY　6　150　2011年11月

DOI： 10.1186/1748-717X-6-150 　

ISSN：1748-717X
Long-term Results of Chemoradiotherapy for Solitary Lymph Node Metastasis after Curative Resection of Esophageal Cancer 査読有り

K. Jingu, H. Ariga, K. Nemoto, R. Umezawa, K. Takeda, S. Yamada

Int J Radiat Oncol Biol Phys　81　(2)　319-319　2011年10月1日
ステージI食道癌の治療戦略手術可能と不可stage I食道癌に対する放射線化学療法 2つの前向き試験長期成績比較

神宮啓一, 有賀久哲, 奈良崎覚太朗, 武田賢, 梅澤玲, 菅原俊幸, 山田章吾, 宮田剛, 小野寺浩, 根本建二

日本食道学会学術集会プログラム・抄録集 65回　97-97　2011年9月
前立腺癌を限局化するために7つの共平面場を用いた3次元原体照射後の晩期直腸・尿毒性の臨床予測因子(Clinical predictors of late rectal and urinary toxicity after three-dimensional conformal radiotherapy using seven coolanar fields to localize prostate cancer)

武田賢, 小川芳弘, 有賀久哲, 小藤昌志, 坂谷内徹, 久保園正樹, 奈良崎覚太朗, 梅澤玲, 清水栄二, 白田佑子, 山田章吾, 仲田栄子, 高井良尋, 根本建二

Japanese Journal of Radiology　29　(Suppl.I)　12-12　2011年1月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
当院における上咽頭癌の放射線治療成績

小藤昌志, 小川芳弘, 有賀久哲, 武田賢, 坂谷内徹, 藤本圭介, 久保園正樹, 奈良崎覚太朗, 梅澤玲, 山田章吾

Japanese Journal of Radiology　5-5　2011年1月
易出血性傍咽頭間隙腫瘍の治療経験査読有り

梅澤玲, 小川芳弘, 有賀久哲, 武田賢, 小藤昌志, 藤本圭介, 坂谷内徹, 久保園正樹, 奈良崎覚太朗, 清水栄二, 白田佑子, 田邉隆哉, 山田章吾, 高井良尋, 仲田栄子

Japanese Journal of Radiology　29　(1)　5-5　2011年1月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
当科における小児頭頸部腫瘍の検討査読有り

小川芳弘, 有賀久哲, 武田賢, 小藤昌志, 藤本圭介, 坂谷内徹, 久保園正樹, 奈良崎覚太朗, 梅澤玲, 清水栄二, 白田佑子, 田邉隆哉, 山田章吾, 仲田栄子, 高井良尋

Japanese Journal of Radiology　29　(1)　5-5　2011年1月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
頭頸部癌放射線治療の線量分布に与えるPTV・耳下腺の体積変化および位置変化の影響 Adaptive IMRTの為の基礎研究査読有り

小山翔, 仲田栄子, 高井良尋, 三津谷正俊, 小川芳弘, 有賀久哲, 武田賢, 小藤昌志, 藤本圭介, 坂谷内徹, 久保園正樹, 奈良崎覚太郎, 梅澤玲, 山田章吾

Japanese Journal of Radiology　29　(1)　11-11　2011年1月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
肺定位照射後肺障害の検討査読有り

白田佑子, 小川芳弘, 有賀久哲, 武田賢, 坂谷内徹, 小藤昌志, 久保園正樹, 奈良崎覚太朗, 梅澤玲, 清水栄二, 田邊隆哉, 山田章吾, 高井良尋

Japanese Journal of Radiology　29　(1)　11-11　2011年1月
化学放射線療法が奏功した膵腺房細胞癌の1例査読有り

清水栄二, 久保園正樹, 小川芳弘, 有賀久哲, 武田賢, 小藤昌志, 坂谷内徹, 奈良崎覚太朗, 梅澤玲, 白田佑子, 田邊隆哉, 山田章吾, 仲田栄子, 高井良尋, 松下晴雄, 高橋ちあき, 藤本俊裕, 戸嶋雅道

Japanese Journal of Radiology　29　(1)　11-11　2011年1月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
東北大学におけるRapidArcの初期治療経験査読有り

三津谷正俊, 佐藤清和, 佐藤直志, 小川芳弘, 有賀久哲, 武田賢, 小藤昌志, 坂谷内徹, 久保園正樹, 奈良崎覚太朗, 梅澤玲, 清水栄二, 白田佑子, 山田章吾, 仲田栄子, 高井良尋

Japanese Journal of Radiology　29　(1)　12-12　2011年1月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
前立腺癌外照射後の晩期直腸障害査読有り

武田賢, 小川芳弘, 有賀久哲, 小藤昌志, 坂谷内徹, 藤本圭介, 奈良崎覚太朗, 梅澤玲, 平出智道, 山田章吾, 高井良尋

Japanese Journal of Radiology　28　8-8　2010年7月
肺癌術後の孤立性肺病変に対する定位放射線治療査読有り

小藤昌志, 小川芳弘, 有賀久哲, 武田賢, 藤本圭介, 坂谷内徹, 奈良崎覚太朗, 梅澤玲, 山田章吾, 仲田栄子, 高井良尋

Japanese Journal of Radiology　28　(Suppl.I)　8-8　2010年7月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
食道癌に対する温存療法適応因子の検討

有賀久哲, 小川芳弘, 武田賢, 小藤昌志, 藤本圭介, 坂谷内徹, 奈良崎覚太朗, 梅澤玲, 山田章吾

Japanese Journal of Radiology　28　(1)　7-7　2010年7月
Focal dose escalation using FDG-PET-guided intensity-modulated radiation therapy boost for postoperative local recurrent rectal cancer: a planning study with comparison of DVH and NTCP 査読有り

Keiichi Jingu, Hisanori Ariga, Tomohiro Kaneta, Yoshihiro Takai, Ken Takeda, Lindel Katja, Kakutaro Narazaki, Takahiro Metoki, Keisuke Fujimoto, Rei Umezawa, Yoshihiro Ogawa, Kenji Nemoto, Masashi Koto, Masatoshi Mitsuya, Naruhiro Matsufuji, Shoki Takahashi, Shogo Yamada

BMC CANCER　10　127　2010年4月

DOI： 10.1186/1471-2407-10-127 　

ISSN：1471-2407
Results of Intraoperative Radiotherapy for Pancreatic Cancer in the Last Decade: Comparing with Historical Results 査読有り

K. Jingu, H. Ariga, Y. Ogawa, R. Umezawa, M. Koto, K. Takeda, S. Yamada

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　78　(3)　S311-S311　2010年

ISSN：0360-3016
[Thyrotropin-releasing hormone (TRH)]. 査読有り

Yamada M, Umezawa R

Nihon rinsho. Japanese journal of clinical medicine　63 Suppl 8　220-223　2005年8月

ISSN：0047-1852

︎全件表示 ︎最初の5件までを表示

MISC 97

放射線治療を受けた椎体転移患者における予後予測因子の検討

武田一也, 武田一也, 梅澤玲, 山本貴也, 高橋紀善, 鈴木友, 岸田桂太, 尾股聡, 神宮啓一

日本癌治療学会学術集会(Web)　61st　2023年
東北大学病院における進行肺癌IMRT症例について時変共変量となる因子を含めた遡及的解析

山本貴也, 突田容子, 片桐佑, 梅澤玲, 石川陽二郎, 高椅紀善, 鈴木友, 武田一也, 岸田桂太, 神宮敬一

日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集　35th　2022年
放射線治療

神宮啓一, 梅澤玲, 山本貴也, 石川陽二郎, 高橋紀善, 武田一也, 鈴木友, 寺村聡司, 尾股聡

日本気管食道科学会会報　72　(2)　84-87　2021年4月
出版者・発行元： (NPO)日本気管食道科学会
ISSN： 0029-0645

eISSN： 1880-6848
高リスク前立腺癌MRI画像の定量解析による予後予測の検討

川端広聖, 武田一也, 松下晴雄, 梅澤玲, 山本貴也, 石川陽二郎, 片桐佑, 田坂俊, 鈴木友, 寺村聡司, 尾股聡, 佐藤雄太, 角谷倫之, 武田賢, 神宮啓一, 大田英揮

Japanese Journal of Radiology　39　(Supplement)　2021年

ISSN： 1867-1071
東北大学病院における子宮頸癌術後照射の検討

山本貴也, 梅澤玲, 久保園正樹, 松下晴雄, 石川陽二郎, 片桐佑, 武田一也, 田坂俊, 鈴木友, 神宮啓一, 徳永英樹, 八重樫伸生

Japanese Journal of Radiology　39　(Supplement)　2021年

ISSN： 1867-1071
小型肺癌に対する定位手術的放射線治療の初期経験

山本貴也, 松下晴雄, 角谷倫之, 伊藤謙吾, 千葉貴仁, 梅澤玲, 石川陽二郎, 片桐佑, 武田一也, 田坂俊, 鈴木友, 神宮啓一

Japanese Journal of Radiology　39　(Supplement)　2021年

ISSN： 1867-1071
食道癌照射後再発に対する過分割照射の有効性と安全性

武田一也, 松下晴雄, 梅澤玲, 山本貴也, 石川陽二郎, 片桐佑, 田坂俊, 鈴木友, 寺村聡司, 川端広聖, 尾股聡, 佐藤雄太, 角谷倫之, 伊藤謙吾, 千葉貴仁, 神宮啓一

Japanese Journal of Radiology　39　(Supplement)　2021年

ISSN： 1867-1071
MRI画像を用いたJacobian解析による全脳照射後の脳萎縮評価

石川陽二郎, 角谷倫之, 根本光, 細谷祐里, 松下晴雄, 梅澤玲, 山本貴也, 片桐佑, 武田一也, 田坂俊, 鈴木友, 尾股聡, 佐藤雄太, 伊藤謙吾, 千葉貴仁, 神宮啓一

Japanese Journal of Radiology　39　(Supplement)　2021年

ISSN： 1867-1071
肺癌局所再発例にサルベージ照射が著効した1例

佐藤雄太, 松下晴雄, 梅澤玲, 山本貴也, 石川陽二郎, 武田一也, 田坂俊, 鈴木友, 川端広聖, 尾股聡, 神宮啓一

Japanese Journal of Radiology　39　(Supplement)　2021年

ISSN： 1867-1071
心臓原発血管肉腫に対して放射線治療を施行した1例

山本貴也, 松下晴雄, 梅澤玲, 石川陽二郎, 片桐佑, 武田一也, 田坂俊, 福井勝哉, 鈴木友, 寺村聡司, 川端広聖, 岸田圭太, 尾股聡, 神宮啓一, 城田英和

Japanese Journal of Radiology　39　(Supplement)　2021年

ISSN： 1867-1071
頭頸部がんに対する根治放射線治療後の口腔関連QOL長期的推移

神宮啓一, 高橋紀善, 田坂俊, 梅澤玲, 山本貴也, 石川陽二郎, 武田一也, 鈴木友, 角谷倫之, 松下晴雄

頭頸部癌　47　(3)　2021年

ISSN： 1349-5747
膵癌に対する予防域を含めた放射線治療における3DCRTとIMRTでの急性期有害事象の比較

梅澤玲, 中川圭, 水間正道, 山本貴也, 石川陽二郎, 海野倫明, 神宮啓一

日本癌治療学会学術集会(Web)　59th　2021年
前立腺癌放射線治療後に発生した恥骨radiation-induced sarcomaの1例

尾股聡, 梅澤玲, 綿貫宗則, 佐藤聡子, 田邊隆哉, 神宮啓一

臨床放射線　66　(6)　2021年

ISSN： 0009-9252
【Q&Aでまとめる! 予後予測・治療効果予測の画像検査】消化管・肝・胆・膵胸部食道癌に対する根治的放射線化学療法の治療効果を予測する画像検査方法は何か?

高橋紀善, 梅澤玲, 古積麻衣子, 山本貴也, 武田一也, 松下晴雄, 石川陽二郎, 鈴木友, 角谷倫之, 勝田義之, 伊藤謙吾, 神宮啓一

臨床放射線　65　(8)　881-885　2020年8月
出版者・発行元：金原出版(株)
ISSN： 0009-9252
頭頸部がんに対する放射線治療後の口腔内QOLの長期的変化(3D-CRT vs. IMRT)

神宮啓一, 高橋紀善, 田坂俊, 梅澤玲, 山本貴也, 石川陽二郎, 武田一也, 鈴木友, 松下晴雄

頭頸部癌　46　(2)　160-160　2020年7月
出版者・発行元： (一社)日本頭頸部癌学会
ISSN： 1349-5747

eISSN： 1881-8382
局所進行頭頸部扁平上皮癌における予防的リンパ節照射線量の検討プロペンシティスコア・マッチング解析

鈴木友, 神宮啓一, 松下晴雄, 梅澤玲, 久保園正樹, 山本貴也, 石川陽二郎, 武田一也, 川端広聖, 岸田桂太, 寺村聡司, 尾股聡, 佐藤雄太, 石田英一, 村田隆紀

頭頸部癌　46　(2)　184-184　2020年7月
出版者・発行元： (一社)日本頭頸部癌学会
ISSN： 1349-5747

eISSN： 1881-8382
局所進行直腸癌に対するTS-1/CPT-11併用術前化学放射線療法の多施設共同臨床第II相試験の長期成績 SAMRAI-2

宮本裕士, 馬場秀夫, 大屋夏生, 佐藤武郎, 早川和重, 冨田尚裕, 的場周一郎, 肥田侯矢, 西舘敏彦, 坂田耕一, 内藤剛, 梅澤玲, 久保亜貴子, 有賀久哲, 笹野仲史, 竹内正弘, 坂井義治, 渡邊昌彦

日本大腸肛門病学会雑誌　73　(7)　325-325　2020年7月
出版者・発行元： (一社)日本大腸肛門病学会
ISSN： 0047-1801

eISSN： 1882-9619
体幹部定位放射線治療における視認下能動的呼吸停止システム基盤の開発研究

石川陽二郎, 角谷倫之, 梶川智博, 田中祥平, 松下晴雄, 梅澤玲, 山本貴也, 武田一也, 片桐佑, 田坂俊, 福井勝哉, 鈴木友, 川端広聖, 岸田桂太, 寺村聡司, 尾股聡, 神宮啓一

Japanese Journal of Radiology　38　(Suppl.)　3-3　2020年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 1867-1071

eISSN： 1867-108X
Sturge-Weber症候群に合併したびまん性脈絡膜血管腫に放射線治療を行なった1例

石川陽二郎, 松下晴雄, 梅澤玲, 山本貴也, 武田一也, 片桐佑, 田坂俊, 福井勝哉, 鈴木友, 川端広聖, 岸田桂太, 寺村聡司, 尾股聡, 神宮啓一

Japanese Journal of Radiology　38　(Suppl.)　9-9　2020年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 1867-1071

eISSN： 1867-108X
80歳を超える後期高齢者食道癌放射線治療に化学療法併用は必要か

神宮啓一, 高橋紀善, 松下晴雄, 梅澤玲, 山本貴也, 石川陽二郎, 武田一也, 片桐佑, 田坂俊, 福井勝哉, 鈴木友, 川端広聖, 岸田桂太, 寺村聡司, 尾股聡

Japanese Journal of Radiology　38　(Suppl.)　9-9　2020年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 1867-1071

eISSN： 1867-108X
中期経過観察された食道癌化学放射線療法後における心事故と心臓MRI所見の関連性

梅澤玲, 角谷倫之, 松下晴雄, 山本貴也, 石川陽二郎, 片桐佑, 武田一也, 福井勝哉, 田坂俊, 鈴木友, 川端広聖, 岸田桂太, 寺村聡司, 尾股聡, 伊藤謙吾, 高山佳樹, 千葉貴仁, 神宮啓一, 大田英揮, 高瀬圭

Japanese Journal of Radiology　38　(Suppl.)　9-9　2020年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 1867-1071

eISSN： 1867-108X
肺定位放射線治療後の放射線誘発肺障害に対するCT画像評価の検討

山本貴也, 角谷倫之, 松下晴雄, 梅澤玲, 石川陽二郎, 高橋紀善, 片桐佑, 神宮啓一, 森下陽平, 佐藤嘉尚, 武田賢

Japanese Journal of Radiology　38　(Suppl.)　10-10　2020年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 1867-1071

eISSN： 1867-108X
Precision medicineに向けたRadiomicsの試み-放射線治療医の立場から-

高橋紀善, 梅澤玲, 山本貴也, 武田一也, 松下晴雄, 石川陽二郎, 田坂俊, 鈴木友, 角谷典之, 神宮啓一

日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集　33rd　2020年
心臓原発血管肉腫に対して化学放射線治療を施行した1例

山本貴也, 城田英和, 井上千裕, 松下晴雄, 梅澤玲, 石川陽二郎, 石岡千加史, 神宮啓一

臨床放射線　64　(11)　1369‐1374　2019年10月10日

DOI： 10.18888/rp.0000001033 　

ISSN： 0009-9252
【循環器症候群(第3版)-その他の循環器疾患を含めて-】心筋疾患放射線照射による心筋障害

神宮啓一, 梅澤玲

日本臨床　別冊　(循環器症候群I)　263-265　2019年9月
出版者・発行元： (株)日本臨床社
ISSN： 0047-1852
舌がん以外の頭頸部がんに対する低線量率密封小線源治療

岸田桂太, 神宮啓一, 松下晴雄, 梅澤玲, 山本貴也, 石川陽二郎, 高橋紀善, 片桐佑, 田坂俊, 武田一也, 福井勝哉, 鈴木友, 川端広聖, 寺村聡司, 伊藤謙吾, 角谷倫之, 千葉貴仁, 高山佳樹

Japanese Journal of Radiology　37　(Suppl.)　4-4　2019年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 1867-1071

eISSN： 1867-108X
放射線肺臓炎の発生予測における治療前CTのradiomics解析の有用性

武田一也, 山本貴也, 高橋紀善, 松下晴雄, 梅澤玲, 石川陽二郎, 片桐佑, 田坂俊, 福井勝哉, 鈴木友, 川端広聖, 寺村聡司, 岸田桂太, 神宮啓一, 角谷倫之, 伊藤謙吾, 千葉貴仁, 高山佳樹

Japanese Journal of Radiology　37　(Suppl.)　6-6　2019年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 1867-1071

eISSN： 1867-108X
食道癌放射線治療後晩期有害事象としての胸水(心嚢液)貯留重症例の検討

松下晴雄, 梅澤玲, 山本貴也, 石川陽二郎, 高橋紀善, 片桐佑, 田坂俊, 武田一也, 福井勝哉, 鈴木友, 川端広聖, 寺村聡司, 岸田桂太, 神宮啓一, 角谷倫之, 伊藤謙吾, 千葉貴仁, 高山佳樹

Japanese Journal of Radiology　37　(Suppl.)　6-6　2019年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 1867-1071

eISSN： 1867-108X
I期食道癌に対する放射線化学療法後の再発形式

寺村聡司, 高橋紀善, 梅澤玲, 松下晴雄, 山本貴也, 石川陽二郎, 片桐佑, 武田一也, 田坂俊, 福井勝哉, 鈴木友, 岸田桂太, 川端広聖, 神宮啓一

Japanese Journal of Radiology　37　(Suppl.)　12-12　2019年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 1867-1071

eISSN： 1867-108X
FDG-PET/CTでのTexture解析を用いた胸部食道癌に対する放射線化学療法の予後予測検討

高橋紀善, 梅澤玲, 武田一也, 松下晴雄, 山本貴也, 石川陽二郎, 片桐佑, 田坂俊, 岸田桂太, 寺村聡司, 神宮啓一, 高浪健太郎

Japanese Journal of Radiology　37　(Suppl.)　13-13　2019年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 1867-1071

eISSN： 1867-108X
炎症性腸疾患症例における急性期・晩期放射線障害の後方視的検討

鈴木友, 松下晴雄, 梅澤玲, 山本貴也, 石川陽二郎, 高橋紀善, 片桐佑, 福井勝哉, 武田一也, 田坂俊, 川端広聖, 岸田桂太, 寺村聡司, 神宮啓一

Japanese Journal of Radiology　37　(Suppl.)　14-14　2019年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 1867-1071

eISSN： 1867-108X
膵臓癌における原発巣に対するリスク臓器・リンパ節領域の呼吸変動による位置変化に関する検討

梅澤玲, 梅澤玲, 脇田明尚, 伊藤芳紀, 中村哲志, 岡本裕之, 高橋加奈, 稲葉浩二, 村上直也, 井垣浩, 神宮啓一, 伊丹純

日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集　32nd　2019年
当院における塩化ラジウム(223Ra)の初期経験

太田瑛梨, 鎌田裕基, 外山由貴, 齋藤美穂子, 高浪健太郎, 高瀬圭, 高橋紀善, 石川陽二郎, 山本貴也, 梅澤玲, 松下晴雄, 神宮啓一

核医学　55　(1)　37-37　2018年12月
出版者・発行元： (一社)日本核医学会
ISSN： 0022-7854

eISSN： 2189-9932
FDG-PETは局所進行食道癌における生命予後を改善せず

神宮啓一, 松下晴雄, 梅澤玲, 山本貴也, 石川陽二郎, 高橋紀善, 角谷倫之, 高浪健太郎

核医学　55　(1)　41-41　2018年12月
出版者・発行元： (一社)日本核医学会
ISSN： 0022-7854

eISSN： 2189-9932
転移・再発腫瘍に対する放射線治療/転移性脊椎腫瘍の治療のアプローチ転移・再発腫瘍に対する高精度放射線治療

神宮啓一, 山本貴也, 松下晴雄, 梅澤玲

日本癌治療学会学術集会抄録集　56回　PD4-1　2018年10月
出版者・発行元： (一社)日本癌治療学会
【食道癌(第2版)-基礎・臨床研究の進歩-】食道癌の治療化学放射線療法術前補助化学放射線療法

神宮啓一, 梅澤玲, 山本貴也, 高橋紀善, 武田一也

日本臨床　76　(増刊8 食道癌)　389-391　2018年10月
出版者・発行元： (株)日本臨床社
ISSN： 0047-1852
【核医学の放射線治療への新規応用】FDG-PET/CTを用いた放射線治療の予後予測

高橋紀善, 梅澤玲, 高浪健太郎, 山本貴也, 武田一也, 松下晴雄, 石川陽二郎, 片桐佑, 神宮啓一

臨床放射線　63　(9)　969-978　2018年9月
出版者・発行元：金原出版(株)
DOI： 10.18888/rp.0000000545 　

ISSN： 0009-9252
食道癌に対する放射線治療の変遷と将来

神宮啓一, 梅澤玲, 高橋紀善, 山田章吾

日本食道学会学術集会プログラム・抄録集　72回　12-12　2018年6月
出版者・発行元： (NPO)日本食道学会
放射線療法分野の問題点と今後の課題

伊藤芳紀, 澁谷景子, 中村聡明, 大栗隆行, 染谷正則, 堀正和, 高橋昌太郎, 篠藤誠, 梅澤玲

膵臓　33　(3)　311-311　2018年5月
出版者・発行元： (一社)日本膵臓学会
ISSN： 0913-0071

eISSN： 1881-2805
放射線療法分野の問題点と今後の課題

伊藤芳紀, 澁谷景子, 中村聡明, 大栗隆行, 染谷正則, 堀正和, 高橋昌太郎, 篠藤誠, 梅澤玲

膵臓　33　(3)　311-311　2018年5月
出版者・発行元：日本膵臓学会
ISSN： 0913-0071
Native T1値と細胞外容積分画を用いた放射線心筋傷害の評価

高木英誠, 大田英揮, 高瀬圭, 梅沢玲, 神宮啓一

Japanese Journal of Radiology　36　(Suppl.)　2-2　2018年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 1867-1071

eISSN： 1867-108X
FDG-PETは局所進行食道癌における生命予後を改善せず

神宮啓一, 松下晴雄, 梅澤玲, 山本貴也, 石川陽二郎, 高橋紀善, 角谷倫之, 高浪健太郎

核医学(Web)　55　(1)　2018年

ISSN： 2189-9932
当院における塩化ラジウム(²²³Ra)の初期経験

太田瑛梨, 鎌田裕基, 外山由貴, 齋藤美穂子, 高浪健太郎, 高瀬圭, 高橋紀善, 石川陽二郎, 山本貴也, 梅澤玲, 松下晴雄, 神宮啓一

核医学(Web)　55　(1)　2018年

ISSN： 2189-9932
【胸部の最新画像情報2018】胸部悪性腫瘍に対する化学放射線療法に伴う心臓合併症の画像所見

高浪健太郎, 梅澤玲, 神宮啓一, 高瀬圭

臨床放射線　63　(1)　53-60　2018年1月
出版者・発行元：金原出版(株)
DOI： 10.18888/rp.0000000308 　

ISSN： 0009-9252

詳細を見る詳細を閉じる

胸部悪性腫瘍に対して、化学療法と放射線療法を併用する化学放射線療法(CRT)が広く行われており、長期生存が期待できるようになった。それに伴い、化学療法に用いられる薬剤による心臓疾患、放射線照射野内に心臓が含まれることによる心臓疾患が長期生存例で問題となっている。これらCRT関連心臓疾患について概説し、それらの画像所見と画像を用いた早期検出と予防の可能性について述べた。
心臓MRI検査を用いた食道癌化学放射線療法後の心筋障害に対する前向き研究

梅澤玲, 角谷倫之, 大田英揮, 中島祐二朗, 齋藤正英, 高橋紀善, 高瀬圭, 神宮啓一

日本癌治療学会学術集会抄録集　55回　P127-3　2017年10月
出版者・発行元： (一社)日本癌治療学会
【腫瘍に対する放射線治療-高度化・個別化治療へ-】先端放射線治療癌腫別放射線治療食道癌

神宮啓一, 梅澤玲, 山本貴也, 高橋紀善, 武田一也

日本臨床　75　(8)　1229-1233　2017年8月
出版者・発行元： (株)日本臨床社
ISSN： 0047-1852
心臓MRI検査を用いた食道癌化学放射線療法後の心筋障害に対する前向き研究

梅澤玲, 角谷倫之, 大田英揮, 高橋紀善, 高瀬圭, 神宮啓一

日本食道学会学術集会プログラム・抄録集　71回　P27-7　2017年6月
出版者・発行元： (NPO)日本食道学会
早期子宮体癌における腟断端再発に対する治療検討

永井智之, 橋本千明, 海法道子, 豊島将文, 徳永英樹, 島田宗昭, 梅澤玲, 久保薗正樹, 八重樫伸生

日本婦人科腫瘍学会雑誌　35　(3)　544-544　2017年6月
出版者・発行元： (公社)日本婦人科腫瘍学会
ISSN： 1347-8559
【放射線治療情報BOOK 2016】 (DIVISION 4)より高精度の照射のために CLINICAL REPORT より高精度の照射のためにGold Anchorマーカ

稲葉浩二, 島聖, 土田圭祐, 小林和馬, 原田堅, 梅澤玲, 高橋加奈, 村上直也, 伊藤芳紀, 井垣浩, 伊丹純

Rad Fan　14　(14)　88-89　2016年11月
出版者・発行元： (株)メディカルアイ
ISSN： 1348-3498
Prediction of symptomatic cardiac toxicity in the patients who underwent chemoradiotherapy for esophageal cancer by myocardial fatty acid metabolic imaging using I-123 BMIPP SPECT/CT

K. Takanami, A. Arai, R. Umezawa, K. Jingu, K. Takase

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING　43　S545-S546　2016年10月

ISSN： 1619-7070

eISSN： 1619-7089
子宮子宮頸がんの治療戦略当院における子宮頸癌術後照射3DCRTからIMRTへの移行による晩期腸管毒性軽減

土田圭祐, 村上直也, 加藤友康, 島聖, 柏原大朗, 小林和馬, 原田堅, 梅澤玲, 高橋加奈, 稲葉浩二, 井垣浩, 伊藤芳紀, 伊丹純

日本癌治療学会学術集会抄録集　54回　MS10-2　2016年10月
出版者・発行元： (一社)日本癌治療学会
子宮再発婦人科腫瘍の治療戦略子宮頸がん術後骨盤内再発に対する救済組織内照射の治療成績

村上直也, 加藤友康, 宮本雄一郎, 島聖, 土田圭祐, 柏原大朗, 小林和馬, 原田堅, 梅澤玲, 高橋加奈, 稲葉浩二, 井垣浩, 伊藤芳紀, 伊丹純

日本癌治療学会学術集会抄録集　54回　MS37-2　2016年10月
出版者・発行元： (一社)日本癌治療学会
前立腺高リスク前立腺がんの治療戦略高リスク前立腺癌に対する放射線治療における線量増加の検討

梅澤玲, 稲葉浩二, 中村哲志, 脇田明尚, 岡本裕之, 土田圭祐, 柏原大朗, 小林和馬, 原田堅, 高橋加奈, 村上直也, 伊藤芳紀, 井垣浩, 伊丹純

日本癌治療学会学術集会抄録集　54回　MS48-4　2016年10月
出版者・発行元： (一社)日本癌治療学会
脳腫瘍転移性脳腫瘍治療の進歩単発性脳転移の術後照射局所照射と全脳照射の比較検討

井垣浩, 原田堅, 梅澤玲, 宮北康二, 島聖, 土田圭祐, 柏原大朗, 小林和馬, 稲葉浩二, 高橋加奈, 村上直也, 伊藤芳紀, 成田善孝, 伊丹純

日本癌治療学会学術集会抄録集　54回　WS14-3　2016年10月
出版者・発行元： (一社)日本癌治療学会
乳腺乳房温存療法早期乳がん術後の3次元原体放射線治療による加速乳房部分照射前向き試験7年の結果

高橋加奈, 岡本裕之, 島聖, 土田圭祐, 柏原大朗, 小林和馬, 原田堅, 梅澤玲, 稲葉浩二, 村上直也, 井垣浩, 伊藤芳紀, 加賀美芳和, 伊丹純

日本癌治療学会学術集会抄録集　54回　WS17-1　2016年10月
出版者・発行元： (一社)日本癌治療学会
前立腺がんに対してサイバーナイフを用いた定位放射線治療(SBRT)の初期経験

稲葉浩二, 土田圭祐, 柏原大朗, 小林和馬, 原田堅, 梅澤玲, 高橋加奈, 村上直也, 伊藤芳紀, 井垣浩, 伊丹純

日本癌治療学会学術集会抄録集　54回　P56-1　2016年10月
出版者・発行元： (一社)日本癌治療学会
東北大学病院における喉頭癌T2症例の検討

山本貴也, 松下晴雄, 菅原俊幸, 久保園正樹, 梅澤玲, 角谷倫之, 石川陽二郎, 古積麻衣子, 高橋紀善, 伊藤謙吾, 片桐佑, 武田賢, 土橋卓, 神宮啓一, 小川武則, 香取幸夫

Japanese Journal of Radiology　34　(Suppl.)　5-5　2016年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 1867-1071

eISSN： 1867-108X
より高精度の照射のために Gold Anchorマーカ

稲葉浩二, 島聖, 土田圭祐, 小林和馬, 原田堅, 梅澤玲, 高橋加奈, 村上直也, 伊藤芳紀, 井垣浩, 伊丹純

Rad Fan　14　(14)　2016年

ISSN： 1348-3498
【外科医に求められる積極的緩和医療-延命と症状緩和の狭間で】緩和医療における放射線療法の役割

伊藤芳紀, 井垣浩, 村上直也, 稲葉浩二, 高橋加奈, 梅澤玲, 関井修平, 原田堅, 北口真由香, 小林和馬, 柏原大朗, 土田圭祐, 伊丹純

臨床外科　70　(13)　1454-1461　2015年12月
出版者・発行元： (株)医学書院
DOI： 10.11477/mf.1407211013 　

ISSN： 0386-9857

eISSN： 1882-1278
【分子標的治療薬と放射線治療の併用】頭頸部癌のcetuximab併用放射線療法の成績

稲葉浩二, 渡辺悟, 柏原大朗, 小林和馬, 北口真由香, 原田堅, 関井修平, 梅澤玲, 高橋加奈, 村上直也, 伊藤芳紀, 井垣浩, 下谷久美, 本間義崇, 吉本世一, 伊丹純

臨床放射線　60　(13)　1677-1680　2015年12月
出版者・発行元：金原出版(株)
ISSN： 0009-9252

詳細を見る詳細を閉じる

2013年2月〜2014年5月、頭頸部癌15例(53〜85歳)に対して、cetuximabによるbioradiotherapyを施行した。治療内容はcetuximabを放射線療法開始の1週間前に400mg/m2、それ以降は1週間ごとに250mg/m2で投与し、放射線療法は週5回、1回2Gyの照射を行った。Cetuximabの使用回数は4〜9コースであり、予定量の70%以上を投与した患者の割合は64%であった。Grade 3以上の有害事象は皮膚炎80%、粘膜炎67%、消化管出血13%、白血球減少7%であり、有害事象のため入院が必要になった割合は73%であった。放射線療法完遂後8週目時点の奏効割合は80%であった。観察期間中央値24.2ヵ月で、2年局所制御割合は73.3%、2年無再発生存率は66.7%、2年全生存割合は65.5%、2年疾患特異的生存割合は72.7%であった。Cetuximab併用放射線療法の奏効割合は日本の第II相臨床試験と同等であったが、治療完遂割合は過去の臨床試験より低かった。
Chemoradiation Therapy for Esophageal Cancer Did Not Decrease Survival During the Later Period Compared With Surgery Alone at More Than 10 Year Follow-up

H. Ariga, K. Jingu, T. Kamei, R. Umezawa, K. Nemoto, S. Miyazaki, T. Yoshioka

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　93　(3)　E161-E161　2015年11月

ISSN： 0360-3016

eISSN： 1879-355X
Treatment Outcomes of Intensity Modulated Radiation Therapy for Clinical Stage I/II Hypopharyngeal Cancer

Y. Ito, N. Murakami, K. Inaba, K. Takahashi, R. Umezawa, H. Igaki, S. Sekii, K. Harada, M. Kitaguchi, K. Kobayashi, T. Kashihara, S. Yoshimoto, J. Itami

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　93　(3)　E348-E348　2015年11月

ISSN： 0360-3016

eISSN： 1879-355X
Recurrence Pattern After Definitive Chemoradiation Therapy for Cervical Esophageal Cancer

S. Sekii, Y. Ito, K. Kato, R. Umezawa, K. Takahashi, K. Inaba, N. Murakami, H. Igaki, J. Itami

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　93　(3)　E158-E158　2015年11月

ISSN： 0360-3016

eISSN： 1879-355X
食道癌化学放射線療法における心臓照射線量と心筋脂肪酸代謝障害の関連 BMIPP SPECT/CTによる経時的評価

高浪健太郎, 荒井晃, 梅澤玲, 角谷倫之, 竹内孝至, 神宮啓一, 高瀬圭

日独医報　60　(2)　240-240　2015年11月
出版者・発行元：バイエル薬品(株)
ISSN： 0912-0351
有害事象をいかに防止するか?放射線心筋障害の機序と対策

神宮啓一, 梅澤玲, 松下晴雄, 久保園正樹, 角谷倫之, 白田佑子, 山本貴也, 石川陽二郎, 古積麻衣子, 高橋紀善, 片桐佑

臨床放射線　60　(10)　1221-1224　2015年10月10日
出版者・発行元：金原出版(株)
ISSN： 0009-9252
Association between radiation dosimetry of the heart and the myocardial fatty acid metabolic impairment due to chemoradiation-therapy : Prospective study using I-123 BMIPP SPECT/CT

K. Takanami, R. Umezawa, N. Kadoya, A. Arai, K. Jingu, K. Takase

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING　42　S284-S285　2015年10月

ISSN： 1619-7070

eISSN： 1619-7089
【有害事象をいかに防止するか?】放射線心筋障害の機序と対策

神宮啓一, 梅澤玲, 松下晴雄, 久保園正樹, 角谷倫之, 白田佑子, 山本貴也, 石川陽二郎, 古積麻衣子, 高橋紀善, 片桐佑

臨床放射線　60　(10)　1221-1224　2015年10月
出版者・発行元：金原出版(株)
ISSN： 0009-9252
泌尿器尿路上皮がんに対する集学的治療尿路上皮がんに対するIMRTを用いた高線量放射線治療の初期成績

稲葉浩二, 原智彦, 篠田康夫, 込山元清, 柏原大朗, 小林和馬, 原田堅, 関井修平, 梅澤玲, 高橋加奈, 村上直也, 伊藤芳紀, 井垣浩, 藤元博行, 伊丹純

日本癌治療学会誌　50　(3)　1288-1288　2015年9月
出版者・発行元： (一社)日本癌治療学会
ISSN： 0021-4671
頭頸・口腔頭頸部がんに対する新規治療開発 T1-2声門部喉頭癌根治的放射線治療における組織学的予後因子の検討

村上直也, 森泰昌, 吉本世一, 伊藤芳紀, 柏原大朗, 小林和馬, 原田堅, 北口真由香, 関井修平, 高橋加奈, 梅澤玲, 稲葉浩二, 井垣浩, 伊丹純

日本癌治療学会誌　50　(3)　2171-2171　2015年9月
出版者・発行元： (一社)日本癌治療学会
ISSN： 0021-4671
【甲状腺癌の治療戦略】甲状腺がんに対する放射線治療

神宮啓一, 丸岡伸, 梅澤玲, 高橋紀善

癌と化学療法　42　(6)　666-669　2015年6月
出版者・発行元： (株)癌と化学療法社
ISSN： 0385-0684
臨床病期I期、II期下咽頭癌に対する強度変調放射線治療の治療成績

伊藤芳紀, 村上直也, 稲葉浩二, 高橋加奈, 井垣浩, 梅澤玲, 関井修平, 原田堅, 小林和馬, 柏原大朗, 松本文彦, 小林謙也, 槇大輔, 吉本世一, 伊丹純

頭頸部癌　41　(2)　199-199　2015年5月
出版者・発行元：日本頭頸部癌学会
ISSN： 1349-5747

eISSN： 1881-8382
【がん放射線治療の最前線】放射線治療の合併症と対策

神宮啓一, 松下晴雄, 梅澤玲

日本医師会雑誌　144　(2)　269-271　2015年5月
出版者・発行元：日本医師会
ISSN： 0021-4493
縦隔へ照射既往のある異時性第二肺癌に対する定位放射線治療成績の検討

山本貴也, 角谷倫之, 久保園正樹, 佐藤清和, 片桐佑, 松下晴雄, 菅原俊幸, 梅澤玲, 岸和馬, 伊藤謙吾, 武田賢, 神宮啓一

臨床放射線　60　(4)　556-563　2015年4月
出版者・発行元：金原出版(株)
ISSN： 0009-9252

詳細を見る詳細を閉じる

縦隔へ中央値60Gyの通常分割照射後3年以上経過し、異時性第二肺癌に対して定位放射線治療を行った7例(全例男性・年齢中央値80歳)の治療成績について検討した。第一癌は食道癌5例、肺癌2例、治療は二次元放射線治療3例、三次元治療4例、7例中5例で同時併用化学療法を行った。異時性肺癌の腫瘍径は中央値1.8cm、病理診断は扁平上皮癌2病変、臨床診断5病変であった。第一癌と第二癌とのインターバルは中央値99.4ヵ月、定位放射線後観察期間は中央値15.9ヵ月であった。期間中の死亡は4例(原病死0)、生存3例中1例で局所再発を認めた。1年生存率は71.4%、3年生存率は38.0%で、生存期間中央値は28.8ヵ月であった。放射線治療のインターバルが長い方で予後不良の傾向を認めた。有害事象は、Grade 5が3例に疑われ、放射線肺炎のGrade 3:2例、Grade 2:2例を認めた。通常分割放射線治療後の定位放射線治療は、生命予後を延長するとは限らないと考えられた。
【膵癌・胆道癌-基礎と臨床の最新研究動向-】胆道癌腺癌胆嚢癌治療胆嚢癌放射線治療の現状と展望

神宮啓一, 梅澤玲

日本臨床　73　(増刊3 膵癌・胆道癌)　590-594　2015年3月
出版者・発行元： (株)日本臨床社
ISSN： 0047-1852
pT3前立腺癌術後PSA failureに対する放射線単独局所治療成績

神宮啓一, 梅澤玲, 松下晴雄, 菅原俊幸, 久保園正樹, 阿部恵子, 藤本俊裕, 山本貴也, 石川陽二郎, 古積麻衣子, 高橋紀善, 角谷倫之, 藤田幸男, 伊藤謙吾

Japanese Journal of Radiology　33　(Suppl.)　11-11　2015年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 1867-1071

eISSN： 1867-108X
Re: MRI findings of radiation-induced myocardial damage in patients with oesophageal cancer. A reply

R. Umezawa, H. Ota, K. Jingu

Clinical Radiology　70　677-678　2015年1月1日

DOI： 10.1016/j.crad.2015.02.008 　

ISSN： 0009-9260
Clinical Factors With Respect to Cervical Body Volume Reduction During Definitive External Beam Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma

K. Takeda, S. Dobashi, S. Komori, K. Chida, N. Kadoya, K. Itoh, T. Sugawara, M. Kubozono, R. Umezawa, Y. Ishikawa, T. Yamamoto, T. Fujimoto, M. Kozumi, Y. Onozato, T. Suzuki, H. Matsushita, K. Jingu

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　90　S511-S511　2014年9月

ISSN： 0360-3016

eISSN： 1879-355X
Impact of Tumor Attachment to the Pleura Measured by a Pretreatment CT Image on Outcome of Stage I NSCLC Treated With Stereotactic Body Radiation Therapy

T. Yamamoto, N. Kadoya, N. Takahashi, H. Matsushita, Y. Shirata, T. Sugawara, M. Kubozono, R. Umezawa, K. Abe, S. Fujimoto, Y. Ishikawa, M. Kozumi, K. Takeda, K. Jingu

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　90　S614-S615　2014年9月

ISSN： 0360-3016

eISSN： 1879-355X
頭頸部癌を対象とした198Au密封小線源治療の線量計算

伊藤謙吾, 角谷倫之, 藤田幸男, 岸和馬, 佐藤清和, 武田賢, 土橋卓, 梅澤玲, 久保園正樹, 松下晴雄, 神宮啓一

臨床放射線　59　(9)　1219-1225　2014年9月
出版者・発行元：金原出版(株)
ISSN： 0009-9252

詳細を見る詳細を閉じる

頭頸部癌を対象とした198Au密封小線源治療の線量計算について検討した。198Au線源を刺入した口辱扁平上皮癌患者2例を対象とした。症例1は73歳女で、腫瘍および周辺の粘膜下5mmに10個の線源を永久刺入した。症例2は65歳男で、腫瘍および周辺の粘膜下5mmに14個の線源を永久刺入した。2例は、永久刺入で腫瘍に85Gyが投与されるようにモールド法を用いて線源配置を決定した。刺入された線源周辺の正常組織への照射を可能な限り減らすため、アクリルと鉛板で構成されたマウスピースを飲食時以外装着するように指導した。モンテカルロ計算によって算出した値をVariSeedに登録し、線量計算に使用した。VariSeedに登録することで、三次元的な線量分布の算出と高分解能CT画像との重ね合わせが可能となった。
Future Direction of Image-Guided Radiotherapy for Localized Prostate Cancer for more Precise and Conformal Treatment Delivery

Ken Takeda, Rei Umezawa, Yohjiro Ishikawa, Noriyuki Kadoya, Kengo Ito, Toshiyuki Sugawara, Masaki Kubozono, Takaya Yamamoto, Maiko Kozumi, Suguru Dobashi, Koichi Chida, Haruo Matsushita, Keichi Jingu

J Radiol Radiat Ther　2014年7月1日
出版者・発行元： SciMedCentral
心臓MRI検査を用いた放射線治療後の心筋変化の検出

梅澤玲, 高瀬圭, 大田英揮, 高浪健太郎, 金田朋洋, 神宮啓一, 高橋昭喜

日独医報　59　(1)　114-114　2014年6月
出版者・発行元：バイエル薬品(株)
ISSN： 0912-0351
頭頸部癌に対する適応放射線治療の基礎研究頭頸部外部放射線治療期間中の頸部体積減少について

小森慎也, 武田賢, 土橋卓, 角谷倫之, 藤田幸男, 伊藤謙吾, 山本貴也, 梅澤玲, 松下晴雄, 神宮啓一, 岸和馬, 佐藤清和

臨床放射線　59　(5)　733-739　2014年5月
出版者・発行元：金原出版(株)
ISSN： 0009-9252

詳細を見る詳細を閉じる

外部放射線治療を施行した頭頸部癌112例(中咽頭癌50例・下咽頭癌62例)を対象に、照射期間中に観察された頸部体積減少に関連する臨床因子を調査した。性別、同時化学放射線療法実施の有無とその種類、胸部食道同時照射実施の有無、病期分類の計4項目について、因子間で頸部体積の減少量に有意差があるかを評価した。その結果、全例で頸部体積は治療前に比べ治療期間中に有意に減少し、減少率は中央値6.4%(1.2〜23.7%)であった。下咽頭癌症例においては、抗癌剤TPFを用いた同時化学療法併用群は非併用群に比べ頸部体積減少率が有意に高かった。また、中咽頭癌・下咽頭癌ともにN3症例では頸部体積減少率が高い傾向があった。以上の結果は、適応放射線治療が有効な症例を選別する際の指針になり得ると考えられた。
北日本放射線治療施設における子宮頸癌術後腟断端再発に関する治療方針北日本放射線腫瘍学研究会アンケート調査結果

神宮啓一, 久保園正樹, 松下晴雄, 菅原俊幸, 梅澤玲, 阿部恵子, 藤本俊裕, 山本貴也, 石川陽二郎, 田邊隆哉, 古積麻衣子, 高橋紀善

臨床放射線　59　(4)　574-578　2014年4月
出版者・発行元：金原出版(株)
ISSN： 0009-9252

詳細を見る詳細を閉じる

北日本放射線治療施設における子宮頸癌術後腟断端再発に関する治療方針について北日本放射線腫瘍学研究会アンケート調査から検討した。22施設の放射線治療専門医より回答が得られた。施設にはすべて常勤の産婦人科医があった。各放射線治療施設の婦人科癌の年間症例数は、0〜9症例7施設、10〜29症例9施設、30〜49症例4施設、50症例以上2施設であった。High dose rate(HDR)-Remote after loading system(RALS)の保有率は55%であった。2000年以降で子宮頸癌術後腟断端再発の経験症例数は、0〜5症例59%、5〜10症例9%、10〜19症例23%、20症例以上9%であった。
【前立腺癌局所治療後再発の診断、治療】前立腺癌局所治療後再発の治療前立腺全摘後再発に対する救済放射線療法の適応と課題

三塚浩二, 梅澤玲, 神宮啓一, 荒井陽一

泌尿器外科　27　(2)　165-172　2014年2月
出版者・発行元：医学図書出版(株)
ISSN： 0914-6180
Clinical factors relevant to regional body volume changes during radical external radiotherapy for head and neck cancer

S. Komori, K. Takeda, S. Dobashi, N. Kadoya, Y. Fujita, K. Ito, T. Yamamoto, R. Umezawa, H. Matsushita, K. Jingu, K. Kishi, K. Sato

Japanese Journal of Clinical Radiology　59　733-739　2014年1月1日

ISSN： 0009-9252
Methods for treatment of postoperative recurrence of uterine cervical cancer in the vaginal stump: Results of a survey by NJRTOG

Keiichi Jingu, M. Kubozono, H. Matsushita, T. Sugawara, R. Umezawa, K. Abe, T. Fujimoto, T. Yamamoto, Y. Ishikawa, T. Tanabe, M. Kozumi, N. Takahashi

Japanese Journal of Clinical Radiology　59　574-578　2014年1月1日

ISSN： 0009-9252
Evaluation of dose calculation accuracy of modified CBCT using multi -level-threshold algorithm

Yusuke Onozato, Noriyuki Kadoya, Yukio Fujita, Yoshiyuki Katsuta, Suguru Dobashi, Ken Takeda, Kazuma Kishi, Kiyokazu Satou, Keiko Abe, Rei Umezawa, Eiji Shimizu, Toshiyuki Sugawara, Keiichi Jingu, Haruo Matsushita

IFMBE Proceedings　39 IFMBE　1799-1802　2013年4月16日

DOI： 10.1007/978-3-642-29305-4_473 　

ISSN： 1680-0737
新しい治療戦略シリーズ泌尿器科領域における放射線治療最先端前立腺癌におけるIMRTの成績とQOL

並木俊一, 武田賢, 石戸谷滋人, 高井良尋, 奈良崎覚太朗, 梅澤玲, 山田章吾, 神宮啓一, 荒井陽一

日本泌尿器科学会雑誌　104　(2)　120-120　2013年3月
出版者・発行元： (一社)日本泌尿器科学会
ISSN： 0021-5287
21世紀の子宮頸癌I期、II期放射線治療

久保園正樹, 松下晴雄, 菅原俊幸, 神宮啓一, 清水栄二, 梅澤玲, 阿部恵子, 白田佑子, 石川陽二郎, 山本貴也, 古積麻衣子, 有賀久哲, 小川芳弘, 山田章吾

Japanese Journal of Radiology　31　(Suppl.I)　11-11　2013年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 1867-1071

eISSN： 1867-108X
心筋脂肪酸シンチグラフィーによる照射野に含まれた心筋代謝変化に関する検討

梅澤玲, 高瀬圭, 高浪健太郎, 大田英揮, 神宮啓一, 金田朋洋, 高橋昭喜

日独医報　57　(1)　105-105　2012年8月
出版者・発行元：バイエル薬品(株)
ISSN： 0912-0351
上咽頭癌に対する強度変調放射線治療において局所再発が増えるか?(第1報)

神宮啓一, 阿部恵子, 小藤昌志, 松下晴雄, 藤本圭介, 菅原俊幸, 清水栄二, 梅澤玲, 武田賢, 山田章吾

頭頸部癌　38　(2)　195-195　2012年5月
出版者・発行元：日本頭頸部癌学会
ISSN： 1349-5747
食道癌放射線治療後に放射線心筋障害が疑われた症例の画像所見

高浪健太郎, 梅澤玲, 高瀬圭, 高橋昭喜

日独医報　56　(2)　264-264　2011年12月
出版者・発行元：バイエル薬品(株)
ISSN： 0912-0351
局所型前立腺癌に対する3次元原体照射後の晩期消化管障害に関連する臨床因子(Clinical Predictors of Late Gastrointestinal Toxicity after Three-dimensional Conformal Radiotherapy for Localized Prostate Cancer)

武田賢, 有賀久哲, 神宮啓一, 久保園正樹, 菅原俊幸, 梅澤玲, 清水栄二, 土橋卓, 角谷倫之, 藤田幸男, 根本建二, 山田章吾

東北大学医学部保健学科紀要　20　(2)　103-108　2011年7月
出版者・発行元：東北大学医学部保健学科
ISSN： 1348-8899

詳細を見る詳細を閉じる

局所前立腺癌患者88例(年齢中央値71歳)を対象に、三次元原体照射療法を行った。各患者に対する総照射量は74Gy(1日当たり2Gy)であった。National Comprehensive Cancer Networkによるリスク分類は低リスク6例、中リスク45例、高リスク37例であった。腫瘍の病期はT1 39例、T2 34例、T3 15例で、アンドロゲン枯渇療法は56例に施行されていた。これら患者で晩期消化管(GI)障害の有無を調べたところ、グレード2とグレード3の障害が各1例ずつ認められ、発症率は3%であった。血管疾患のため抗凝固剤/抗凝集剤(A/A)で治療されていた患者とGI疾患の既往を有する患者はグレード2または3の晩期GI障害の発現が高かった。単分散分析では、A/A治療およびGI疾患の既往は晩期GI障害の発現と有意に相関していた。
F-18 FDG・I-123 BMIPP・心臓MRIで放射線心筋障害が疑われた3症例

梅澤玲, 高瀬圭, 高浪健太郎, 神宮啓一, 有賀久哲, 金田朋洋, 大田英揮, 高橋昭喜, 山田章吾

日本医学放射線学会学術集会抄録集　70回　S209-S209　2011年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 0048-0428
子宮頸癌におけるセンチネルリンパ節の有用性の検討

梅澤玲, 岩間英範, 小篠隆広, 高山和人, 阿部祐也, 小田隆晴

山形県立病院医学雑誌　42　(2)　119-121　2008年7月
出版者・発行元：山形県病医誌編集委員会
ISSN： 0389-0848

詳細を見る詳細を閉じる

Ia1期〜Ib2期の子宮頸癌8例を対象に染色法を用いてセンチネルリンパ節の同定を行い、その有用性について検討した。その結果、6例でセンチネルリンパ節が染色され、同定率は75%で、特異度は100%、偽陰性率は0%であった。転移を認めた症例は1例のみであったが、感度は100%、偽陽性率は0%であった。
吐血と下血を訴えて来院した67歳、男性の症例

深瀬和利, 笹生俊一, 細田奈生, 高橋智子, 松田徹, 三好寛明, 梅澤玲, 松村勇輝, 星宣次, 後藤敏和, 江口真里子, 鈴木克典, 鈴木昌幸, 鈴木康之, 真島佑介, 佐々木真太郎, 松田暁子, 吉澤和哉, 石川博康, 飯澤肇, 手塚康二

山形県立病院医学雑誌　42　(1)　60-80　2008年1月
出版者・発行元：山形県病医誌編集委員会
ISSN： 0389-0848
労作時の下腿の重苦しさと息切れを訴え、間もなく下腿浮腫をきたした症例

堀野智史, 後藤敏和, 田村元, 川野研悟, 梅澤玲, 佐藤啓, 閑野将行, 武田祐介, 下山貴子, 五味瑠美子, 嶋村之秀, 村上弥沙子, 青木竜男, 中川隆行, 江口真里子, 石岡大輔, 辻本雄太, 羽尾清貴, 藤川拓也, 三浦友来, 石川朗, 高梨以美, 鈴木昌幸, 笹生俊一

山形県立病院医学雑誌　41　(1)　39-62　2007年1月
出版者・発行元：山形県病医誌編集委員会
ISSN： 0389-0848

︎全件表示 ︎最初の5件までを表示

講演・口頭発表等 65

放射線療法分野の問題点と今後の課題

伊藤芳紀, 澁谷景子, 中村聡明, 大栗隆行, 染谷正則, 堀正和, 高橋昌太郎, 篠藤誠, 梅澤玲

膵臓　2018年5月
II・III期食道癌CRTにおける血液検査データと予後との関連

武田一也, 松下晴雄, 久保園正樹, 田邊隆哉, 石川陽二郎, 山本貴也, 古積麻衣子, 高橋紀善, 片桐佑, 田坂俊, 福井勝哉, 鈴木友, 角谷倫之, 伊藤謙吾, 千葉瑞己, 神宮啓一, 武田賢, 土橋卓, 梅澤玲

Japanese Journal of Radiology　2018年2月
心臓MRI検査を用いた食道癌化学放射線療法後の心筋障害に対する前向き研究

梅澤玲, 角谷倫之, 大田英揮, 中島祐二朗, 齋藤正英, 高橋紀善, 高瀬圭, 神宮啓一

日本癌治療学会学術集会抄録集　2017年10月
心臓MRI検査を用いた食道癌化学放射線療法後の心筋障害に対する前向き研究

梅澤玲, 角谷倫之, 大田英揮, 高橋紀善, 高瀬圭, 神宮啓一

日本食道学会学術集会プログラム・抄録集　2017年6月
前立腺がんに対してサイバーナイフを用いた定位放射線治療(SBRT)の初期経験

稲葉浩二, 土田圭祐, 柏原大朗, 小林和馬, 原田堅, 梅澤玲, 高橋加奈, 村上直也, 伊藤芳紀, 井垣浩, 伊丹純

日本癌治療学会学術集会抄録集　2016年10月
乳腺乳房温存療法早期乳がん術後の3次元原体放射線治療による加速乳房部分照射前向き試験7年の結果

高橋加奈, 岡本裕之, 島聖, 土田圭祐, 柏原大朗, 小林和馬, 原田堅, 梅澤玲, 稲葉浩二, 村上直也, 井垣浩, 伊藤芳紀, 加賀美芳和, 伊丹純

日本癌治療学会学術集会抄録集　2016年10月
脳腫瘍転移性脳腫瘍治療の進歩単発性脳転移の術後照射局所照射と全脳照射の比較検討

井垣浩, 原田堅, 梅澤玲, 宮北康二, 島聖, 土田圭祐, 柏原大朗, 小林和馬, 稲葉浩二, 高橋加奈, 村上直也, 伊藤芳紀, 成田善孝, 伊丹純

日本癌治療学会学術集会抄録集　2016年10月
前立腺高リスク前立腺がんの治療戦略高リスク前立腺癌に対する放射線治療における線量増加の検討

梅澤玲, 稲葉浩二, 中村哲志, 脇田明尚, 岡本裕之, 土田圭祐, 柏原大朗, 小林和馬, 原田堅, 高橋加奈, 村上直也, 伊藤芳紀, 井垣浩, 伊丹純

日本癌治療学会学術集会抄録集　2016年10月
子宮再発婦人科腫瘍の治療戦略子宮頸がん術後骨盤内再発に対する救済組織内照射の治療成績

村上直也, 加藤友康, 宮本雄一郎, 島聖, 土田圭祐, 柏原大朗, 小林和馬, 原田堅, 梅澤玲, 高橋加奈, 稲葉浩二, 井垣浩, 伊藤芳紀, 伊丹純

日本癌治療学会学術集会抄録集　2016年10月
子宮子宮頸がんの治療戦略当院における子宮頸癌術後照射3DCRTからIMRTへの移行による晩期腸管毒性軽減

土田圭祐, 村上直也, 加藤友康, 島聖, 柏原大朗, 小林和馬, 原田堅, 梅澤玲, 高橋加奈, 稲葉浩二, 井垣浩, 伊藤芳紀, 伊丹純

日本癌治療学会学術集会抄録集　2016年10月
Metabolic tumor volumeはIII期進行食道癌に対する放射線化学療法の予後因子となる

高橋紀善, 梅澤玲, 神宮啓一

日本食道学会学術集会プログラム・抄録集　2016年7月
手術不適応非小細胞肺癌III期に対する放射線治療成績東北大学病院200例超の解析結果

片桐佑, 松下晴雄, 菅原俊幸, 梅澤玲, 久保園正樹, 山本貴也, 石川陽二郎, 古積麻衣子, 高橋紀善, 角谷倫之, 木田智士, 伊藤謙吾, 神宮啓一, 土橋卓, 武田賢

Japanese Journal of Radiology　2016年2月
3D-IGBTにおける独立線量計算の有効性の検討

伊藤謙吾, 角谷倫之, 木田智士, 高橋紀善, 古積麻衣子, 山本貴也, 石川陽二郎, 梅澤玲, 久保園正樹, 菅原俊幸, 松下晴雄, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　2016年2月
FDG-PET/CTでのMetabolic tumor volumeを用いた肺定位放射線治療に対する予後予測の検討

高橋紀善, 松下晴雄, 菅原俊幸, 梅澤玲, 久保園正樹, 石川陽二郎, 山本貴也, 片桐佑, 古積麻衣子, 角谷倫之, 木田智士, 伊藤謙吾, 神宮啓一, 土橋卓, 武田賢

Japanese Journal of Radiology　2016年2月
縦隔へ40Gy以上照射された根治的放射線治療後、異時性肺癌に対する定位放射線治療成績の検討

山本貴也, 松下晴雄, 菅原俊幸, 梅澤玲, 久保園正樹, 石川陽二郎, 古積麻衣子, 片桐佑, 高橋紀善, 角谷倫之, 伊藤謙吾, 木田智士, 神宮啓一, 土橋卓, 武田賢

Japanese Journal of Radiology　2016年2月
胸部食道癌II/III期に対する根治的化学放射線治療成績予後因子の検討

梅澤玲, 松下晴雄, 菅原俊幸, 久保園正樹, 山本貴也, 石川陽二郎, 片桐佑, 古積麻衣子, 高橋紀善, 角谷倫之, 木田智士, 伊藤謙吾, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　2016年2月
前立腺癌74Gy照射の治療成績

石川陽二郎, 松下晴雄, 菅原俊幸, 梅澤玲, 久保園正樹, 山本貴也, 片桐佑, 古積麻衣子, 高橋紀善, 角谷倫之, 木田智士, 伊藤謙吾, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　2016年2月
東北大学病院における喉頭癌T2症例の検討

山本貴也, 松下晴雄, 菅原俊幸, 久保園正樹, 梅澤玲, 角谷倫之, 石川陽二郎, 古積麻衣子, 高橋紀善, 伊藤謙吾, 片桐佑, 武田賢, 土橋卓, 神宮啓一, 小川武則, 香取幸夫

Japanese Journal of Radiology　2016年2月
縦隔放射線療法と関連した心筋代謝疾患の評価パイロットスタディ(Assessment of Myocardial Metabolic Disorder Associated with Mediastinal Radiotherapy: a pilot study)

梅澤玲, 高浪健太郎, 松下晴雄, 菅原俊幸, 久保園正樹, 山本貴也, 石川陽二郎, 片桐佑, 古積麻衣子, 高橋紀善, 角谷倫之, 木田智士, 伊藤謙吾, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　2016年2月
切除可能食道癌に対する化学放射線療法と手術療法の前向き比較長期成績

有賀久哲, 梅澤玲, 神宮啓一, 亀井尚, 宮崎修吉, 根本建二, 吉岡孝志

Japanese Journal of Radiology　2016年2月
泌尿器尿路上皮がんに対する集学的治療尿路上皮がんに対するIMRTを用いた高線量放射線治療の初期成績

稲葉浩二, 原智彦, 篠田康夫, 込山元清, 柏原大朗, 小林和馬, 原田堅, 関井修平, 梅澤玲, 高橋加奈, 村上直也, 伊藤芳紀, 井垣浩, 藤元博行, 伊丹純

日本癌治療学会誌　2015年9月
臨床病期I期、II期下咽頭癌に対する強度変調放射線治療の治療成績

伊藤芳紀, 村上直也, 稲葉浩二, 高橋加奈, 井垣浩, 梅澤玲, 関井修平, 原田堅, 小林和馬, 柏原大朗, 松本文彦, 小林謙也, 槇大輔, 吉本世一, 伊丹純

頭頸部癌　2015年5月
東北大学病院における食道腺癌に対する放射線治療経験

高橋紀善, 松下晴雄, 菅原俊幸, 梅澤玲, 久保園正樹, 阿部恵子, 山本貴也, 古積麻衣子, 角谷倫之, 藤田幸男, 伊藤謙吾, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　2015年2月
甲状腺MALTリンパ腫に対し放射線治療を行い長期経過観察中の症例

平塚裕介, 松下晴雄, 菅原俊幸, 梅澤玲, 久保園正樹, 阿部恵子, 山本貴也, 古積麻衣子, 高橋紀善, 角谷倫之, 藤田幸男, 伊藤謙吾, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　2015年2月
当院での乳房温存術後boost(追加)照射について

松下晴雄, 菅原俊幸, 梅澤玲, 久保園正樹, 阿部恵子, 藤本俊裕, 山本貴也, 石川陽二郎, 古積麻衣子, 高橋紀善, 角谷倫之, 藤田幸男, 伊藤謙吾, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　2015年2月
4D-CTとdeformable image registrationを用いた肺機能イメージングの開発と治療計画への応用

角谷倫之, 藤田幸男, 伊藤謙吾, 高橋紀善, 古積麻衣子, 山本貴也, 阿部恵子, 梅澤玲, 久保園正樹, 菅原俊幸, 松下晴雄, 神宮啓一, 土橋卓, 武田賢

Japanese Journal of Radiology　2015年2月
乳癌上腕骨転移照射後の上腕浮腫、末梢神経障害に対し200回超の高気圧酸素療法(HBO)を施行、奏効している症例

松下晴雄, 菅原俊幸, 梅澤玲, 久保園正樹, 阿部恵子, 山本貴也, 古積麻衣子, 高橋紀善, 角谷倫之, 藤田幸男, 伊藤謙吾, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　2015年2月
骨軟部悪性腫瘍に対する放射線治療成績

古積麻衣子, 松下晴雄, 菅原俊幸, 久保園正樹, 梅澤玲, 阿部恵子, 山本貴也, 角谷倫之, 藤田幸男, 伊藤謙吾, 高橋紀善, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　2015年2月
VariSeedを用いたAu-198密封小線源治療の線量分布計算

伊藤謙吾, 角谷倫之, 藤田幸男, 高橋紀善, 古積麻衣子, 山本貴也, 阿部恵子, 梅澤玲, 久保園正樹, 菅原俊幸, 松下晴雄, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　2015年2月
モンテカルロ法を用いた四次元線量分布計算コードの開発

藤田幸男, 角谷倫之, 伊藤謙吾, 高橋紀善, 古積麻衣子, 山本貴也, 阿部恵子, 梅澤玲, 久保園正樹, 菅原俊幸, 松下晴雄, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　2015年2月
pT3前立腺癌術後PSA failureに対する放射線単独局所治療成績

神宮啓一, 梅澤玲, 松下晴雄, 菅原俊幸, 久保園正樹, 阿部恵子, 藤本俊裕, 山本貴也, 石川陽二郎, 古積麻衣子, 高橋紀善, 角谷倫之, 藤田幸男, 伊藤謙吾

Japanese Journal of Radiology　2015年2月
胸部食道癌II/III期に対する根治的化学放射線治療成績

梅澤玲, 神宮啓一, 亀井尚, 宮田剛

日本食道学会学術集会プログラム・抄録集　2014年7月
呼吸性移動によるSUVmaxの減弱に対する補正法の検討

角谷倫之, 藤田幸男, 山本貴也, 白田佑子, 阿部恵子, 梅澤玲, 久保園正樹, 菅原俊幸, 松下晴雄, 神宮啓一, 土橋卓, 武田賢, 金田朋洋

Japanese Journal of Radiology　2014年2月
食道悪性黒色腫の2例

木下知, 松下晴雄, 菅原俊幸, 久保園正樹, 梅澤玲, 阿部恵子, 角谷倫之, 藤田幸男, 白田佑子, 田邊隆哉, 山本貴也, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　2014年2月
食道癌術後再発に対する放射線化学療法予後因子多変量解析結果

神宮啓一, 松下晴雄, 菅原俊幸, 久保園正樹, 梅澤玲, 阿部恵子, 角谷倫之, 藤田幸男, 田邊隆之, 白田佑子, 山本貴也, 武田賢, 土橋卓, 根本建二

Japanese Journal of Radiology　2014年2月
膀胱癌に対する放射線治療の検討

梅澤玲

Japanese Journal of Radiology　2014年2月
I期非小細胞肺癌定位照射の予後因子

白田佑子, 久保園正樹, 菅原俊幸, 松下晴雄, 阿部恵子, 梅澤玲, 角谷倫之, 藤田幸男, 田邊隆哉, 山本貴也, 土橋卓, 神宮啓一, 武田賢, 小藤昌志

Japanese Journal of Radiology　2014年2月
前立腺癌体外照射における前立腺sizeと晩期直腸出血の検討

山本貴也, 松下晴雄, 菅原俊幸, 久保園正樹, 梅澤玲, 阿部恵子, 角谷倫之, 藤田幸男, 白田佑子, 田邊隆哉, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　2014年2月
二次発がんを生じた後に不幸な経過をたどった若年性上咽頭癌の1例

古積麻衣子, 松下晴雄, 菅原俊幸, 神宮啓一, 清水栄二, 梅澤玲, 阿部恵子, 白田佑子, 石川陽二郎, 山本貴也, 角谷倫之, 藤田幸男, 武田賢, 土橋卓, 久保園正樹, 有賀久哲, 山田章吾

Japanese Journal of Radiology　2013年2月
術後食道癌孤立性リンパ節転移再発に対する放射線化学療法治療長期成績

神宮啓一, 松下晴雄, 菅原俊幸, 久保園正樹, 清水栄二, 梅澤玲, 阿部恵子, 白田佑子, 石川陽二郎, 山本貴也, 古積麻衣子, 山田章吾, 武田賢, 有賀久哲, 根本建二

Japanese Journal of Radiology　2013年2月
21世紀の子宮頸癌I期、II期放射線治療

久保園正樹, 松下晴雄, 菅原俊幸, 神宮啓一, 清水栄二, 梅澤玲, 阿部恵子, 白田佑子, 石川陽二郎, 山本貴也, 古積麻衣子, 有賀久哲, 小川芳弘, 山田章吾

Japanese Journal of Radiology　2013年2月
頭頸部癌術後予防照射の検討

松下晴雄, 菅原俊幸, 神宮啓一, 清水栄二, 梅澤玲, 阿部恵子, 白田佑子, 石川陽二郎, 山本貴也, 古積麻衣子, 角谷倫之, 藤田幸男, 武田賢, 土橋卓, 久保園正樹, 有賀久哲, 山田章吾

Japanese Journal of Radiology　2013年2月
東日本大震災における東北大学放射線治療科の活動報告

山本貴也, 神宮啓一, 松下晴雄, 菅原俊幸, 久保園正樹, 梅澤玲, 清水栄二, 山田章吾, 武田賢, 有賀久哲

Japanese Journal of Radiology　2013年2月
食道癌放射線治療後、F-18 FDG・I-123 BMIPPシンチ・心筋遅延造影MRI検査にて放射線心筋障害が疑われた3症例

梅澤玲

Japanese Journal of Radiology　2013年2月
stage I食道癌に対する放射線化学療法手術可能と不可症例の長期成績比較

神宮啓一, 松下晴雄, 菅原俊幸, 久保園正樹, 梅澤玲, 清水栄二, 阿部恵子, 白田佑子, 石川陽二郎, 山本貴也, 古積麻衣子, 武田賢, 山田章吾, 根本建二, 有賀久哲

Japanese Journal of Radiology　2013年2月
I期非小細胞肺癌に対する定位放射線治療成績と予後因子の検討

山本貴也, 角谷倫之, 白田佑子, 松下晴雄, 菅原俊幸, 梅澤玲, 阿部恵子, 神宮啓一, 武田賢, 土橋卓

日本医学放射線学会学術集会抄録集　2013年2月
上咽頭癌に対する強度変調放射線治療において局所再発が増えるか?(第1報)

神宮啓一, 阿部恵子, 小藤昌志, 松下晴雄, 藤本圭介, 菅原俊幸, 清水栄二, 梅澤玲, 武田賢, 山田章吾

頭頸部癌　2012年5月
前立腺癌に対する外照射(non-IMRT)による高線量処方時の直腸線量制限

石川陽二郎, 角谷倫之, 藤田幸男, 神宮啓一, 松下晴雄, 菅原俊幸, 梅澤玲, 阿部恵子, 山田章吾, 武田賢

日本医学放射線学会学術集会抄録集　2012年2月
膀胱癌に対する放射線治療の検討

梅澤玲

Japanese Journal of Radiology　2012年2月
放射線誘発性髄膜腫に対し過分割放射線治療を行った1例

山本貴也, 神宮啓一, 有賀久哲, 武田賢, 菅原俊幸, 久保園正樹, 梅澤玲, 清水栄二, 阿部恵子, 白田佑子, 田邊隆哉, 石川陽二郎, 山田章吾

Japanese Journal of Radiology　2012年2月
上咽頭癌に対する強度変調放射線治療において局所再発が増えるか?(第1報)

神宮啓一, 阿部恵子, 松下晴雄, 菅原俊幸, 清水栄二, 梅澤玲, 山田章吾, 小藤昌志, 藤本圭介, 武田賢

日本医学放射線学会学術集会抄録集　2012年2月
ステージI食道癌の治療戦略手術可能と不可stage I食道癌に対する放射線化学療法 2つの前向き試験長期成績比較

神宮啓一, 有賀久哲, 奈良崎覚太朗, 武田賢, 梅澤玲, 菅原俊幸, 山田章吾, 宮田剛, 小野寺浩, 根本建二

日本食道学会学術集会プログラム・抄録集　2011年9月
当院における前立腺小細胞癌の治療経験

阿部恵子, 有賀久哲, 武田賢, 菅原俊幸, 久保園正樹, 神宮啓一, 梅澤玲, 清水栄二, 白田佑子, 山田章吾

日本医学放射線学会学術集会抄録集　2011年2月
F-18 FDG・I-123 BMIPP・心臓MRIで放射線心筋障害が疑われた3症例

梅澤玲, 高瀬圭, 高浪健太郎, 神宮啓一, 有賀久哲, 金田朋洋, 大田英揮, 高橋昭喜, 山田章吾

日本医学放射線学会学術集会抄録集　2011年2月
東北大学におけるRapidArcの初期治療経験

三津谷正俊, 佐藤清和, 佐藤直志, 小川芳弘, 有賀久哲, 武田賢, 小藤昌志, 坂谷内徹, 久保園正樹, 奈良崎覚太朗, 梅澤玲, 清水栄二, 白田佑子, 山田章吾, 仲田栄子, 高井良尋

Japanese Journal of Radiology　2011年1月
化学放射線療法が奏功した膵腺房細胞癌の1例

清水栄二, 久保園正樹, 小川芳弘, 有賀久哲, 武田賢, 小藤昌志, 坂谷内徹, 奈良崎覚太朗, 梅澤玲, 白田佑子, 田邊隆哉, 山田章吾, 仲田栄子, 高井良尋, 松下晴雄, 高橋ちあき, 藤本俊裕, 戸嶋雅道

Japanese Journal of Radiology　2011年1月
前立腺癌を限局化するために7つの共平面場を用いた3次元原体照射後の晩期直腸・尿毒性の臨床予測因子(Clinical predictors of late rectal and urinary toxicity after three-dimensional conformal radiotherapy using seven coolanar fields to localize prostate cancer)

武田賢, 小川芳弘, 有賀久哲, 小藤昌志, 坂谷内徹, 久保園正樹, 奈良崎覚太朗, 梅澤玲, 清水栄二, 白田佑子, 山田章吾, 仲田栄子, 高井良尋, 根本建二

Japanese Journal of Radiology　2011年1月
頭頸部癌放射線治療の線量分布に与えるPTV・耳下腺の体積変化および位置変化の影響 Adaptive IMRTの為の基礎研究

小山翔, 仲田栄子, 高井良尋, 三津谷正俊, 小川芳弘, 有賀久哲, 武田賢, 小藤昌志, 藤本圭介, 坂谷内徹, 久保園正樹, 奈良崎覚太郎, 梅澤玲, 山田章吾

Japanese Journal of Radiology　2011年1月
当科における小児頭頸部腫瘍の検討

小川芳弘, 有賀久哲, 武田賢, 小藤昌志, 藤本圭介, 坂谷内徹, 久保園正樹, 奈良崎覚太朗, 梅澤玲, 清水栄治, 白田佑子, 田邉隆哉, 山田章吾, 仲田栄子, 高井良尋

Japanese Journal of Radiology　2011年1月
当院における上咽頭癌の放射線治療成績

小藤昌志, 小川芳弘, 有賀久哲, 武田賢, 坂谷内徹, 藤本圭介, 久保園正樹, 奈良崎覚太朗, 梅澤玲, 山田章吾

Japanese Journal of Radiology　2011年1月
肺定位照射後肺障害の検討

白田佑子, 小川芳弘, 有賀久哲, 武田賢, 坂谷内徹, 小藤昌志, 久保園正樹, 奈良崎覚太朗, 梅澤玲, 清水栄二, 田邊隆哉, 山田章吾, 高井良尋

Japanese Journal of Radiology　2011年1月
易出血性傍咽頭間隙腫瘍の治療経験

梅澤玲, 小川芳弘, 有賀久哲, 武田賢, 小藤昌志, 藤本圭介, 坂谷内徹, 久保園正樹, 奈良崎覚太朗, 清水栄二, 白田佑子, 田邉隆哉, 山田章吾, 高井良尋, 仲田栄子

Japanese Journal of Radiology　2011年1月
前立腺癌外照射後の晩期直腸障害

武田賢, 小川芳弘, 有賀久哲, 小藤昌志, 坂谷内徹, 藤本圭介, 奈良崎覚太朗, 梅澤玲, 平出智道, 山田章吾, 高井良尋

Japanese Journal of Radiology　2010年7月
肺癌術後の孤立性肺病変に対する定位放射線治療

小藤昌志, 小川芳弘, 有賀久哲, 武田賢, 藤本圭介, 坂谷内徹, 奈良崎覚太朗, 梅澤玲, 山田章吾, 仲田栄子, 高井良尋

Japanese Journal of Radiology　2010年7月
食道癌に対する温存療法適応因子の検討

有賀久哲, 小川芳弘, 武田賢, 小藤昌志, 藤本圭介, 坂谷内徹, 奈良崎覚太朗, 梅澤玲, 山田章吾

Japanese Journal of Radiology　2010年7月

︎全件表示 ︎最初の5件までを表示

共同研究・競争的資金等の研究課題 6

膵癌に対する拡大局所定位放射線治療の臨床開発と応用

梅澤玲

2022年4月1日～ 2025年3月31日
食道癌に対する心筋線量軽減による心毒性低下を図った放射線治療の確立

梅澤玲

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Early-Career Scientists

研究種目：Grant-in-Aid for Early-Career Scientists

研究機関：Tohoku University

2019年4月～ 2022年3月

詳細を見る詳細を閉じる

本研究につき、当院倫理委員会に速やかに申請を行い、承認を頂いた。本研究に関しては、放射線腫瘍医・放射線診断医・循環器内科で協議しながら、詳細なプロトコール（適応症例・治療内容（照射範囲・照射線量・化学療法など）・検査項目・治療後の評価など）を作成した。現在、化学放射線治療で根治が期待できる食道癌症例（早期食道癌T1N0M0症例）に対して症例収集を行っている。本研究に対して患者様に十分な説明を行い、同意の得られた症例に本研究を行っている。治療前の心臓の状態について、心臓MRI・心臓超音波・心電図・採血などを用いて詳細に調べており、明らかに異常所見を認めていないことを確認してており、患者様自身の自覚症状も認めていないことを確認した。放射線治療計画については、強度変調放射線治療（IMRT）を用いて心臓・心筋への線量を低減するように設定しており、従来の照射方法（3次元原体照射：3DCRT）と比較しても少ないことを確認している。心筋に照射されている詳細な線量については、deformable image registration（DIR）という手法を用いることで、輪郭と線量分布を変形する事が可能である。この手法に関して、放射線医学物理士と協議しながら、正確な心筋への線量分布を作成している。化学放射線治療に関しては、どの症例もプロトコール通り施行している。治療後の心臓検査をしている症例は現時点ではいないので、治療後の心臓障害の評価はできていない。今後は心事故の有無も含めて十分に経過観察する予定である。また本試験で施行される強度変調放射線治療の品質管理ならびに線量分布に関する内容を国際学会で発表した。
心臓MRI検査を用いた放射線治療前後での心筋変化とその臨床的意義の検討

梅澤玲, 角谷倫之, 大田英揮, 神宮啓一

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)

研究種目：Grant-in-Aid for Young Scientists (B)

研究機関：Tohoku University

2014年4月～ 2017年3月

詳細を見る詳細を閉じる

放射線治療前、治療後半年後、治療後1年半後に、心臓MRI検査を施行した。10Gy毎に各線量域を設定し、各線量域での照射前後においてのGd造影効果の信号強度変化を調べた。照射後半年後に検査した19例中13例（68%）で、1年半後に検査した12例中9例（75%）で、線量依存性に信号強度の変化を認めた。特に30Gy以上照射されている領域で信号強度の変化が明らかに出現した（20-30Gy領域では半年後・1年半後に1.1%・1.9%に対し、40-50Gy領域では35.7%・17.5%の信号強度変化が認められた。食道癌化学放射線療法後の心筋障害が線量依存性に出現する事が示唆された。
心臓ＭＲＩ検査を用いた放射線治療後の心筋変化の検出

梅澤玲

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Research Activity Start-up

研究種目：Grant-in-Aid for Research Activity Start-up

研究機関：Tohoku University

2012年8月～ 2015年3月

詳細を見る詳細を閉じる

根治が期待できる胸部食道癌症例を対象に心臓MRI検査を施行し、放射線治療前後で照射部位に一致した心筋変化を検討した。心臓MRIは、放射線治療前と治療後6か月経過した時点で撮像した。2015年3月の時点で25症例で本試験の同意を頂き、予定された化学放射線治療を施行し、大きな合併症なく終了した。そのうち20例で照射後6カ月後のMRIの撮像した。照射後のMRI撮像時に、臨床症状を呈する症例はいなかった。心筋変化に関する詳細な検討は、後日報告する予定である。
リピオドールマーキングを用いた婦人科腫瘍に対する放射線治療の有用性に関する前向き研究
放射線防護剤としてのニカラベンの実用化競争的資金

梅澤玲

︎全件表示 ︎最初の5件までを表示